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ABSTRACT
Elastin, a primary component of elastic arteries, maintains structural stability of
the cyclically recoiling artery, and critically regulates vascular cell behavior. Accelerated
degradation of elastic matrix, such as that seen in vascular pathologies like abdominal
aortic aneurysms (AAA), can therefore severely compromise vessel homeostasis. Tissue
engineering and in-situ matrix repair strategies evaluated so far are primarily limited in
inducing adult vascular cells to replicate the complex elastic matrix assembly process,
and restore lost matrix integrity. Previously, our lab established the elastogenic benefits
of concurrent delivery of TGF-β1 and HA-oligomers (together termed elastogenic factors,
EFs), within 2D cultures of rat aortic smooth muscle cells (SMCs). Since SMCs are
known to switch to a synthetic, highly matrix producing phenotype, in a manner that
cannot be replicated in vivo, we sought to develop a relevant 3D in vitro model system,
where the benefits of EFs can be replicated. We chose a 3D collagen-gel model since the
presence of a collagenous matrix is centric to replicating vascular tissue architecture and
mechanics. Further, vascular cells, regardless of the choice of scaffolds, robustly
synthesize

collagen.

Examining

the

impact

of

a

pre-existing

collagenous

microenvironment on the ability of the SMCs to synthesize fibrous elastic matrix in
response to provided EFs, is pertinent to its clinical translation.
In the first set of studies, we examined a dose range of EFs on inducing rat SMCsseeded within 3D collagen gel constructs. Relative to untreated control, all the three
doses tested showed up to a 2-fold up-regulation in gene expression of the elastin
crosslinking enzyme, lysyl oxidase, and increased the accumulation of matrix elastin up
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to 5-fold. The lowest dose combination of 0.1 ng/ml TGF-β1 and 0.2 µg/ml HA-o, was
evaluated to be most elastogenic, and this was utilized in subsequent studies. Next, we
evaluated the application of cyclic strains at varying frequencies in improving EFinduced elastic matrix output, and to obtain matrix and cell orientation in a manner
similar to that required in vivo. Further, we tested this system on human SMCs seeded
within tubular collagen-gel constructs, to examine if they respond to EF-treatment similar
to rat SMCs. A bimodal trend in elastic matrix output was observed with increasing
frequencies. Relative to static controls, constructs treated with EFs at 2.5% strains and
1.5 Hz were found to improve contractile SMC phenotype, up-regulate elastin gene
expression up to 7-fold, and increase elastic matrix content by 5-fold. These parameters
were therefore chosen for application in subsequent studies. The presence of high
concentrations of matrix degrading proteases, such as MMPs-2 and -9, inherent to AAA
wall, as well as within our 3D system, can compromise the accumulation and efficient
assembly of newly synthesized elastic matrix components. In the next set of studies, we
demonstrated that addition of Doxycycline (DOX), a non-specific MMP inhibitor, along
with EFs, suppressed MMP-2 gene expression, within static and dynamic (2.5% strain at
1.5 Hz) tubular constructs, and markedly improved overall elastic matrix synthesis.
Since the effects of EFs and DOX are highly dose-dependent, the successful in
vivo translation of their benefits relies on their controlled and targeted delivery
specifically to the site of disease. In the final set of studies, we tested the effects of TGFβ1 and DOX released from PLGA nanoparticles, incorporated within the cyclically
stretched tubular 3D model optimized in previous studies. We were able to successfully
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demonstrate that such localized delivery was able to induce elastogenesis in a manner
similar to exogenous delivery of the same factors.
Overall, these results will be useful towards addressing a fundamental and widely
absent aspect in vascular engineering, that of inducing adult vascular cells to replicate
biological and structural mimics of native elastic fiber networks.

iv

ACKNOWLEDGEMENTS
I would first like to thank my advisor Dr. Anand Ramamurthi, for his utmost
support, mentorship and guidance throughout the course of my time as a Ph.D. student.
He has been extremely understanding and supportive even during times when I have been
very undeserving of it. His perspectives as a scientist, as well as that as an individual,
have played an important role in shaping mine, and will always remain a source of
inspiration. It is also thanks to his career path, that I have had the privilege to meet and be
amidst some very fine scientists and individuals in 3 great institutes and cities.
I would next like to thank my academic advisor, Dr.Martine LaBerge. She has
always been highly encouraging and has at several occasions, gone out of her way to
show me support. I would next like to thank my committee members, Dr. Naren
Vyavahare and Dr.Jiro Nagatomi, who have given many valuable suggestions in shaping
my thesis work.
I would next like to thank Ryan, Barry, Kevin, Dr.Gao and all members of the
Design and Prototype core who have played a huge role in kick starting my bioreactor
studies. I have learnt a great deal from them. I would also like to thank Diane and Mei
from the Imaging Core for their help with histology and TEM.
Among my peers, I would first like to start off by thanking ex-members of the
Ramamurthi lab, Emily and Carmen. My fundamentals and values as a scientist would
not have been as strong had it not been for their mentorship and insight, which I must add,
might have been very frustrating for them at times. In Emily, especially, I have found a
great friend and a source of inspiration. I would next like to thank Chris, especially for

v

his help with all the mechanical testing procedures and PCR. I would also like to thank
Bala and Pratik for their help and support through all the frustrating days of nanoparticle
study optimization. All of their support and work has greatly contributed to my thesis. I
would also like to thank other members of the Ramamurthi lab who have in many ways
contributed to my learning curve- Durba, Shyam, Dennis, Sahithya, Ganesh, and last but
not the least, Partha. Partha will always remain a great source for energy boosters, and a
great friend. I have learnt a great deal from them in many facets of my time as a member
of this lab, and also had fun in the process.
I would also like to thank all the faculty and staff members of Clemson BioE and
MUSC, and staff and scientists at the Cleveland Clinic. They have all in their own ways,
played an important role in shaping my perspectives as a scientist.
Lastly, I would like to thank my family, my extended family, and my small circle
of close friends, for whose love, support, distractions, prayers, and belief in me and my
abilities, I will always be indebted to. My parents, Venkataraman and Pushpa, my sister,
Sukanya, and my husband, Sathya have been my greatest sources of inspiration, love and
support. Anything I say beyond this would only do injustice to just how much of a role
they have played in all facets of my life, especially in the last four years of my time as a
PhD. student.

vi

TABLE OF CONTENTS
TITLE PAGE ............................................................................................................... i
ABSTRACT ................................................................................................................. ii
ACKNOWLEDGEMENTS ........................................................................................v
LIST OF FIGURES ................................................................................................... xi
LIST OF TABLES .....................................................................................................xv
CHAPTER
I

INTRODUCTION........................................................................................................1
1.1. BACKGROUND ...............................................................................................1
1.2. 3D CULTURE MODEL FOR INCLUDED ELASTIN SYNTHESIS ............5
1.3. STUDY OBJECTIVES AND AIMS .................................................................7
1.4. PROJECT INNOVATION AND IMPORTANCE ............................................8
1.5. ORGANIZATION OF DISSERTATION .........................................................9

II LITERATURE REVIEW .........................................................................................11
2.1. ELASTIN: PRIMARY COMPONENT OF ELASTIC FIBER ECM..............11
2.1.1. Distribution of Elastin .......................................................................11
2.1.2. Chemical Composition of Elastin ......................................................12
2.1.3. Elastin Synthesis and Assembly into Elastic Fibers ..........................13
2.1.4. Elastic Fiber Maturation, Breakdown and Turnover .........................16
2.2. ELASTIN AND THE VASCULATURE.........................................................18
2.2.1. Elastic Arteries: Structure and Function ............................................19
2.2.2. Matrix and Cellular Components of elastic arteries and their roles ...22
2.2.3. Role of Elastin in Physiochemical Regulation of Vascular Cells ......25
2.2.4.Contribution of Elastin to Vascular Mechanics and Vascular
Homeostasis ........................................................................................27
2.3. VASCULAR ELASTINOPATHIES ..............................................................29
2.3.1. Genetic Disorders ...............................................................................29
2.3.2. Acquired Disorders: Abdominal Aortic Aneurysms...........................30
2.4. STRATEGIES TO RESTORE ELASTIC MATRIX ......................................32
2.4.1. Strategies to Replace Diseased Vessel Wall .......................................32
2.4.2. Strategies to Prevent Matrix Degradation ...........................................35
2.4.3. Strategies for In vitro Tissue Engineering and In situ Repair of
Vascular Elastic Matrix .....................................................................38

vii

TABLE OF CONTENTS (CONT.)
III INVESTIGATING INDUCED ELASTOGENESIS BY VASCULAR
SMCS IN AN IN VITRO 3-D COLLAGEN-GEL
MICROENVIRONMENT ......................................................................................48
3.1. INTRODUCTION ............................................................................................48
3.2. MATERIALS AND METHODS ....................................................................50
3.2.1. Isolation and Culture of Rat Aortic Smooth Muscle Cells ............50
3.2.2. Fabrication of Cellularized Collagen Constructs ..........................50
3.2.3. Construct Compaction ....................................................................52
3.2.4. DNA Assay for Cell Quantification ..............................................53
3.2.5. RT-PCR for mRNA expression of Tropoelastin, Collagen and
LOX ................................................................................................53
3.2.6. Fastin Assay for Elastin Content ....................................................54
3.2.7. Western Blotting for LOX and MMPs –2 and –9 ..........................55
3.2.8. Gelatin Zymography for Detection of MMP–2 and –9 ..................56
3.2.9. Visualization of Elastic Matrix and Mineralization .......................57
3.2.10. Mechanical Testing of 3-D Constructs .........................................58
3.2.11. Statistical Analysis .......................................................................59
3.3. RESULTS .........................................................................................................59
3.3.1. Cell Quantification ........................................................................59
3.3.2. Elastic Matrix Content....................................................................60
3.3.3. MMP Protein Analysis ...................................................................64
3.3.4. Mechanical Properties of Constructs ..............................................65
3.3.5. Visualization of Elastic Matrix ......................................................66
3.4. DISCUSSION .................................................................................................69
3.5. CONCLUSIONS ..............................................................................................76

IV IMPACT OF DYNAMIC CONDITIONING ON INDUCED
ELASTOGENESIS BY CELLS IN 3D COLLAGENOUS
MICROENVIRONMNETS ....................................................................................77
4.1.INTRODUCTION .............................................................................................77
4.2.MATERIALS AND METHODS ......................................................................79
4.2.1. Design, Construction and Principle of Operation of
Bioreactor for Dynamic Cell Culture .........................................79
4.2.2. Fabrication of Tubular Collagen Gel Constructs ..........................83
4.2.3. Compaction of Tissue Constructs...................................................86
4.2.4. DNA Assay for Cell Quantification ...............................................87
4.2.5. RT-PCR for mRNA Expression of SMC Phenotypic Markers
and Matrix Proteins .......................................................................87
4.2.6. Fastin Assay for Elastin Content ....................................................89

viii

TABLE OF CONTENTS (CONT.)
4.2.7. Western Blotting for Cellular and Matrix Proteins .......................90
4.2.8. Gelatin Zymography for Detection of Enzyme Activities of
MPPs - 2 and -9 .............................................................................91
4.2.9. Visualization of Elastic Matrix ......................................................92
4.2.10. Mechanical Testing of Constructs ...............................................93
4.2.11. Statistical Analysis .......................................................................94
4.3. RESULTS .........................................................................................................95
4.3.1. Compaction of Tissue Constructs .................................................95
4.3.2. Cell Quantification ........................................................................95
4.3.3. Analysis of SMC Phenotypic Markers ..........................................96
4.3.4. Elastic Matrix Synthesis ................................................................99
4.3.5. MMP -2 Production and Activity ...............................................102
4.3.6. MMP -9 Production and Activity ...............................................104
4.3.7. Matrix Ultrastructure ..................................................................105
4.3.8. Mechanical Properties of Constructs ..........................................110
4.4. DISCUSSION ...............................................................................................111
4.5. CONCLUSIONS ............................................................................................119

V IMPACT OF MMP-INHIBITION ON OUTCOMES OF INDUCED
ELASTOGENESIS IN STATICALLY AND DYNAMICALLY
CULTURED TISSUES ...........................................................................................120
5.1. INTRODUCTION ..........................................................................................120
5.2. MATERIALS AND METHODS ...................................................................121
5.3. RESULTS .......................................................................................................122
5.3.1. Construct Compaction .................................................................122
5.3.2. Cell Quantification ......................................................................123
5.3.3. Analysis of SMC Markers ...........................................................123
5.3.4. Elastic Matrix Content .................................................................127
5.3.5. MMP -2 Production and Activity ................................................130
5.3.6. MMP -9 Production and Activity ................................................134
5.3.7. Matrix Ultrastructure ...................................................................136
5.4. DISCUSSION ...............................................................................................136
5.5. CONCLUSIONS ............................................................................................145

VI

EVALUATION OF ELASTOGENIC EFFECTS DUE TO LOCALIZED
NANOPARTICULATE DELIVERY OF DOX AND TGF-β1
IN 3-D COLLAGEN–GEL TUBES ...................................................................146
6.1. INTRODUCTION ..........................................................................................146

ix

TABLE OF CONTENTS (CONT.)
6.2. MATERIALS AND METHODS ...................................................................147
6.2.1. Synthesis of TGFβ-1 and DOX loaded Nanoparticles .................147
6.2.2. Release Profile of Factors from NPs ...........................................148
6.2.3. Formulation of NP-loaded Collagen Constructs ..........................149
6.2.4. Retention of NPs within Collagen Gels .......................................150
6.2.5. Compaction of Tissue Constructs ................................................151
6.2.6. DNA Assay for Cell Quantification .............................................151
6.2.7. RT-PCR for mRNA Expression of SMA Phenotypic
Markers and Matrix Proteins ........................................................152
6.2.8. Fastin Assay for Elastin Content ..................................................152
6.2.9. Western Blotting for Cellular and Matrix Proteins .....................153
6.2.10.Gelatin Zymography for Detection of Enzyme Activities
of MMPs -2 and -9 .....................................................................154
6.2.11.Visualization of Elastic Matrix ...................................................154
6.2.12. Statistical Analysis .....................................................................155
6.3. RESULTS .......................................................................................................155
6.3.1. Nanoparticles Size and Release Profiles ......................................155
6.3.2. Nanoparticle Retention and Effects on Cell Density....................156
6.3.3. Compaction of Tissue Constructs.................................................158
6.3.4. Cell Quantification .......................................................................160
6.3.5. Analysis of SMC Markers ...........................................................160
6.3.6. Elastic Matrix Content..................................................................161
6.3.7. Analysis of MMPs -2 and -9 .......................................................164
6.3.8. Matrix Ultrastructure ....................................................................168
6.4. DISCUSSION ...............................................................................................168
6.5. CONCLUSIONS ...........................................................................................177

VII CONCLUSIONS AND FUTURE OUTLOOK ...................................................179
7.1. OVERALL CONCLUSIONS ........................................................................179
7.2. FUTURE OUTLOOK ....................................................................................186

REFERENCES ...............................................................................................................190

x

LIST OF FIGURES
Figure

Page

2.1

Tropoelastin transport and assembly via EBP…………………………

2.2

Tropoelastin assembly on microfibrillar scaffolds in ECM…………… 15

2.3

SEM of elastic fibers during development and aging………………….

2.4

Anatomy of elastic artery……………………………………………… 19

2.5

Assembly of collagen fiber bundles…………………………………… 24

2.6

Non-linear tensile properties of elastic arteries………………………..

28

2.7

Cartoon representation of dilated AAA………………………………..

31

2.8

Schematic of EVAR vs. open repair for AAA………………………… 35

3.1

Statically loaded RASMC-seeded 3D collagen gel……………………

52

3.2

Cell proliferation in 3D collagen gels………………………………..

60

3.3

Effect of treatment conditions on RASMC mRNA expression……….

61

3.4

Elastic matrix outcomes of elastogenic factor doses in static gels…….

61

3.5

LOX mRNA expression in response to elastogenic factor treatment….

62

3.6

Fold change In lox protein content ……………………………………

62

3.7

Western blots and zymograms of MMPs-2, 9 and LOX........................

63

3.8

Semi quantitative analysis of change in MMP protein content………..

65

3.9

Semi quantitative analysis of change in MMP enzyme activity………

65

3.10

Collagen gel contraction in response to change in TGF- HA-o dose….

66

3.11

Tensile properties of elastogenic factor treated collagen gels…………

67

xi

14

17

LIST OF FIGURES (CONT.)
3.12

VVG-stained sections of collagen gels………………………………

68

3.13

Immunofluorescent images of elastin within collagen gels……………

68

3.14

Elastic fiber alignment and no. of aligned fibers in constructs………

69

3.15

Von kosa staining in treated collagen constructs………………………

69

4.1

Bioreactor set for cyclic, circumferential strains………………………

80

4.2

Tissue culture chamber of bioreactor………………………………….. 82

4.3

Cyclic stretch induced changes in construct compaction……………...

95

4.4

Change in cell densities in response to dynamic and EF stimulation….

96

4.5

mRNA expression of SMC phenotypic markers…................................

98

4.6

Western blots of SMC contractile markers…………………………….

98

4.7

Changes in mRNA expression of elastic matrix components…………. 100

4.8

Matrix elastin content …………………………………………………

4.9

Influence of treatment conditions on mRNA expression of MMP-2….. 103

4.10

MMP-2 protein content in response to treatment conditions………….. 104

4.11

MMP-2 enzyme activity.........................................................................

104

4.12

MMP-9 protein content………………………………………………

105

4.13

VVG-stained sections tubular collagen gel constructs………………...

106

4.14

Elastin immunolabeled sections……………………………………….. 107

4.15

Fibrillin immunolabeled sections……………………………………… 108

4.16

TEM images of constructs treated with EFs and stretched at 1.5 Hz…

xii

101

109

LIST OF FIGURES (CONT.)
4.17

Stress vs. strain curved of ring sections of constructs………………....

112

4.18

Tensile and yield properties of constructs……………………………..

113

5.1

Effect of treatment conditions on construct compaction………………

124

5.2

Changes in cell density in response to EF+DOX+cylcic stretch………

124

5.3

mRNA expression and protein content of SMC markers……………...

125

5.4

mRNA expression of elastic matrix proteins…………………………..

129

5.5

Matrix elastin content after 24 days of treatment……………………...

130

5.6

Influence of DOX incorporation on MMP-2 mRNA expression……… 131

5.7

Changes in MMP-2 protein content…………………………………… 132

5.8

Variation in MMP-2 enzyme activity among treatment conditions…… 133

5.9

Treatment outcomes towards MMP-9 protein content………………...

135

5.10

VVG-stained sections tubular collagen gel constructs………………

137

5.11

Elastin-Immunolabeled sections of constructs………………………… 138

5.12

Fibrillin-immunolabeled sections of constructs……………………….. 139

6.1

Release profile of DOX and TGF-β1 from PLGA nanoparticles……...

156

6.2

Cy5 tagged BSA NP retention within collagen gels…………………...

157

6.3

Changes in cell density in response to varying NP concentrations……

158

6.4

Construct compaction post treatment…………………………………

159

6.5

Cell densities in EDC, BNP and ANP…………………………………

159

6.6

Effects over delivery mode on SMC phenotypic mRNA expression….

161

xiii

LIST OF FIGURES (CONT.)
6.7

SMC phenotypic marker expression in response to NP delivery……...

161

6.8

mRNA expressions of elastic matrix proteins………………………....

163

6.9

Differences in elastic matrix content between the 2 delivery mode…...

164

6.10

Effects of NP-based delivery on LOX protein content………………...

164

6.11

mRNA expression of MMPs -2 and -9………………………………...

165

6.12

Protein quantities of MMPs -2 and -9…………………………………. 166

6.13

Zymography of MMPs -2 and -9………………………………………

6.14

Representative images of Elastic staining……………………………... 169

6.15

Effect of agent delivery mode on elastic matrix ultrastructure………... 170

xiv

167

LIST OF TABLES
Table

Page

2.1

List of genetic disorders affecting elastic matrix proteins……………………. 30

2.2

Summary of combinatorial strategies for elastic matrix engineering………… 45

3.1

Primer sequences for genes used in chapter 3 studies………………………...

55

4.1

Aim 2A experimental set-up………………………………………………...

86

4.2

Human Primer sequences for gene expression studies……………………….. 89

5.1

Aim 2B experimental set-up………………………………………………...

122

6.1

Aim 3 experimental set-up………………………………………………........

151

xv

CHAPTER ONE
INTRODUCTION

1.1. BACKGROUND
Elastin is one of the primary structural proteins found in the ECM of several
connective tissues. It crucially maintains configurations of tissues and regulates cell
signaling pathways involved in morphogenesis, injury response, and inflammation1-2.
Specifically, within elastic arteries, it comprises of 50% of the dry tissue weight, playing
a major role in maintaining overall vascular homeostasis3-4. While the elastic matrix is
responsible for providing vessels the necessary recoil and compliance to accommodate
blood flow5, intact elastic fibers also regulate vascular smooth muscle cell (VSMC)
behavior through mechano–transduction1, particularly during morphogenesis and disease
progression2.
Innate homeostatic maintenance of elastin within the extracellular matrix (ECM)
is a lifelong process that involves its early synthesis and maturation, slow degradation/
turnover, and limited replacement of structural and signaling proteins involved in
elastogenesis6-7. Once injured, the elastic matrix is not actively repaired, due to (a) poor
elastin precursor (tropoelastin) synthesis by adult cells, (b) inefficient recruitment,
crosslinking and organization of tropoelastin into an intact, mature elastic matrix, and (c)
further degradation due to the generated matrix metalloproteases (MMPs) and elastinpeptides7-10 Accelerated degradation of the matrix, as encountered in several vascular
diseases such abdominal aortic aneurysms (AAA)11, coupled with the inability of adult
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vascular smooth muscle cells (SMCs) to regenerate lost matrix8, can thus severely
compromise vascular tissue integrity and even result in fatal rupture of vessel wall12.
Therefore, the failure to reinstate a healthy elastic matrix, when damaged by injury or
disease, or when congenitally malformed or absent, such as that seen within abdominal
aortic aneurysms, can adversely impact vascular tissue homeostasis 13-15.
AAAs are conditions wherein localized thinning and dilation of the wall of
abdominal aortae occur, leading to gradual loss of elasticity, resultant local increase in
diameter, which can ultimately lead to rupture11. A vessel that has expanded in diameter
by at least 50% is generally considered to be aneurismal16-17. Initiation and progression of
AAA has been attributed primarily to chronic matrix proteolysis by MMPs and
inflammatory cells that infiltrate the vessel wall in response to smoking, chronic
vasculitis, atherosclerosis, calcified lipid deposits, vascular hypertension, and less
frequently, inherited conditions11, 16. This is coupled with the absence of intrinsic signals
in adult vascular cells to regenerate lost elastic matrix or to successfully repair the
disrupted aortic vessel wall matrix18. The accelerated loss of elastic matrix and vessel
wall integrity, and continuous fluctuations in hemodynamic pressures lead to the
abnormal ballooning of an aneurysm19. AAAs typically grow about 1 cm/year to
catastrophically rupture causing hemorrhage and embolisms. In the United States alone,
the estimated incidence for AAAs is about 60 in every 100,000 people per year16, 20, with
a fatality rate of more than 15,000 individuals a year, i.e. about 80% of AAA patients17,
21

. While advances in high resolution CT and MRI techniques now enable early detection

of AAAs, the conditions are frequently asymptomatic until well developed22.
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Currently the most common approach to treat aortic aneurysms is the surgical
replacement of the diseased section of the vessel using synthetic grafts, either by an open
surgical repair, or more recently, by Endovascular Aneurysm Repair (EVAR)23. Although
synthetic grafts help to isolate the aneurysm and prevent vessel rupture by providing an
alternative pathway for blood flow, they do not accommodate for the loss of functional
properties of elastic matrix, pose additional complications due to compliance mismatch
between the synthetic graft material and the native blood vessels, and do not aid in
regression of the diseased state24. Several device-related complications such as lack of
endothelialization, prevalence of various types of endoleaks, implant migration and
fatigue affect long-term patency of the implant, necessitating surgical intervention (>
30% of cases within 6 years)25-26. Synthetic grafts continue to have a failure rate of >
50% within 10 years26.
Restoring an intact elastic matrix is essential not only to sustain the structural
requirements of the vessel wall, but also to maintain healthy vascular cell functioning,
both of which are equally critical for vascular homeostasis14, 18. Tissue engineering (TE)
and matrix regenerative strategies have therefore been extensively investigated to develop
biomechanically functional and self-renewing vessel components with the aim to mimic a
viable elastic aorta27. However, a large body of this work has been unsuccessful in
inducing substantial synthesis or regeneration of intact, mature, matrix elastin10,

28-33

.

Studies observing reasonable induction of elastogenesis have done so only by utilizing
naturally elastogenic neonatal or juvenile SMCs; success in inducing elastogenesis in
adult cells has been limited to demonstrating moderate increases in mRNA expressions of
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tropoelastin34-36. The translational ability of these vascular TE approaches is therefore
limited. Strategies for successful tissue engineering of elastic matrix-rich vascular
constructs by adult SMCs are critical and currently unmet.
Previously, our lab established the elastogenic benefits of exogenous hyaluronan
oligomers (HA-o; ~756 Da) and TGF-β1 in 2-D-cultures of healthy rat aortic SMCs
(RASMCs)

37

. TGF-β1 has shown to increase elastin mRNA levels (by ~ 30-fold) and

enhance production of LOX, critical for crosslinking collagen and elastin, and fiber
organization in situ38-39. It has also shown to decrease proteolysis by reducing MMP
expression and up-regulating TIMP-1, 2, and 3 mRNA expressions40-41. Hyaluronan (HA)
also appears to stabilize elastin fibers once formed, against elastase degradation. In
addition to this, HA is known to enhance formation of mature matrix elastin by 1)
coacervating soluble tropoelastin via their positive lysine residues and 2) facilitating lysyl
oxidase (LOX)-mediated oxidation and crosslinking of tropoelastin into insoluble elastic
fibers42-43. Studies from our lab have also confirmed such up-regulation and demonstrated
elastogenic synergy between HA oligomers (~ 756 Da) and growth factors such as TGFβ137, 44.
The two primary criteria to be satisfied in order to obtain a highly organized and
mature elastic matrix in vitro, or to restore lost matrix via in situ repair, are 1) inducing
VSMCs to synthesize and organize sufficient elastic matrix, and 2) maintaining a balance
between increase in matrix production and suppression of degradative proteases. While
TGF-β1- HA-o dose combinations enhance elastin synthesis several fold, their
insufficiencies in suppressing MMP activity limits the accumulation of mature-matrix.
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Studies in our lab have therefore investigated dose-specific benefits of Doxycycline
(DOX), a modified tetracycline, in combination with the above factors, to improve elastic
matrix output. Known to be a global, non-specific MMP inhibitor, systemic delivery of
DOX has been clinically shown to reduce the rate of AAA growth and progression of
disease, a likely outcome of reduced elastic matrix proteolytic disruption45-47.
One of the main limitations of previous studies testing the efficacy of various
elastogenic factors was that they were all performed in 2D cultures of VSMCs. VSMCs
are known to take up a highly synthetic phenotype, displaying significantly higher
proliferation ratios and increased ability to synthesize ECM proteins compared to that
seen in vivo. Moreover, the matrix ultrastructure in such environments is not replicative
of that needed within intact tissues in vivo. It is therefore important to test the effects of
the elastogenic factors within micro-environmental conditions that more closely evoke
the native vascular tissue.

1.2. 3D CULTURE MODEL FOR INDUCED ELASTIN SYNTHESIS
The presence of collagenous matrix is centric to replicating vascular tissue
architecture and mechanics48. Collagen gels have been extensively investigated as 3-D
scaffolding models for vascular TE since the pioneering work of Weinberg and Bell in
198649-50. SMC-seeded collagen gels are actively remodeled in a process called
fibrillogenesis, emulating a 3-D environment similar to that seen in the arterial media in
vivo51. SMCs seeded within such scaffolds can therefore be expected to behave in a
manner more representative of a healthy phenotype52-53, compared to other synthetic or
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natural scaffolds such as polyglycolic acid (PGA)54 or fibrin28. Moreover, vascular cells,
regardless of the choice of scaffolds, robustly synthesize collagen10, 27. This is also true in
case of auto-regenerative phenomena within proteolytically-disrupted vascular tissues in
vivo, such as AAAs, where a fibrotic collagen-rich matrix first accumulates16, 55. It is
therefore further imperative to examine the impact of a pre-existing collagenous
microenvironment on the ability of VSMCs to synthesize fibrous elastic matrix in
response to provided elastogenic factors56.
As described in the previous section, one of the limitations of elastic matrix
engineering approaches is the lack of sufficient conversion of induced elastin synthesis
into an organized and aligned elastic ECM, similar to that needed in vivo. Numerous
studies in literature point towards benefits of cyclic dynamic conditioning to significantly
influence cell phenotype, alignment, matrix deposition, and growth factor release by both
native and cultured SMCs57-59.
Lastly, it is important to note that the factors that have been tested so far in vitro
can only be translated in vivo when their delivery is highly localized at the site of disease.
This is important not only to ensure higher availability for efficient and timely response,
but more so since the cellular response to these factors are very different depending on
their location in the vasculature. For example, while the effects of TGF-β1 delivery
generate a highly desirable response by VSMCs in AAAs, within thoracic aortae, it is
involved in initiation and progression of aneurysms60-61. Moreover, the therapeutic
concentrations can be more sensitively controlled and sustained via a localized delivery
from polymeric scaffolds such as nanoparticles.
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The 3D model system that we have utilized in this thesis is therefore comprised of
1) collagen gel constructs seeded with adult vascular cells, which are 2) subjected to
cyclic mechanical distensions, and 3) treated with various dose combinations of TGF-β1,
HA-o and DOX, with and without their delivery through nanoparticles.
The results will be useful towards addressing a fundamental and widely absent
aspect in vascular tissue engineering, that of being able to engineer elastic tissue
constructs containing biological and structural mimics of native elastic fiber networks.

1.3. STUDY OBJECTIVES AND AIMS
The specific aims are designed based on the background and results from previous
studies discussed in the sections above. They are as follows:
Aim 1: Investigate basal and induced elastogenesis in static, 3-D collagen gel
constructs. A range of TGF-β1 and HA-o dose-combinations will be exogenously
delivered to investigate elastin regeneration and matrix orientation by healthy adult
RASMCs within static, 3-D constructs of collagenous microenvironments.
Aim 2: (A) Determine benefits of cyclic distension on induced elastogenesis within
tubular collagen constructs. Healthy human aortic SMCs (HASMCs) will be cultured
within tubular collagen-gel constructs subjected to cyclic strains over a range of
frequencies within a pulsatile bioreactor. The most significantly elastogenic dose
combination of TGF-β1 and HA-o selected from Aim 1 will be concurrently delivered to
the cultures under dynamic straining. Static cultures with and without TGF-β1 and HA-o
will serve as the biologic controls.
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(B) Demonstrate that inhibition of matrix metalloproteases improves elastic
matrix output and quality. HASMCs cultured under dynamic conditions that are most
conducive to elastic matrix deposition in Aim 2A will be further cultured in the presence
of exogenous DOX, a modified tetracycline that inhibits synthesis and activity of MMPs.
Cultures without DOX treatment will serve as controls.
Effects of the above conditions on elastin synthesis, gelatinase synthesis and
activity, matrix deposition and orientation, matrix yield and overall architecture will be
evaluated in comparison to the respective biological controls.
Aim 3: Evaluate benefits of localized, controlled delivery of elastogenic factors and
Doxycycline within tubular collagen-gel cultures over exogenous delivery:
Nanoparticle encapsulation and in vitro release study of TGF-β1, HA-o and DOX will be
performed. These nano-particles will then be incorporated within collagen gels (at
concentrations optimized in Aims 1 and 2 prior to gel polymerization, for localized and
sustained delivery of these factors to HASMC cultures within.

1.4. PROJECT INNOVATION AND IMPORTANCE
Poor elastogenic potential of adult vascular cells combined with lack of strategies
to efficiently improve mature elastic matrix yield have thus far deterred successful
regenerative efforts in elastic vasculature. This study therefore aims at addressing these
issues by 1) utilizing the elastogenic potential of TGF-β1 and HA-o in combination with
2) dynamic conditioning for enhancing matrix assembly within 3-D collagen gel
constructs seeded with adult vascular SMCs. Aim 1 of this study would first establish an
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optimum dose combination of TGF-β1 and HA-o within collagen gels maintained under
static strains. Following this, Aim 2 will utilize the benefits of the above factors in the
presence of cyclic strains in order to achieve a well aligned, mature elastic matrix. The
application of cyclic strains in combination with targeted delivery of optimized factors
will be studied in Aim 3. Translational potential of the above methods will also be
reflected in Aims 2 and 3 with the utilization of adult human VSMCs.
The results will be most useful towards addressing a fundamental and widely
absent aspect in vascular tissue engineering, that of reinstating an intact, mature and
viable elastic matrix by adult vascular cells.

1.5. ORGANIZATION OF DISSERTATION
Chapter 2 presents an overview of elastin and elastic matrix components of the
vasculature, their roles in regulating vascular mechanics and cell behavior during
development, aging and disease, and a review of current strategies for vascular elastic
matrix regeneration and repair.
Chapter 3 evaluates outcomes of induced elastogenesis of adult rat SMCs seeded
within 3D collagen gel constructs maintained under static tension, to a range of TGF-β1
and HA-o dose combination. The most elastogenic dose combination (termed
elastogenic factors or EFs) is chosen from the outcomes of this study for application in
subsequent studies of this project.
Chapter 4 discusses outcomes of combined effects of EF-treatment and varying
cyclic strain frequencies within human aortic SMC-seeded tubular collagen gel constructs,
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towards improving matrix assembly and alignment. The cyclic strain frequency most
conducive to elastic matrix synthesis and alignment is evaluated and utilized in
subsequent studies.
Chapter 5 evaluates how Doxycycline-mediated MMP suppression within
cyclically strained and EF-treated SMCs seeded in tubular collagen gel constructs further
improve outcomes of crosslinked, mature matrix elastin.
Chapter 6 discusses the benefits of localized delivery of TGF-β1 and Doxycycline
from PLGA nanoparticles, over their exogenous delivery, within cyclically stretched
SMC-seeded tubular collagen constructs.
Finally Chapter 7 details overall conclusions derived from this project and
suggestions for future directions based on this work.
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CHAPTER TWO
LITERATURE REVIEW

2.1. ELASTIN: PRIMARY COMPONENT OF ELASTIC FIBER ECM
Elastin is distributed throughout the body, however it is primarily found in elastic
fibers of circulatory, respiratory and integumentary system that require elastic resilience
to maintain important tissue functions3, 62. Ultrastructure analysis of elastic fibers reveal
two morphologically distinct parts: a 10-12 nm microfibrillar component, primarily
fibrillin-1, surrounding the more abundant, amorphous core of elastin8. During early
stages of fetal development, the elastin precursor, tropoelastin, is deposited within these
fibrillin-rich microfibril templates within the extracellular space6-7. This helps the
monomer units to coalesce, allowing the Copper-dependent Lysyl oxidase (LOX) enzyme
to crosslink the units forming a mature elastic matrix43.

2.1.1. Distribution of Elastin
The elastic property of various connective tissues such as arteries, lungs, elastic
cartilage and skin is provided by a complex three dimensional network of elastic fibers
within their ECM63. These fibers are primarily made up of structural proteins such as
elastin and microfibrils, along with various glycosaminoglycans (GAG) and
proteoglycans63-64.
Elastin, the main contributor to the elastic recoil in these tissues, is the
predominant protein of mature elastic fibers65. The distribution, structural organization
and the elastin : microfibril ratio vary between tissues of different organs depending on
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physiological role, their mechanical functions and age of tissue8, 66. Elastic fibers are
associated with other essential ECM proteins like collagen, surrounded by GAGs and
proteoglycans, which support the mechanical properties specific to the tissue and help
maintain their native cell physiology 8. In the medial layer of elastic arteries, elastic fibers
form concentric fenestrated lamellae separated by collagen and smooth muscle cell (SMC)
layers, which impart resilience to the vessel wall during systolic pressures, and recoil
during diastole, maintaining blood flow and volume5. Within mammalian skin, elastin is
found primarily in the reticular dermis as large, flat, undulated and perforated sheets,
running parallel to the skin surface, which are replaced by a more microfibril-rich elaunin
fibers in the middle dermis, and oxytalan fibers in the papillary dermis consisting only of
microfibrillar glycoproteins7. The alveolar expansion and recoil during breathing is
supported by thin, highly branched elastic fibers present along the blood vessel walls
throughout the respiratory tree62. While thick elastic fibers ~ 100µm are found in elastic
ligaments of the vertebral column, a thin network of elastic fibers, ~57µm, interspersed
with collagen fibers is found within elastic and articular cartilage5, 67.

2.1.2. Chemical Composition of Elastin
Purified elastin is found to be rich in hydrophobic amino acids such as glycine
(33%), alanine (24%), valine (15%) and proline (11%), has very low acidic and basic
amino acids, and contains no hydroxylisine residues3, 68-69. The hydrophobic segments of
the elastin polypeptide, present as β-sheets, alternate with the crosslinking α-helical
domains rich in lysine and alanine residues3. The highly stable elastic characteristics are
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maintained by the presence of disulfide bonds and tetrafunctional, heterocyclic
desmosine (and its isoforms) crosslinks within the α-helical domains6, 68.

2.1.3. Elastin Synthesis and Assembly into Elastic Fibers
In humans, elastin is synthesized as tropoelastin, a 72kDa alkali-soluble protein,
by the elastin gene present as a single copy on chromosome 770-71. Tropoelastin consists
of about 750-800 residues, typically grouped into ‘hydrophobic’ domains that alternate
with lysine-rich ‘crosslinking’ domains. The hydrophobic sequences are highly repetitive
and usually consist of overlapping di-, tri-, tetra-, penta-, hexa-and nano-peptides of
aliphatic amino acids like proline (P), alanine (A), valine (V), leucine (L), isoleucine
(I)and glycine (G), of which G and V are more commonly found. The crosslinking
domains consist of lysyl residues within P-and A-rich regions. These domains are coded
for by the 36 exons of the gene, which have more than 70% homology among various
species of vertebrates72. The variations are primarily seen in the hydrophobic regions,
while domains that contribute to important structural features remain conserved. The
most conserved region of the translated protein is the positively charged, hydrophilic Cterminus, which consists of the only two cysteine residues found in the protein. This aids
in the formation of disulfide bonds3, 8, 69.
Intracellularly, like most other proteins, tropoelastin is secreted posttranscriptionally by the endoplasmic reticulum, hydroxylated on a number of proline
residues and packaged by Golgi apparatus, following which, it is transported to the
extracellular space by transcytosis, where it coascervates on microfibrillar pre-scaffolds.
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Tropoelastin transport is mediated by the elastin binding complex, a group of three cell
membrane proteins. Two of its subuints, 55 and 61kDa, form a transmembrane link
between the cytoskeleton and intracellular compartment. The third subunit, a 67kDa
protein called elastin-binding protein (EBP), binds the hydrophobic VGVAPG sequence
on tropoelastin, the cell membrane and galactosugars on microfibrils73. This binding of
galactosugars to the lectin site on EBP lowers its affinity for both tropoelastin and the
cell-binding site. The bound tropoelastin is therefore released, coascervated on fibrillin
scaffold and EBP dissociates from the membrane (Figures 2.1 and 2.2).

Figure 2.1: Schematic of tropoelastin transport into the extracellular space mediated by
the three subunits of elastin binding protein (EBP)73
Though galactosugar-containing microfibrillar proteins aid in coordinated release of
tropoelastin, an excess of galactose-containing components such as glycoproteins,
glycosaminoglycans, or galactolipids in the ECM may adversely affect elastin assembly
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by inducing premature release of tropoelastin and elastin-binding protein from the cell
surface8, 74. Secreted tropoelastin molecules aggregate in the extracellular space on loose,
pre-existing bundles of microfibrils that behave as scaffolds for elastic matrix assembly.
Microfibrils (fibrillin 1, 2, fibulin 4, 5), appear as 12nm long, electron dense tubes,
grouped in small bundles near the plasma membrane. Within each bundle, tropoelastin
molecules gradually coalesce, generating a central core of elastin. As the fibers mature,
these bundles slowly move towards the periphery8, 66.

Figure 2.2: Overview of steps involved in tropoelastin transport and assembly on
microfibrillar scaffolds in ECM. Adapted from Wagenseil, J.P., et.al, 20078

According to conventional electron microscopy, it was long believed that electron
dense microfibrils surround an amorphous matrix core. However, recently it was shown
that the amorphous appearance of elastin core was in fact an artifact, and that elastin

15

molecules are organized as 5-nm thick filaments forming a three-dimensional network
along the fiber. Further studies have shown that, besides elastin, a number of matrix
constituents such as vitronectin, LOX, decorin, osteopontin and biglycan epitopes are
also present within normal elastic fibers, which are perhaps equally important in
maintaining elastic fiber integrity.
Crosslinking of elastin is initiated by a family of copper dependent enzymes
called lysyl oxidase (LOX), which catalyze oxidative deamination of lysine residues into
allysine. Specifically, lysyl ε-amino groups present on the α-chain domains of adjacent
tropoelastin molecules are oxidized into a δ-aldehyde, an allysine. Approximately 40
lysine residues in 16 crosslinking domains of tropoelastin have been estimated to
eventually participate in forming the bi-, tri-, and tetra functional crosslinks of the
polymer that equips it with high resilience. LOX mediated crosslinking occurs early in
the assembly phase and is critical for matrix elastin formation43,

75-76

. Subsequent

formation of the elastin crosslinks by isodesmosine and desmosine occur as a series of
spontaneous condensation reaction77. Inhibition of LOX activity through copper
deficiency or through the administration of enzymatic inhibitors results in weakened
connective tissue throughout the body78.

2.1.4. Elastic Fiber Maturation, Breakdown and Turnover
Studies have shown that most of the elastic matrix deposited as a neonate, and
elastic fibers mature into completely formed matrix by around 16 years of age, following
which, very little remodeling of the matrix occurs in a healthy adult vasculature (Figure
2.3)7.
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Figure 2.3: Scanning electron micrographs showing elastic fiber formation and
breakdown with age. (1), (2) Elastin is assembled on microfibrillar scaffolds at the
fetal stage. (3 A, B and C) Mature elastic fiber bundles are formed until 16 years of
age. After this elastic fibers start to slowly and progressively degrade with age (3D,
4A, 5). Adapted from Pasquali-Ronchetti , et al., 19977

As minimal turnover occurs in healthy tissues, half life of vascular elastin is very
long (approximately 70 years). The degradation of elastin is the result of a proteolytic
cascade that involves the cooperation of several degradative enzyme types such as serine
proteases, matrix metalloproteinases, and cysteine proteases. These may be present in
latent forms under healthy physiologic conditions, and can become activated following
vessel wall injury79-80.
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Matrix-metalloproteases (MMPs), a family of Zinc-dependent enzymes, are
typically involved in elastin turnover in healthy vessels81. Vascular SMCs release
numerous MMPs that are capable of digesting individual components of the ECM and are
normally regulated by tissue inhibitors of metalloproteases (TIMPs)82. A balance between
MMPs and TIMPs is maintained at all times within healthy tissues to ensure healthy
matrix reorganization for cell migration and structural homeostasis of the vessel80, 83-84.
Integrins are the primary ECM receptors for mechano-transduction, responsible for
mediating matrix remodeling, either directly or indirectly85.

2.2. ELASTIN AND THE VASCULATURE
The largest arteries branching out from the heart, the aorta of systemic circulation,
and pulmonary artery of the pulmonary circulation, along with their main branches, the
branchiocephalic, common carotid, subclavian, thoracic, abdominal and common iliac
arteries are classified as elastic arteries. Elastin constitutes 50% of dry tissue weight of
the these arteries and plays a crucial role in maintaining unidirectional flow of blood.
They typically have an internal diameter >10 mm. These arteries further branch out into
the muscular arteries that have a lower elastic matrix content, higher number of smooth
muscles cells and a thinner intima. They have an internal diameter of 0.1-10 mm. These
further branch out to the arterioles (< 0.1 mm diameter) and the capillaries (~5 µm
diameter), that have thinner walls, more cells and serve to transport blood through all
tissues67.
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2.2.1. Elastic Arteries: Structure and Function
The elastic arteries have three main structural and functional layers: (1) the
innermost tunica intima, (2) the tunica media or the middle layer and (3) tunica
adventitia or the outermost layer (Figure 2.4). Each layer has a specific cell type and a
distinct ECM composition, which together play a role in maintaining circulation and
homeostasis throughout the body67.

Figure 2.4: Anatomy elastic artery showing the three layers of the blood vessel,
tunica intima, tunica media, and tunica adventitia. Adapted from Patel et.al., 200610

Tunica intima consists of a layer of endothelial cells resting on a basement
membrane, surrounded by a sub-endothelial space and a less conspicuous internal elastic
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lamina, which separates intima from the medial layer. The endothelial cells have flat,
elongated squamous epithelial cell morphology, with their long axis parallel to the
direction of blood flow. They are 10-20 µm in diameter and 1-2 µm thick67. These cells
are highly resistant to shear stress imparted by continuous flow of blood. Along with the
adjoining basement membrane, this layer regulates important functions to maintain
vascular homeostasis including 1) maintaining selective transport of cells and molecules
across the vessel wall, 2) preserving a non-thrombogenic barrier between blood and the
sub-endothelial layers by secreting various anti-thrombogenic substances and
anticoagulants like prostacyclin and thrombomodulin respectively, 3) modulating blood
flow and vascular resistance by secreting vascodilators like NO and constrictors like
endothelin, 4) regulating cell growth, immune response and lipoprotein oxidation, and 5)
maintaining extracellular matrix of the basal lamina. Any injury or abnormality in the
endothelial layer would therefore disrupt the vessel wall integrity and homeostasis as
seen in inflammatory diseases of the vasculature such as aortic aneurysms86.
Tunica Media is usually the thickest layer of the elastic vessel wall. It is defined
by the internal elastic lamina (IEL) following the intima and external elastic lamina (EEL)
adjoining the adventitia. Elastin is distributed as fenestrated sheets or lamellae, the
number and thickness of which vary linearly with the blood pressure and cyclic tension
experienced by the wall5, 87. Concentric layers of SMCs, collagen fibers and thin layers of
proteoglycan-rich ECM are present between the elastic lamellae. This layer helps
accommodate the pulsatile flow of blood and provide mechanical resilience to the vessel.
While elastin acts a reservoir of tensile load, distributing stresses evenly throughout the
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vessel wall, collagen bears the tensile load and restricts the extent of distension5. The
SMCs are spindle shaped with an elongated nucleus, arranged in a low-pitch spiral with
respect to the long axis of the vessel67. Though it was found that their elimination from
the wall of a mature aorta does not significantly alter its static mechanical properties, the
cells actively respond to changes in cyclic stretch, endothelial growth factors and
inflammatory processes, in remodeling the medial ECM9. The secretion of collagen and
elastin by these cells is dependent on the frequency, magnitude and duration of cyclic
strain transmitted to the SMCs5. Under normal homeostatic conditions, they remain in a
contractile, non-proliferating phenotype, expressing surface markers such as SM-α-actin,
calponin, SM22, SM-myosin heavy chain etc88. However under pathologic conditions
such as hypertension, injury to endothelium, inflammatory reactions, response to various
growth factors such as transforming growth factor-β1 (TGF−β1), tumor necrosis factor-α
(TNF-α), platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF),
insulin-like growth factor-1 (IGF-1), interleukin-1 (IL-1) etc, SMCs can switch to a
proliferating, synthetic phenotype, which in turn also alter the vascular matrix
composition and mechanics89-90. This has been discussed in detail in subsequent sections.
Tunica adventitia is the outermost layer of the vessel wall, defined as the region
outside the EEL in elastic arteries. It consists of fibroblasts that maintain a matrix rich in
collagen type-I, which helps prevent rupture of the vessel at high pressures. Vasavasorum, the small blood vessels providing nourishment to large elastic and muscular
arteries and vessel innervations are usually present in this layer. Recent studies have
shown that this layer may possess injury-sensing capabilities and home progenitor cells
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capable of differentiating into SMCs67. Recent studies have shown that the adventitia
may be sensitive to injury and may also house progenitor cells capable of repopulating
the media and intima91.
Functionally, the elastic arteries facilitate in maintaining the uniform flow of
blood through the vasculature, while at the same time maintaining blood volume and
pressure. During the systolic phase, the ventricles contract and pump blood into the
elastic arteries, and simultaneously, the arterial wall distends. The extent of distension is
limited by the presence of collagen fibers in the medial and adventitial layers. Following
this, during diastole, when the heart does not generate additional pressure, these vessels
recoil due to the presence of elastic fibers, therefore maintaining blood flow, restoring
baseline pressure and triggering the closure of the semilunar valves to prevent back-flow
of blood into the heart, while the cycle continues. In effect, these arteries store a portion
of the stroke volume with each systole and release the same during diastole. This helps
decrease the load on the heart, minimizes systolic flow and maximizes diastolic flow
through the arterioles, a phenomenon called ‘windkessel effect’5.

2.2.2. Matrix and Cellular Components of elastic arteries and their roles
While on the one hand, the vascular ECM is responsible for supporting the
structural and mechanical properties of the vessel wall, they also provide instructions to
regulate cellular phenotype by binding to specific cell receptors to activate gene
expressions, control growth factor activity and maintain cell functions. The ECM
comprises of three main components: (a) structural proteins like elastin and collagen, (b)
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fibrous proteins like fibrillin, laminin etc, and (c) proteoglycans. These interact with each
other, the cellular components and the surrounding environment to maintain homeostasis.
Collagen is present within the ECM of all three layers of the vessel wall and is
primarily responsible for its load bearing properties. It consists of three α-helical
polypeptide chains, composed of Gly-Pro and 4-Hydroxyproline, of which the side chains
of Gly alone occupy the interior of the helix, while that of Pro and Hydroxy-pro face
outward, helping in coalescing and crosslinking pro-collagen molecules92. 17 different
collagen types have been identified in a mouse aorta depending on the helical size, of
which collagen types I, III, IV, V and VI were found to have highest expression levels,
whose distribution varies depending on the region in the vasculature. Types I, III and IV
are fibrillar collagen, of which I and III are mainly load bearing. While type I is
predominant in the media and type III is primarily found in the adventitia4. Mutations in
genes encoding either of the two types result in fragile blood vessels prone to rupture.
Type V collagen is found within the media and basement membranes, and plays a role in
collagen fibril nucleation and assembly. This has been demonstrated in mice deficient in
this gene that die during early stages of embryogenesis due to lack of fiber formation.
Type VI is also a fibrillar collagen that associates with fibrillin-1 of oxytalan fibers,
connecting the elastic lamellae with the basement membrane and the SMCs with other
ECM components92. Lysyl oxidase helps crosslink fibrillar collagen, by converting the
lysine and hydrozylysine residues in the non-helical telopeptides into aldehydes, forming
bi-functional crosslinks. 1-4 crosslinks are found per collagen unit. This helps aggregate
the 10–30 nm diameter collagen fibrils into densely packed 500-3000 nm thick fiber
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bundles for achieving much higher tensile properties43, 76, 93-94(Figure 2.5).

Figure 2.5: Schematic of collagen fiber assembly showing aggregation of collagen
fibrils into densely packed 500-3000 nm thick fibers95
The amorphous ground substance surrounding cells of the vasculature consist of
glycosaminoglycans (GAGs) and proteoglycans (PGs). GAGs (e.g., hyaluronan,
chondroitin sulfate, dermatan sulfate, heparin sulfate, and keratin sulfate) are long unbranched polysaccharides consisting of a repeating disaccharide unit of an N-acetylhexosamine and hexuronic acid, either or both of which may be sulfated95-96. PGs are
complex macromolecules that contain a core protein, covalently bound to at least one
GAG chain97. They are closely associated with collagen and elastic fibers in the ECM .
These molecules are characterized by high anionic charge densities, due to the presence
of sulfate and carboxylate groups on their uronic acid residue95. These polysaccharides
can therefore become highly hydrated and resist compressive forces, while at the same
time permit diffusion of nutrients, hormones and metabolites between blood and tissue.
The importance of these properties is obvious in certain avascular tissues like cartilages9596

.
As discussed in the previous section, in elastic arteries, and most muscular arteries,
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elastin contributes up to 50% of the tissue’s dry weight. Within these vessels, elastin is
organized as concentric fibers and lamellae around the vessel lumen, that alternate with
layers of SMCs and collagen within the tunica media. The roles of elastin in elastic
arteries is discussed in detail in the following section3.

2.2.3. Role of Elastin in Physiochemical Regulation of Vascular Cells
ECM-cell interactions in all tissues is synergistic that tightly regulate
developmental transitions, response to injury and overall homeostasis. Elastin, being an
important ECM component of elastic tissues, therefore contributes to both structural and
biochemical state of a tissue and the cells within. This section elaborates the various
functions of elastin as an ECM protein.
SMCs interact with their ECM components through anchoring junctions like
adherins and hemidesmosomes98. This in turn regulates their proliferation, migration, and
in general, cell viability99. Mature, intact elastin also affects actin stress fiber orientation
within SMCs. The integrity of the ECM is therefore important for regulating cell
phenotype. For example, in healthy, mature vascular tissues, SMCs exist in a quiescent
state, whose migration is inhibited by the intact, elastin-rich ECM. The matrix
remodeling maintained by a tight balance between MMPs and TIMPS, is also achieved
through SMC interaction with intact elastin. However, during an injury to the media, that
causes degradation of the elastic matrix, the healthy SMC phenotype is found to switch to
a synthetic, non-contractile, proliferative phenotype, characterized by increased migration,
proliferation and secretion of disorganized, fibrous ECM18. In several in vitro studies, this
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phenomenon was supported by the observation that exogenous elastin added to healthy or
diseased SMCs cultured within collagen gels, inhibited their proliferation and migration
in a dose dependent manner100.
Elastin peptides, generated as a result of elastin breakdown, also increase SMC
motility and proliferation. These peptides are known to induce tyrosine-dependent
phosphorylation of β-tubulin, various microtubule associated proteins, α-actin and
troponin-T, which increase SMC cytoskeletal reorganization and motility. Additionally,
elastin derived peptides are also known to induce MMP release, which further contribute
to matrix remodeling98, 101.
Arterial calcification, a common phenomenon in various inflammatory vascular
pathologies localized to regions of intima and media, usually occurs following lipid
deposition, macrophage infiltration and SMC proliferation102. Studies have shown that
genetic or induced aberration of the lamellar elastin, or the associated microfibrils that
mediate SMC interaction with elastin, can interrupt SMC-elastin signaling and induce
SMCs to assume an inflamed, synthetic phenotype, characterized 44,45 by increased Ca2+
influx, subsequent calcium deposition and matrix hardening80,
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. Elastin peptides

interact with the elastin-laminin receptor (ELR) present on the surface of various cell
types like fibroblasts, lymphocytes, SMCs and ECs. When activated, the ELR receptor
induces a G-protein linked activation of phospholipase C104-105. This results in the
increase in intracellular concentration of calcium, which in turn phosphorylates MAP
kinase, triggering a series of events like overexpression of MMPs, increased ionic influx
etc106-107.
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2.2.4. Contribution of Elastin to Vascular Mechanics and Vascular Homeostasis
The stresses imparted on a vessel wall include (1) shear stress from blood flow
across the lumen, (2) longitudinal stress from surrounding tissue and (3) circumferential
stress from surrounding tissue5. SMCs of adult elastic arteries contribute little to the
passive mechanical properties of the vessel, unlike in smaller vessels. The complex ECM
they synthesize, therefore defines the mechanical properties of a mature vessel. These
include: (a) high resilience, that restore a large portion of the energy utilized during
systole, by elastic recoil during diastole, (b) subsequent low hysteresis or energy loss
during cardiac cycles, and (c) non-linear elasticity, that protect the wall from rupture by
stiffening with increasing pressure. This non-linearity exists due the deformation of
elastin at low strains, and collagen at higher strains. For the same reason, single constants
like Young’s modulus cannot be used to describe vascular wall properties. It is therefore
represented in terms of physiologic modulus, which corresponds to incremental elastic
stress values within the physiological strain values. Physiologic modulus for a human
thoracic aorta is 0.6-1MPa (Figure 2.6)5.
The medial elastin, woven into an interconnecting lamellar network, transfers
stress uniformly throughout the vessel wall. Collagen, arranged in bundles between the
lamellar networks, become circumferentially aligned as pressure increases, but lack a
definite arrangement at physiological pressures108. Physiologic pressure is the region in a
stress-strain curve, where the stresses are transferred from the elastic to the inextensible
components of the wall5. Elastin has high reversible distensibility and deforms to large
extensions with small forces. Its properties of recoil are said to be ‘rubber’ like, i.e., when
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unstretched, it has maximum disorder, therefore maximum entropy. When stretched,
order is introduced in the direction of stretch, reducing entropy. When the external force
is removed, recoil occurs spontaneously, to return to the original state of maximum
entropy and disorder65, 80, 109-110.

Figure 2.6: Non-linear tensile properties of elastic arteries. Elastin is the primary loadbearing protein of these vessels within physiologic strains5

To establish the importance of elastin in vascular mechanics, a study was
conducted in a knock out model of mice deficient in elastin gene (ELN). It was observed
that these mice had tortuous, stenotic and stiff vessels that showed little diameter change
between systole and diastole. Due to the absence of elastic recoil, the ventricular
pressures increased in an attempt to maintain cardiac output, and SMCs proliferated on
the luminal side to lower wall stress by increasing wall thickness and decreasing inner
diameter. The proliferation continued till the lumen was completely occluded18.
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SMCs continually respond to changes in hemodynamic pressures and remodel the
ECM to normalize stresses across the wall. During development, while these changes are
important to layout the required vessel matrix, in adult tissues, these responses often
result in pathological remodeling of the vessel. Since collagen is the ECM protein most
expressed by SMCs, remodeling involves deposition of collagen, which increases wall
stiffness. This can further change hemodynamics of the vessel wall and start a negative
feedback cycle that can lead to multiple cardiovascular complications5.

2.3. VASCULAR ELASTINOPATHIES
Abnormalities of vascular matrix elastin may be broadly classified into two types:
(a) genetic and/or congenital, and (b) acquired vascular disease. While most genetic
diseases lack the required signaling pathway to lay down a mature elastic matrix,
acquired diseases usually involve an injury induced inflammation, where macrophagederived proteases degrade the vascular elastin. In either of these cases, elastin-smooth
muscle cell (SMC) signaling pathways are disrupted, causing SMCs to switch to an
activated, synthetic phenotype. This in turn causes downstream effects of SMC hyperproliferation and medial thickening, further results in decreased arterial compliance and
pathogenesis of the vasculature14.

2.3.1. Genetic Disorders
Genetic abnormalities affecting the elastic matrix can occur due to mutations in
the genes encoding elastin, fibrillin (FBLN), such as in Marfan’s syndrome111, and
fibulin-4 (FBN4)112. While, defects in the elastin gene (ELN), such as Williams-Beuren
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syndrome113, Supravalvular Aortic Stenosis (SVAS)114, and Autosomal recessive Cutis
Laxa115, directly result in impaired synthesis and deposition of mature elastic fibers,
mutations in fibulin and fibrillin genes lead to defective microfibrillar scaffolds, which in
turn impair matrix assembly15. These defects primarily affect the cardiovascular system,
and can often be fatal. They are discussed in further detail in Table 2.1.
Mutant
gene

Effects

Williams–
Beuren113
Syndrome,
SVAS114

Elastin gene
on
chromosome
7q11

Abnormal deposition of elastin in arterial walls,
increased proliferation of SMCs, formation of
hyperplastic intimal lesions; elastinolytic enzymes
secreted by arterial smooth muscle cells contribute
to arterial lesions

Marfan’s
syndrome111

Fibrillin-1
gene on
chromosome
15q21.1

Defective
elastic-fiber
assembly;
increased
microfibril/elastic fiber degradation; enhanced
TGF-b signaling, Results in Vascular disease,
including aortic aneurysms and dissections, and
skeletal and ocular defects

Autosomal
recessive
Cutis Laxa115

Elastin gene
on
chromosome
7q11

Abnormal structure of dermal and vascular elastic
fibers Results in inelastic skin, severe aortic disease
and pulmonary emphysema

Disease

Table 2.1: List of genetic abnormalities affecting the elastic matrix proteins

2.3.2. Acquired Disorders: Abdominal Aortic Aneurysms
Vascular pathologies arising from any injury to an intact vessel wall or in the
presence of calcified or lipid deposits would elicit a cascade of inflammatory response
starting with the infiltration of various MMPs and lymphocytes16, 61, 83. This results in
phenotypic variations in SMC behavior and response, massive proteolysis and matrix
reorganization. Under such conditions, the elastic matrix is degraded at an accelerated
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rate resulting in generation of elastin peptides (EP) 104. EP, through their interaction with
elastin-laminin receptors (ELR) on various inflammatory cells, further elicit a variety of
pathologic effects such as MMP over-expression, greater Ca2+ influx, enhanced
vasorelaxation and chemotactic activity19, 107, 116. Studies have shown that soon after the
initiation of an inflammatory response, mRNA expressions of both tropoelastin and procollagen increase within vascular SMCs48. While sufficient deposition of collagen matrix
is observed due to regeneration associated with fibrotic cell response, elastic matrix
regeneration is highly deficient relative to proteolytic elastin degradation. The failure to
reinstate a healthy matrix, when damaged by injury or disease (as seen in aortic
aneurysms), or when congenitally malformed or absent (Marfan’s syndrome), can
therefore severely compromise tissue homeostasis14.

Figure 2.7: Cartoon representing AAA. AAAs are characterized by a localized
dilatation of abnomial aortic wall to > 50% their diameter

AAA is defined as localized thinning and dilation of aortic walls of abdominal
aortae leading to more than 50% increase in their original diameter (Figure 2.7)

16-17

.

Initiation and progression of AAA has been attributed primarily to chronic matrix
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proteolysis by MMPs and inflammatory cells that infiltrate the vessel wall in response to
atherosclerosis, calcified lipid deposits, vascular hypertension or inherited conditions11, 16.
This is coupled with the absence of intrinsic signals in adult vascular cells to regenerate
lost elastic matrix or to successfully repair diseased vessel wall18. The accelerated loss of
elastic matrix and vessel wall integrity, and continuous fluctuations in hemodynamic
pressures lead to abnormal ballooning of an aneurysm19. As mentioned earlier, AAAs
typically grow about 1 cm/year to catastrophically rupture causing hemorrhage and
embolisms, with fatality rates of approximately 80%. In the United States alone, the
estimated incidence for AAAs is about 60 in every 100,000 people per year16, 20.

2.4. STRATEGIES TO RESTORE ELASTIC MATRIX
As discussed so far, elastin plays important roles in maintaining vascular
homeostasis, which when compromised can lead to various complications, and even be
fatal. Its restoration is therefore crucial in reinstating homeostasis. Various strategies
have been developed so far that directly and indirectly target elastin restoration. These
can be broadly grouped into (a) preservative, (b) replacement and (c) regenerative
strategies.

2.4.1. Strategies to Replace Diseased Vessel Wall
When stability of a diseased vascular wall is severely compromised and
aneurysms dilate beyond a critical diameter, vascular grafts are surgically introduced to
isolate the aneurysm and reduce the load on the vessel wall to prevent its rupture.
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Vascular grafts for elastic arteries can be allogenic, xenogenic or artificial polymeric
grafts. Autologous grafts like saphenous vein and mammary artery are usually used for
replacing vessels with smaller diameters117. Allogenic grafts from deceased fetuses,
cryopreserved tissues, cadavers umbilical cords have long been investigated as suitable
tissue replacements for aortic aneurysms, among many other tissues due to similarities in
size and mechanical properties. However issues like donor-specific immune rejection and
high demand-supply ratio of these grafts have made them less popular alternatives118.
Despite developments to improve donor-rejection like uptake of immune-suppressors by
the recipient, decellularization and removal of immunoreactive epitopes and globular
proteins from the grafts prior to implantation, their long-term stability and compatibility
continues to be a problem119.
To minimize donor-recipient supply ratio for transplants, xenogenic grafts have
long been an attractive alternative. However, these grafts experience higher levels of
immune rejection, primarily through complement activation119. Additional issues like
disease transmission, permanent alternation to genetic code, higher thrombogenecity due
to lack of endothelialization, compliance mismatch and mechanical stiffening posttransplantation, physiological and biochemical variations in blood viscosity, liver
metabolism and incompatibility of coagulation factors further lead to long-term graft
rejection and implant-based complications120-121. New strategies to improve long term
graft compatibility like transgenic modifications in pigs to express human complementregulatory proteins are currently being researched122.
Replacement of an aneurismal vessel using synthetic grafts is currently the most
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common approach to treat aortic aneurysms. While they are able to overcome the
immune-rejection issues of allogenic and xenogenic grafts, they are also readily available
and have lower risk of implant-related disease transmission123. The stent-grafts currently
in the market follow similar designs. They primarily consist of a metal skeleton called
‘stent’ that provides a frame for a polymeric ‘graft’, which are either sutured or bonded
together. The graft is usually an elastomer like Dacron™ or poly(tetrafluoroethylene)
(PTFE), while metal alloys like cobolt-chromium and stainless steel make up the stents24.
Various stent-grafts currently available in the market are FDA approved (Zenith®
Endovascular Graft, Cook Inc.; Gore Excluder®, WL Gore & Associates Inc.) while
several others are under various stages of clinical trials, as depicted in124. The grafts are
implanted either by a highly invasive open surgery, or a minimally invasive, catheterdelivered endovascular repair (EVAR), as shown in (Figure 2.8). Both these techniques
have their own benefits and shortcomings, and the choice of stent-graft or the delivery
mode depends on the morphology of the disease, the patient and the surgeon26. Though
synthetic grafts help isolate the aneurysm and prevent vessel rupture by providing an
alternative conduit to blood flow, they are faced with several device-related issues like
lack of endothelialization, various types of endoleaks, implant migration and fatigue,
which affect long-term patency of the implant, and often require additional surgical
intervention25-26. Moreover the graft materials have higher tensile properties compared to
native vessel (~170Mpa for a graft vs. 800-1000 kPa for native aorta) which also lead to
compliance mismatch24. While these grafts may replace the structural role of a blood
vessel, they do not accommodate for the functional properties of elastic vessel ECM,
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neither do they regress the disease25.

Figure 2.8: Cartoon representation of EVAR (left) vs. open surgical repair to treat
AAA using synthetic vascular grafts. Adapted from Encyclopedia of Science

2.4.2. Strategies to Prevent Matrix Degradation
As discussed earlier, matrix degradation is accelerated at the site of aneurysm,
primarily due to the presence of inflammation induced MMP activity. Preservative
strategies therefore target decelerating, or ideally, arresting matrix degradation to prevent
or prolong the need for surgical intervention. These strategies mainly use
pharmacological methods to regulate transcription factors, inhibit MMP and other
protease activity, and introduce crosslinking agents etc. that stabilize matrix degradation.
While these approaches slow down the rate of aneurysm progression and reduce medical
expenses, they do not restore matrix integrity, and are also associated with several side
effects.
Expression and production of various MMPs by resident SMCs and fibroblasts at
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the site of aneurysm accelerates matrix degradation. MMPs 2 and 9 in particular have
been found to accelerate elastin degradation12, 125. Blocking MMP production therefore
has been an obvious strategy to prevent matrix degradation. Various anti-inflammatory
drugs, antibiotics, exogenous tissue-inhibitors of metalloproteases (TIMPs) and inhibitors
of MMP transcription factors have been investigated to inhibit MMP synthesis and
activity at the site of injury20.
Doxycycline (DOX) is a modified tetracycline compound that has been widely
administered as a broad-spectrum antibiotic126. Known to be a global, non-specific MMP
inhibitor, systemic delivery of DOX has been clinically shown to reduce the rate of AAA
growth and progression of disease45-47. Studies exploring the mechanisms of MMP
inhibition have found DOX to significantly reduce protease activity both at transcription
and translation steps of the protein synthesis127-128. Several groups have also specifically
evaluated its effects on gelatinases, i.e., MMPs -2 and -9, proteases that are up-regulated
most in the aneurysm wall and primarily responsible for elastolytic activity, both in vivo
and in vitro129-130. In addition to reducing mRNA expression and total protein production,
DOX also alters the conformation of both the zymogen and the active enzyme by binding
enzyme-associated Ca++131. This makes the proteins more susceptible to proteolysis,
resulting in their fragmentation into smaller molecular weight fractions and an
irreversible loss of enzyme activity131-132. Studies on in vivo rodent models of AAA133-134
and aortic organ cultures135-136 have shown a direct correlation between DOX-mediated
suppression of gelatinase activity and significant reduction in elastin degradation in the
vessel wall.
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Anti-inflammatory drugs like Aspirin and stanins are commonly used by patients
with AAA20. Other inhibitors of MMP activity like indomethacin, dexamethasone and
green tea catechins for MMP 9 and trapidil for MMP 2 have also been studied20. Use of
exogenous TIMPs in the form of either synthetic TIMP or an adenoviral vector with a
native TIMP1 cDNA have shown to inhibit SMC migration and reduce neointimal
hyperplasia formation in a vascular injury model in rats12. Inhibitors of MMP mRNA
transcription like NF-κβ have also been investigated towards preventing matrix
degradation137.
Under healthy conditions, various protease inhibitors bind to proteolytic enzymes
like elastases, and prevent uncontrolled matrix degradation. Absence of such inhibitors,
such as serine-protease inhibitors seen in anti-trypsin deficiency, confirms the importance
of these inhibitors. Another strategy to prevent elastin degradation therefore involves the
use of exogenous elastase inhibitors or transfection of vascular SMCs with genes like α-1
antitrypsin138.
Stabilization of matrix elastin within an aneurysm and prevention of further
degradation by the use of chemical crosslinking agents is another approach to preserve
elastin. Pentagalloyl glucose (PGG), a polyphenol derived from tannic acid, delivered
periadventitially in a vascular injury model in rats, is shown to preserve elastic matrix
integrity by specifically binding to arterial elastin, therefore inhibiting elastin
degeneration attenuating aneurismal progression. PGG however is not shown to interfere
with pathologies related to the disease like inflammation and calcification139.
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2.4.3. Strategies for In vitro Tissue Engineering and In situ Repair of Vascular
Elastic Matrix
The strategies discussed so far only address replacing mechanical properties of an
elastic tissue, but are unable to compensate for the physiochemical roles of elastin. Tissue
engineering techniques offer potential alternatives to address both these essential
requirements for successful restoration of an elastic vascular wall. Though a large
section of tissue engineering research has been devoted to regenerating completely
functional blood vessels, obtaining a mature elastic matrix continues to be a challenge. So
far, scientists have not created a viable vascular graft that possesses the necessary
complex mechanical properties as well as mimics the biological function of a native
artery, specifically elastin, but much progress has been made.
Elastic fiber formation involves several steps of coordinated intracellular
and extracellular activities. Strategies to regenerate elastin have used various
combinations of cell types, culture environments, scaffold materials, growth factors and
dynamic conditioning, each of which, independently and in combination, contribute to
different levels of elastin synthesis and matrix deposition10. Each of these parameters
influencing elastic matrix output are discussed in further detail as follows.

2D vs. 3D Microenvironments: SMCs in native arteries exist within a 3-dimensional
collagen matrix, interspersed with lamellar elastin. Isolated SMCs within a 2-dimensional
culture environment would therefore evoke different responses in terms of cell phenotype
and morphology, expression of various cell markers and growth factors, and type and
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ultrastructure of matrix produced. Several studies have compared SMC behavior in 2-D
culture plates to a 3-D scaffold environment. In one such study, RASMCs cultured on
hyaluronic acid based scaffolds (gels) demonstrated an increased amount of elastin
production, both soluble and insoluble, on the hyaluronan gels, compared to polystyrene
culture plates. Microscopic analysis of the elastin structure further showed smooth,
highly fenestrated sheets composed of fibers, visible along the sheet edges34. In another
study, SMCs cultured within 3-D collagen gels showed lower rates of cell proliferation
and matrix deposition, both collagen and elastin, compared to that seen in 2D collagen
matrices. Similar trends were observed in synthetic scaffolds such as polyglygolic acid
(PGA) and poly-lactic-co-glycolic acid (PLGA) as well. It has been shown that the cells
acquire a more contractile, non-proliferative phenotype, much like in an in vivo condition,
as opposed to a synthetic, proliferative phenotype within 2-D cultures140.This was
additionally confirmed with the observation that tyrosine phosphorylation of FAK and
the number of focal adhesions were far lesser in cells within 3-D collagen matrix, than
those in 2-D cultures. Gene expressions of p21 and TGF-β1 were also shown to be higher
in 3-D cultures141.
Though SMC behavior within 3-D cultures also depend on the nature of scaffold
used, apart from several other culture conditions, it is reasonable to believe that to
translate elastogenic response into vascular graft application, 3-D cultures would be
imperative28.

Growth Factors─Induced Elastogenesis: Of the many growth factors investigated in the
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field of regenerative strategies, insulin-like growth factor-1 (IGF-1)142-144, TGF-β family
of growth factors38, 145 and human recombinant interleukin (IL-1β)146 are found to be
elastogenic at various levels of elastin synthesis and matrix formation. Several methods
of delivering these growth factors have also been explored in various tissue engineering
applications, for example, surface tethered or microsphere encapsulated growth factor
delivery. Variables that determine efficiency of release profile include polymer used, its
pore size, concentration and molecular weights of factors delivered and solvent the
release profile is studied in. However, no direct correlation between delivery mode and
elastogenesis has been established147.
Several studies have demonstrated dose-dependent elastogenic induction of IGF-1
in both confluent cell cultures and in vivo delivery to rats, primarily in terms of
tropoelastin synthesis and mRNA expression. Elastogenic benefits of in vivo
administration of IGF-1 to rats (1.2 mg/kg/day), was found to be tissue and age specific.
While increased tropoelastin synthesis and matrix deposition was observed in the rat
aorta, lung tropoelastin mRNA levels were unaffected. This phenomenon, though
observed throughout the lifetime of the rat, was found to diminish with age142-144.
Studies have also established the contribution of TGF-β family of growth factors
to elastin synthesis during fetal development and in tissue repair. One such study
examined the effects of TGF-β1 and TGF-β2 on human elastin mRNA abundance,
promoter activity, and mRNA stability in cultured human skin fibroblasts and found that
with varying concentrations of TGF-β1 or TGF-β2 for 24 h resulted in a dose dependent
increase in the elastin mRNA steady-state levels, with a maximum enhancement of
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approximately 30-fold being noted with 1 ng/mL. These results demonstrate that TGF-β1
and TGF-β2 are potent enhancers of elastin gene expression and that this effect is
mediated, at least in part, post-transcriptionally38, 145. In addition, TGF-β augments LOXmediated crosslinking of soluble tropoelastin into a mature, insoluble matrix layer38.
Besides growth factors, various biomolecules such as LOX helps to crosslink the
tropoelastin to give elastic fibers148. In the absence of LOX, tropoelastin tends to
associate with GAGs due to the presence of amino groups in the elastin lysine residues,
which offer positive charges for binding with negative charges of GAGs43. Besides, in the
absence of LOX, such electrostatic interaction could be important and prevent newly
synthesized tropoelastin molecules from spontaneous random aggregation far from the
cell surface. Elastogenic benefits of Cu ions/nanoparticles149, calcitriol and retinoic acid
have also been demonstrated in several studies150-152.

HA as an Elastogenic Stimulator: HA is a type high molecular weight GAG found in the
ECM of many tissues. It consists of N-acetyl-D-glucosamine (GlcNAc) and D-glucuronic
acid (GlcA) repeats linked by a β1-4 glycosidic bond. The disaccharide units are linked
by β1-3 bonds to form the HA chain153-155. HA is known to influence various physiologic
functions such as morphogenesis, embryonic development, tissue stability, cell
proliferation, remodelling, migration, differentiation, angiogenesis and wound healing.
This is suggested to be achieved through its interaction with a set of HA-binding matrix
and cell surface receptor proteins called hyaladherins156-158. Among them, CD44, a cell
surface glycoprotein with a molecular weight of ~85 kDa, is known to play an important
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role in HA binding to the cell surface156, 159. The presence of pro-inflammatory cytokines
like IL-1, and growth factors like EGF, TGF-β and BMP-7, is further known to increase
transcription levels of CD-44, therefore improving cell-HA interaction154-155. Studies in
vascular, pulmonary and dermal tissues have reported a close association between GAGs
such as HA and heparin sulfate, and proteoglycans such as versican160. Unlike GAGs like
dermatan and chondroitin sulfates, HA was found to support elastic fiber formation by
playing a key role in the synthesis, organization, and stabilization of elastin by VSMCs42.
This is attributed, in part, to the role of HA in synthesis and organization of microfibrils
(fibrillin), a precursor for elastic fiber deposition, and in part, to its binding of versican,
which in turn interacts with microfibrillar proteins like fibulins-1 and-2, and elastinassociated proteins to form higher-order macromolecular structures important for elastic
fiber assembly158. Recent studies also provide evidence that due to the presence of
charged lysine residues, soluble tropoelastin molecules are coecervated on the highly
anionic surfaces of HA, to facilitate LOX-mediated crosslinking into an insoluble matrix.
HA is also known to stabilize elastin fibers against degradation by elastases43. Several
studies have also been conducted to explain the size-specific effects of HA. Native HA is
a long-chain, stable polymer, with molecular weight > 1000kDa (HMW HA). It hydrates
the ECM and binds growth factors and smaller GAGs. On the other hand, smaller
fragments of HA like Low molecular weight HA (LMW HA) ~100 kDa, and HA
oligosaccharides (HA-o) ~ 2-10 kDa, are capable of binding to cell surface receptors in a
monovalent manner resulting in the stimulation of specific cell signaling cascades, thus
161

influencing their metabolic functions

. LMW HA are synthesized from enzymatically
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digested HMW HA and are found in association with proliferating ECs and SMCs.
Recent studies have also reported that HA 4-mer is the minimum size for HA-SMC
interaction153 . Previous studies conducted in our lab have established size-specific effects
on elastogenesis by RASMCs44, 162-163.

Role of Mechanical Stimulation In Matrix Assembly: Mechanical conditioning is
another consideration for tissue engineering vascular grafts. Elastin synthesis by vascular
SMCs is very sensitive to magnitude, frequency, duration and type of strain applied164-165.
Numerous studies have been conducted to study the effects of dynamic conditioning on
elastogenesis. While shear stresses induce apoptosis and detrimental cell response in
VSMCs, the application of cyclic mechanical stretch simulating distension experienced
by medial SMCs in vivo significantly influence the phenotype, alignment, matrix
deposition, and growth factor release by both native and cultured SMCs58, 164-165. Recent
studies have demonstrated that SMCs, isolated from both rat and human aortae, respond
positively to radial and cyclic strains of < 10% by improving collagen compaction, tensile
strength, circumferential alignment of cells and matrix, and up to a 2-fold increase in
elastin mRNA production 57, 59, 164-166. Changing the frequency of cyclic strains was found
to play a more significant role in regulating the alignment of vascular SMCs in an intact
actin filament-dependent manner; frequency of 1.25 Hz for cyclic strains between 2.5%10% was found to be most effective in influencing SMC response167-169. Cyclic stretchinduced matrix synthesis has been found to be regulated by a tyrosine-kinase dependent
TGF-β pathway170. A mentioned earlier, integrins play a primary role in

43

mechanotransductive effects of external stimuli on vascular cell response85, 171. Excessive
strains of over 10% and beyond 5 Hz frequency have been found to induce apoptotic
response mediated via integrins164.

Scaffolding Materials for Elastic Matrix Engineering: Scaffolds provide a 3-D template
for cellular infiltration and neo-tissue synthesis. Once the desired tissue is formed, the
scaffold material must ideally degrade into non-toxic byproducts. Scaffolds can be
broadly classified into (a) natural and (b) synthetic scaffolds. Apart from the type of
scaffold used, various culture parameters like addition of biomolecules, cell type,
duration of culture, application of mechanical stimuli etc., are interdependent and impact
final outcomes of elastic matrix. Table.2.2 gives an overview of various scaffolds
investigated so far in combination with these parameters towards elastic matrix outcomes.

Targeted Delivery of Elastogenic Factors: In the previous sections, we discussed various
biomolecules as that have been demonstrated, or have the potential for use in elastic
matrix regeneration and repair. The primary considerations in translating their benefits
demonstrated in vitro, into in vivo clinical use is determining an effective dose range, and
more importantly the mode of delivery. This is especially true with the use of
biomolecules that induce a variety of repose depending on their concentrations and tissue
within AAA, at similar doses, TGF-β1 induces antagonistic and adverse reactions within
TAA60, 185. It is therefore crucial to develop strategies that can specifically target a tissue
site and have precise control over their delivery186-188. Strategies for targeted delivery of
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Scaffold

Collagen Type
I

Cell source,
culture
duration
Human
aortic
SMCs, 4-8
days
RASMCs, 5
weeks
Adult
RASMCs, 3
weeks

Fibrin

Silk fibroinbased scaffolds

RASMCs,
neonatal
RASMCs, 4
weeks
Human
aortic ECs+
SMCs, 15
days
Rat SPCderived
SOCs, 3
weeks
Neonatal
RASMCs, 3
weeks

Culture conditions

Elastogenic outcome

References

10% Radial, cyclic
strain

 2-fold mRNA
expression

172

2.5% - 10% Cyclic
strain

Matrix elastin aligned
circumferentially
Tropoelastin
differences negligible,
5-fold  matrix elastin,
elastic fibers oriented
in direction of strain
 Matrix elastin and
fibrillin 1 deposition
compared to control
and collagen scaffolds

Static strain, TGFβ1, HA-o

TGF-β1, insulin

173

28, 31-32

33

-

Platelet-derived
growth factor-BB

Micro-textured
hylan surfaces

Hyaluronic
acid based
scaffolds

PGA

59

Adult
RASMCs, 3
weeks

Surface tethered HA

Canine
Carotid
SMCs, 25
days

5 % strain, 75
beats/min
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High mRNA
expression, low matrix
elastin
174

Differences in matrix
elastin content
insignificant, elastin
present as fenestrated
sheets and loose fibers
(~400 nm)
 tropoelastin, matrix
elastin, desmosine
crosslinks, tightly
continuous and
fenestrated elastin
sheets within fibrillin
microtubules
Matrix elastin around
regions of high cell
densities alone

34, 175

44, 162-163
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PGA+Polycapr
olactone

Bovine
ECs+
SMCs+fibro
blasts, 2
weeks

Polyurethane

Human
coronary
artery SMCs

Polyhydroxyal
kanoate

PCL
Poly(glycerol
sebacate)
(PGS)

Cell sheets

Rabbit
aortic
SMCs, 16
days
Adult
RASMCs,
16 days
Baboon
aortic
SMCs, 3
weeks
Tubular
layers of rat
aortic SMCs
transfected
with splice
variant
versican
(V3)

Concentric layers of
cells-seeded PCL
and PGA, graduated
Pulsatile perfusion

Elastic matrix layout
similar to native
arteries

TGF-β1

 Tropoelastin mRNA
expression, matrix
elastin compared to
2D scaffold

178

-

 Insoluble elastin
levels in higher 4HB
content

179

Electrospun PCL,
TGF-β1, HA-o

Pulsatile perfusion

Absence of
ascorbate in medium

Negligible mRNA
expression changes,
 matrix elastin
Circumferentially
aligned elastic fibers,
19% of total arterial
elastin
 mRNA expression
of tropoelastin,
fibulin-5, fibrillin-1, 
LOX mRNA
expression, 
deposition of
tropoelastin, matrix
elastin and desmosine
crosslinking

177

180

169, 181

182

Table 2.2: Strategies using various combinations of scaffolds, dynamic stimulation, and
cell type and culture duration, towards elastic matrix engineering. Adapted from Bashur
et.al., 2012183

various biomolecules have been achieved through release from polymeric nano- or
micro- carriers189-192, from scaffolds193-200 on which they are surface tethered, or through
a combination of both201-206. Several factors such as topography, degradation products
and their effects, carrier chemistry etc. play a critical role in efficient delivery as well as
in regulating cell response207-209. For example, topography, compliance and scaffold
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chemistry closely regulate cell attachment via integrin signaling210-211. Biomolecules
encapsulated within polymeric carriers, especially growth factors are sensitive to
processing steps as well as the byproducts of polymer degradation, and can often result in
loss of bioactivity60, 212. Along with scaffold chemistry, surface charge is also shown to
influence release profiles as well as efficient uptake of released factor depending on the
tissue site. For example, for targeted delivery within the vasculature, and scaffolds
functionalized with a positive surface charge have shown to improve uptake and
retention213-214.Cationic surfaces have shown to positively influence outcomes in elastic
matrix engineering as well. It has been hypothesized that cationic functionalization
enables interaction with hydrophobic domains in elastin and the crosslinking enzyme,
LOX, while at the same time repels cationic elastase and MMPs, thereby suppressing
proteolytic activity215-216.
While a lot of progress has been made towards vascular matrix engineering and in
situ repair of compromised vessels, regeneration of elastic matrix is still insufficiently
addressed. Nonetheless, various parameters summarized in this chapter, especially when
used in combination, hold promise towards development of successful elastic matrix
engineering strategies for vascular pathologies.
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CHAPTER THREE
INVESTIGATING INDUCED ELASTOGENESIS BY VASCULAR SMCS IN AN
IN VITRO 3-D COLLAGEN-GEL MICROENVIRONMENT

3.1. INTRODUCTION
As discussed in detail in the previous chapters, the elastic matrix is responsible for
providing vessels the necessary recoil and compliance to accommodate blood flow, and
at the same time also regulates vascular smooth muscle cell (SMC) behavior through
mechano–transduction1, particularly during morphogenesis and disease progression2.
Once injured, the elastic matrix is not repaired, due to (a) poor elastin precursor
(tropoelastin) synthesis by adult cells, (b) inefficient recruitment and crosslinking of
tropoelastin into an elastic matrix, and (c) further organization into elastic fibers10. The
failure to reinstate a healthy matrix, when damaged by injury or disease, or when
congenitally malformed or absent, can therefore severely compromise tissue homeostasis.
This is one of the reasons why synthetic graft replacements (e.g. ePTFE) for such
diseased segments, though capable of reinstating vessel elasticity and compliance, are
unable to provide biologic stimuli to restore healthy vascular cell phenotype and tissue
homeostasis.
Alternative strategies to tissue engineer elastic vessel replacements using
autologous adult vascular SMCs seeded on biodegradable scaffolds, natural or synthetic,
have been challenged by poor elastogenicity of these cell types, and lack of knowledge of
materials and methods to biomimetically replicate and enhance tropoelastin synthesis,
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recruitment, crosslinking, and matrix assembly10. The problem of poor elastic matrix
deposition is especially severe in cellular microenvironments within such tissue–
engineered constructs invariably rich in regenerated collagen, which switch SMCs to a
less synthetic, and even less elastogenic phenotype56.
Of potential benefit to overcoming the poor elastogenicity of adult vascular cells,
our laboratory previously determined the synergistic benefits of HA–o and TGF–β1 to
elastin precursor synthesis, elastic matrix deposition, and fiber formation by cultured
adult rat and human SMCs148, 184. We also showed that TGF–β1 increases expression
levels of mRNA for tropoelastin, and that of the matrix crosslinking enzyme, lysyl
oxidase (LOX), while suppressing the activity of matrix degrading matrix
metalloproteinases (MMPs)

148, 217

. Negatively-charged HA is also thought to coacervate

tropoelastin molecules for more efficient localized crosslinking and organization of these
precursors into mature fibers, much like the role of glycosaminoglycans (GAGs) in a
developing aorta34,
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. Our prior data also suggests that oligomeric forms of HA,

specifically 4– and 6– mers, also enhance elastin mRNA expression. The presence of
collagenous matrix is centric to replicating vascular tissue architecture and mechanics48,
and vascular cells, regardless of the choice of scaffolds, robustly synthesize collagen10, 27.
It is therefore imperative to examine the impact of a pre-existing collagenous
microenvironment on the ability of the cells to synthesize fibrous elastic matrix on their
own and also their response to provided elastogenic factors56. Towards utilizing the
above factors to enable and enhance elastic matrix deposition within collagenous tissue,
in the present study, we investigate the effect of these factors at different dose
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combinations within statically loaded 3–dimensional (3–D) cellularized collagen
constructs.

3.2. MATERIALS AND METHODS
3.2.1. Isolation and Culture of Rat Aortic Smooth Muscle Cells
Abdominal aortae were harvested from adult Sprague–Dawley rats according to
animal protocols approved by the Medical University of South Carolina, where this work
was performed. After scraping out the intima and the adventitia, the medial layers of the
aortae were minced into 1–2 mm–long pieces, incubated first in DMEM–F12 (Gibco–
Invitrogen, Carlsbad, CA) containing 20% v/v fetal bovine serum (PAA Scientific,
Dartmouth, MA), 1% v/v Penstrep (Thermo Scientific, Rockford, IL) and 175 U/ml
collagenase II (Worthington Biochemicals, Lakewood, NJ) for one hour at 37 °C. The
pieces were then incubated in a second digestion mixture containing the above solution
supplemented with 0.25 mg/ml of elastase III (Worthington Biochemicals, Lakewood, NJ)
for 45 minutes. The digestate was finally centrifuged at 200g for 5 minutes, and the pellet
re–constituted and cultured in DMEM–F12 containing 20% v/v serum and 1% v/v
Penstrep. Primary rat aortic SMCs (RASMCs) thus obtained, were cultured and passaged
in T–75 flasks. Cells of low passage (P3 – P5) were used to seed the collagen constructs.

3.2.2. Fabrication of Cellularized Collagen Constructs
The inherent nature of cell–seeded collagen to shrink and form a compacted gel
was utilized to fabricate 3–D constructs. Collagen–cell mixtures were aliquoted within
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rectangular (3.8 mm × 2 mm × 1.5 mm) silicone rubber (Smooth–On, Inc., Easton, PA)
wells cast in 100 mm diameter glass petri–dishes218-219. The molds/dishes were steam–
sterilized at 121 ºC for 30 minutes. In order to obtain directed compaction of the collagen
gels under static tension, polyurethane tubes anchored with stainless steel pins (both
sterilized in 1 N HCl for 20 minutes and rinsed in sterile PBS) were anchored to the ends
of each well.
Acid–solubilized type I collagen (BD Biosciences, Bedford, MA) was mixed with
5 × DMEM/F12 and 0.1 N NaOH and added drop wise to titrate the mixture to
physiological pH. RASMCs (passages 3–5) were trypsinized, centrifuged, and re–
suspended in medium and added to the above solution to obtain a final concentration of 2
mg/ml collagen, 1 × 106 cells/ml, 20% v/v serum and 1% v/v Penstrep in DMEM–F12.
All mixing was performed on ice to prevent premature polymerization of collagen when
physiologic pH was attained. Equal volumes of this collagen-SMC mixture were then
aliquoted into each well and cultured in a CO2 incubator at 37 °C. Within a few hours, the
collagen–cell mixture started to gel and anchor around the polyurethane end holders.
These holders prevented longitudinal gel contraction, but enabled contraction in a
direction perpendicular to the long axis of the wells (Figure 3.1).

Figure 3.1: Statically loaded RASMC–seeded 3–D collagen gels. Gels, shown at day
one of culture, were cast within silicone wells and anchored to polyurethane end–
holders
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A sterile cocktail of HA–o and TGF–β1 (Peprotech, Rocky Hill, NJ) was
exogenously supplemented in the growth medium, at six different dose combinations (0.1,
1 and 10 ng/ml of TGF–β1, each with 0.2 and 2 µg/ml of HA–o). Since this is a
pioneering study utilizing a combination of HA–o and TGF–β1 for elastic matrix
synthesis by SMCs within 3-D cultures, there is lack of literature indicating appropriate
doses for such a model. We have therefore extrapolated the dose range for the current
study from our outcomes in 2-D cultures, and utilized a range to include concentrations
of an order of magnitude lower and higher than that used in 2-D cultures in order to
evaluate optimum conditions37, 139, 220. HA oligomer mixtures used in this study primarily
consisted of 4–mers (~ 75%) with 6–mers and 8–mers forming the balance. They were
prepared by digesting high molecular weight HA (1.5 × 106 Da, Genzyme Biosurgery,
Cambridge, MA) with testicular hyaluronidase (40 U/mg at 37 °C; Worthington
Biochemicals, Lakewood, NJ) as we have described previously163. The constructs were
cultured for 21 days and spent medium changed every two days. Spent medium from
each well was pooled with aliquots previously removed from the same wells, and frozen
at –20 °C until biochemically analyzed at the end of the culture period.

3.2.3. Construct Compaction
All constructs were photographed at regular intervals using a digital camera and
their central widths measured using Image–J (NIH, Bethesda, MD) imaging software.
The extent of contraction (compaction ratio) of each construct was measured as a
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percentage difference in width of the well and the central width of the construct at day 21.
At least three measurements were made on each construct.

3.2.4. DNA Assay for Cell Quantification
The DNA content of RASMCs within the collagen constructs was measured at 21
days of culture to estimate to estimate increases to cell number relative to that at seeding.
Briefly, the gels were detached from the holders and digested in 10 mg/ml proteinase–K
(Gibco–Invitrogen, Carlsbad, CA) at 65 °C for 10 hours until the matrix structure was
completely solubilized. The enzyme was inactivated by boiling the solution for ten
minutes. The digested solution was then sonicated for 3 minutes on ice to lyse cells, and
DNA content was measured using a flourometric assay. Cell numbers were calculated
assuming 6 pg of DNA/ cell221. Results were represented in terms of cell proliferation
ratio (cell count at 21 days/ initial seeding density) and as a fold–change in this ratio
compared to control.

3.2.5. RT-PCR for mRNA expression of Tropoelastin, Collagen and LOX
Constructs were harvested in RNA-Later stabilization solution (Qiagen, Valencia,
CA) after 21 days of culture, homogenized using a needle and syringe, RNA extracted
using an RNeasy kit (Qiagen, Valencia, CA), and samples loaded onto RNeasy mini
columns. Total RNA was eluted with 40 μL of RNase-free water, its concentration
determined by absorbance measurement at 260 nm using a Ribo-green assay kit
(Invitrogen, Carlsbad, CA). 200 ng of RNA was reverse transcribed with iScript cDNA
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synthesis kit (Biorad, Hercules, CA) according to the manufacturers’ instructions.
Samples (40 μL) were incubated at 42 ºC for 5 minutes and then reverse transcriptase
(RT) inactivated at 85 ºC for 35 minutes. Gene expression for collagen, elastin and LOX
were evaluated using 1 µl of cDNA with Power SYBR®Green Master Mix (Applied
Biosystems, Foster, CA) (n = 6/case) in the ABI 7500 Real Time PCR System (Applied
Biosystems). A comparative threshold method

222

was used to quantify the mRNA

expression of these genes and was reported as 2–∆∆Ct, with 18s serving as the internal
control. The sequences of all primers are listed in Table 3.1.

3.2.6. Fastin Assay for Elastin Content
Total elastin synthesized by RASMCs was measured using a commercially
available Fastin assay kit (Accurate Scientific and Chemical Corporation, Westbury, NY).
Three distinct elastin fractions were assayed for, namely, (a) tropoelastin, the soluble
precursor of elastin synthesized by cells, present within medium fractions, (b) the less
crosslinked, alkali–soluble matrix elastin, and (c) the highly crosslinked, alkali–insoluble
matrix elastin. Volume fractions from the pooled culture medium were directly used to
measure tropoelastin. To measure matrix elastin, the constructs were first treated with 0.1
N NaOH at 95 °C for one hour and centrifuged. The resulting supernatant consisted of
alkali–soluble matrix elastin, while the pellet comprised of alkali–insoluble matrix elastin.
The soluble matrix fraction was neutralized with an equal volume of 6 N HCl at 110 °C
for 16 hours, dried overnight, reconstituted in water and quantified using the kit. Since
the Fastin kit measures only soluble, α–elastin (~ 60 kDa), the insoluble matrix pellet was
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first solubilized with 0.25 M oxalic acid at 95 °C for one hour, and then filter–centrifuged
with 10 kDa cut–off membranes (Millipore, Billerica, MA). The solubilized matrix
elastin retained above the filters was then quantified with the assay kit. Tropoelastin and
total matrix (alkali –soluble + –insoluble) thus measured were normalized to the cell
count within respective constructs. The matrix yield (i.e. the ratio of matrix elastin/
(tropoelastin + matrix elastin) × 100) was calculated.

Primer Sequence (5’→3’)

Gene
Forward

Lysyl
Oxidase
(LOX)

Reverse

GGACATCTAAGGGCATCACA

Forward

TCC TGG AGC CAC TCT TAC AG

Reverse

CTC TCT CTC CCC AAT TAG CC

Forward

TGC CAA CAC ACA GAG GAG AG

Reverse

Size
(bp)

Accession no.
(Source)

59

185

V01270 (Real
Time Primers)

58

165

NM_007925
(Real Time
Primers)

58

223

NM_010728
(Real Time
Primers)

CGGACAGGATTGACAGATTG

18S

Elastin
(ELN)

Tm
(°C)

CCA GGT AGC TGG GGT TTA CA

Table 3.1: Forward and reverse sequences of primers for rat ELN, LOX, and the housekeeping gene, 18S
3.2.7. Western Blotting for LOX and MMPs –2 and –9
Western blotting was performed to semi–quantitatively compare the amounts of
LOX enzyme protein and of the elastolytic MMPs –2 and –9, synthesized by RASMCs
within constructs subjected to different treatment conditions.

At day 21, harvested

constructs were ground into powder in liquid nitrogen, extracted in RIPA lysis buffer
(750 µl, Invitrogen, Carlsbad, CA) with a protease inhibitor cocktail (Thermo Scientific,
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Rockford, IL), and then assayed for total protein content using a BCA assay kit (Thermo
Scientific, Rockford, IL)223. Volumes equivalent to 3 μg of protein were loaded under
reduced conditions into 4–12% SDS PAGE gel for LOX analysis and 10% SDS PAGE
gel for MMP analysis, along with a pre–stained molecular weight ladder (Invitrogen,
Carlsbad, CA). The gels were then transferred wet onto PVDF membranes. Following
this, the membranes were blocked in TBST (Tris–Buffered Saline with 0.01% v/v Tween
20, pH 7.4) containing 5% w/v milk for an hour, immunostained using polyclonal
antibodies (1:1000 for 1.5 hours) against LOX (Santa Cruz Biotechnology, Inc. Santa
Cruz, CA), MMP–2 (Abcam, Cambridge, MA) and MMP–9 (Millipore, Billerica, MA),
HRP–conjugated secondary antibody (1:10,000 for one hour) (GE Healthcare
Biosciences, Pittsburgh, PA) and detected using an ECL–plus chemiluminogen detection
kit (GE Healthcare Biosciences, Pittsburgh, PA). The blotted membranes were then
stripped and re–probed with β–actin loading control (Abcam, Cambridge, MA). Bands
were quantified using Image–J software (NIH, Bethesda, MD), expressed as relative
density units (RDU) and normalized to control. Analysis was performed on bands
generated from 3 blots per condition.

3.2.8. Gelatin Zymography for Detection of MMP–2 and –9
Volumes containing 5 μg proteins from the digested constructs were loaded per
lane of 10% gelatin zymograms (Invitrogen, Carlsbad, CA) and run alongside a pre–
stained protein ladder (10 kDa–190 kDa; Invitrogen, Carlsbad, CA), and purified protein
standards of MMPs -2 and -9 (Anaspec, Fremont, CA), for 2 hours at 125 V. The gels
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were then washed in 2.5% v/v Triton X– 100 for 30 minutes to remove SDS, following
which they were incubated overnight in a substrate buffer to activate MMPs. The gels
were then stained in Coomassie Brilliant Blue solution (Sigma, St. Louis, MO) for 45
minutes and de–stained (40% v/v methanol, 10% v/v glacial acetic acid) for 1.5 hours
until clear bands were visible against a blue background223. The band intensities were
quantified using Image–J and expressed as RDU values of the experimental cases
normalized to RDU values of control cultures. Analysis was performed on the bands
generated from 3 gels per condition.

3.2.9. Visualization of Elastic Matrix and Mineralization
At 21 days of culture, the constructs were fixed in 4% w/v formalin and
embedded in paraffin. Tissue sections (5 μm thick) were then stained for elastin using a
Verhoeff Van Gieson (VVG)–based elastic–stain kit (ScyTek Laboratories, Inc., Cache,
UT). To visualize elastin using immuno–fluorescence, the sections were incubated in
0.05% w/v Pontamine sky blue (Sigma, St. Louis, MO) for 30 minutes, mounted using
Vectashield containing DAPI (Vector Laboratories, INC. Burlingame, CA), cover–
slipped and observed with a visible–red (Texas red) fluorescent filter. Pontamine sky blue
quenches the auto–fluorescence of elastin and collagen in the visible–green region of the
emission spectrum, and transfers the auto–fluorescence of elastin alone to the red region
of the spectrum224. Elastin–specific fluorescence of sections labeled in this manner was
confirmed by detecting elastic matrix in separate sections from the same sample with a
rabbit anti–rat elastin antibody. Sections were imaged using a fluorescent microscope and
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alignment of elastic fibers in the constructs were quantified by calculating their angular
standard deviation225. Length and angle of individual fibers were measured using Image
Pro software (Bethesda, MD). Elastin deposits with aspect ratio greater than 2 (long axis:
short axis) were assumed to be fibers and only these were used for quantification.
The presence/absence of calcific deposits within constructs was ascertained by
labeling sections with a Von Kossa–based calcium–staining kit (ScyTek Laboratories Inc.,
Cache, UT).

3.2.10. Mechanical Testing of 3-D Constructs
Uniaxial mechanical testing was performed on constructs treated with 4 selected
dose combinations: 0.1 ng/ml, 1 ng/ml and 10 ng/ml TGF-β1, each with 0.2 µg/ml HA-o
(n = 10/ case) using Instron 5943 under a 10 N load cell. Only 4 experimental cases were
chosen to perform the mechanical testing based on the observations made using the
various biochemical tests described above: 1) untreated control, 2) 0.2 μg/ml HA-o and
0.1 ng/ml TGF-β1, 3) 0.2 μg/ml HA-o and 1 ng/ml TGF-β1, and 4) 0.2 μg/ml HA-o and
10 ng/ml TGF-β1. The width of constructs was measured optically using a stereoscope,
and thickness measurements using a liner variable differential transducer (LVDT). The
constructs were gripped between serrated metal grips after wrapping the ends with three
layers of paper towel and testing was performed in a saline bath maintained at 37 °C.
Specimens were first preconditioned at a rate of 4 mm/s for 10 cycles followed by load to
failure at an extension rate of 10 mm/min. Load vs. displacement and stress vs. strain
curves were calibrated and elastic moduli calculated for each construct. Failure loads
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were calculated if the specimens do not fail at the grips or due to other artifacts. Tensile
modulus was calculated between 15%-30% strains (85 data points for all constructs).

3.2.11. Statistical Analysis
All quantitative results were analyzed from n = 6 independent repeats of each case and
reported as mean ± standard deviation. Statistical significance between groups was
determined from a one-way analysis of variance (ANOVA) and for  values ≤ 0.05.
Power analysis of our prior data indicates that n = 6 replicates for cell/tissue cultures with
3 independent measurements for each parameter, is sufficient to reliably detect
quantitative differences in outcomes, with a power of ≥ 0.95 (i.e.,  = 0.05, i.e., 5%
chance of claiming a false null hypothesis as true and  = 0.05, i.e., 5% false negative
rate)226.

3.3. RESULTS
3.3.1. Cell Quantification
As seen in Figure 3.2, cell numbers were highest (4.2 ± 0.8 –fold increases over
21 days; 1.4 ± 0.1 –fold vs. non–factor treated control) in constructs cultured with the
lowest dose combination of TGF–β1 (0.1 ng/ml) and HA–o (2 µg/ml), and lowest (1.96 ±
0.23 fold increase over 21 days; 63 ± 13% of cell counts in control cultures at day 21)
within constructs cultured with the highest dose of factors, i.e., TGF–β1 (10 ng/ml) and
HA–o (2 µg/ml).
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Figure 3.2: Effect of elastogenic factors on cell proliferation ratio. Cell numbers
were calculated based on the estimate of 6 pg of DNA per cell, as calculated from
DNA assay, at 0 and 21 days post–seeding, and their ratios determined and
compared to. Differences were deemed to be significant from control cultures for
p < 0.05 (*)
3.3.2. Elastic Matrix Content
Elastic matrix outcomes were quantified in terms of mRNA expressions of
tropoelastin and LOX, quantity of the soluble precursor i.e., tropoelastin, quantity of
matrix components of elastin i.e., alkali-soluble and –insoluble elastin, and LOX protein
content. As seen in Figure 3.3, mRNA expression of elastin remained unchanged relative
to control in all treatment conditions ( > 0.4). Cells within the control constructs
synthesized 4.4 ± 0.5 ng/cell of tropoelastin, 9.4 ± 3.4 pg/cell of matrix elastin,
comprising 4.5 ± 1.8 pg/cell of alkali–soluble matrix elastin and 1.5 ± 1.1 pg/cell of
alkali–soluble fraction. Tropoelastin synthesis per cell was unaffected by culture with
TGF–β1 and HA–o, except at the highest provided dose combination (10 ng/ml TGF–β1
and 2 µg/ml HA–o) at which significant increases (1.5 ± 0.2 – fold vs. control) were
noted (Figure 3.4 A). Consistent with the tropoelastin content though, this difference was
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Figure 3.3: Effect of treatment conditions of mRNA expression of elastin relative
to control constructs. No significant differences were observed between different
conditions (n = 6)

Figure 3.4: Effect of TGF–β1 and
HA–o on elastin synthesis. (A)
Differences in synthesis of
tropoelastin and total matrix
elastin per construct in samples
cultured with HA–o and TGF–β1
relative to control cultures. (B)
Effect of factor treatment on
synthesis of alkali–soluble matrix
elastin and crosslinked, alkali–
insoluble matrix elastin. (C)
Effect of factor treatment on
yields of matrix elastin, i.e. the
fraction of total elastin amounts
produced by cells that is deposited
in the matrix. ‘*’ indicates
differences
from
controls
significant for p < 0.05, and ‘#’
between cases as indicated (n = 6
for each case)

most pronounced in the cases with highest TGF–β1 doses (up to 26.2 ± 2.4 fold increase
compared to control). This increase was significantly higher compared to the lower dose-

61

combinations as well (14.5 ± 3.4 in 0.1 ng/ml TGF–β1, and 11.2 ± 3.1 in 1 ng/ml TGF–
β1). Differences in addition of HA-o with equal doses of TGF–β1 were insignificant in
all cases.

Figure 3.5: Effect of treatment conditions of mRNA expression of LOX relative to
control constructs. Significant differences, indicated by ‘*’ were observed in all
treatment conditions relative to control (n = 6), p < 0.05

Figure 3.6: Fold change in protein levels of LOX in cultures with TGF–β1 and HA–o
factors compared to untreated control cultures, as determined by western blotting.
Differences from control were deemed significant (*) for p < 0.05 (n = 3 per case).

On the other hand, elastic matrix deposition per cell was also significantly greater
in most experimental cases compared to control, with greatest increases (5.4 ± 0.8 and 5.3
± 1.1 – folds vs. control) noted in constructs cultured with the lower dose combinations
of TGF–β1 (0.1 ng/ml) and HA–o (0.2 µg/ml or 2 µg/ml) (Figure 3.4 B). Also noted was
that increases in matrix elastin, especially at the lower provided doses of factors, were
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associated more with increases in the less crosslinked, alkali–soluble matrix elastin
fraction than with the more robustly–crosslinked, alkali–insoluble fraction. At the highest
provided dose combinations, fold increases in both fractions compared to control were
similar, i.e. the ratios of alkali- insoluble to –soluble elastin were the highest (Figure 3.4
C). This finding was consistent with mRNA expression and western blotting analysis for
LOX enzyme (31 kDa) synthesis within cultured constructs. mRNA expression of LOX
was elevated in all treatment conditions relative to control ( < 0.05), with the highest
increase in constructs with 10 ng/ml TGF-β1 with both doses of HA-o (2.56 ± 3.5 –fold,

 < 0.001, relative to control), as seen in Figure 3.5. LOX protein content was also
highest in constructs cultured with 10 ng/ml of TGF–β1 and 0.2 µg/ml of HA–o (3.5 ±
0.5 –fold vs. control). LOX protein synthesis was elevated in all factor-treated cases
compared to control (Figures 3.6 and 3.7). Matrix yields (Figure 3.4 C) were greatest in
constructs cultured with the lower dose combination of factors, i.e. 0.1 ng/ml TGF–β1
with 0.2 µg/ml (0.6 ± 0.2%) 2 µg/ml of HA–o (0.6 ± 0.1%) respectively.

Figure 3.7: Effect of factors on enzyme synthesis and active forms. Representative
immunoblots of (A) MMP–9 and (B) MMP–2 indicating the active and inactive
protein bands for each case, and (C) LOX. (D) Representative gelatin zymogram of
MMP–2 indicating the active and inactive bands
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3.3.3. MMP Protein Analysis
Figure 3.7 shows representative immunoblots of MMPs –2 and –9 and zymogram
of MMP–2. Figure 3.8 compares MMP –2 and –9 amounts measured within collagen
constructs treated with TGF–β1 and HA–o factors, with that measured within untreated
control constructs.
MMP 2 was detected on the Western blots as two distinct bands corresponding to
the zymogen form (~ 72 kDa) and active form (~ 62 kDa). MMP–9 was also detected in
its zymogen (~ 92 kDa) and active (~ 82 kDa) forms. The greatest increases in total
(active and inactive forms) MMP–2 protein amounts over controls was observed within
constructs cultured with the lower dose combinations of the factors In general, MMP–9
synthesis was decreased in factor–treated constructs relative to control, though the
decreases were greatest and statistically significant for constructs cultured with the
highest TGF–β1 factor (10 ng/ml of TGF–β1 and 0.2 µg/ml or 2 µg/ml of HA–o) and
with the lowest dose combination (0.1 ng/ml TGF–β1 and 0.2 µg/ml HA–o).
Figure 3.9 compares active and inactive forms of MMP–2 in factor–treated
constructs with that in control constructs. MMP–9 activity is not shown since the bands
were absent or too faint to be reliably quantified. In general, MMP–2 zymogen levels
were very low, both in control and factor–treated constructs, except those cultured with
low doses of HA–o (0.2 or 2 µg/ml) and TGF–β1 (0.1 ng/ml). The quantities of the active
form of MMP–2 were also mostly similar between constructs, excepting those cultured
with low doses of HA–o (0.2 or 2 µg/ml) and TGF–β1 (0.1 ng/ml), in which significant
increases in enzyme activity was measured.
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Figure 3.8: Differences in total protein synthesis of MMPs –2 and –9 in experimental
cases compared to control, as determined from immunoblotting of the two proteases.
‘*’ indicates statistical difference compared to control for p < 0.05 (n = 3 per case)

Figure 3.9: Effect of factors on MMP–2 quantities as determined by gelatin
zymography. Data represents a fold change in relative density units of zymogram
bands in experimental cases compared to control cultures. Significance in differences
compared to control is indicated by ‘*’ for p < 0.05 (n = 3 per case)

3.3.4. Mechanical Properties of Constructs
The compaction ratio of constructs cultured with the various dose combinations
of TGF–β1 and HA–o was less than that of control constructs cultured without the factors
(Figure 3.10). Compaction ratios were the lowest in constructs that received one of the
two lowest dose combinations, specifically, 0.1 ng/ml TGF–β1 and 2 µg/ml HA–o (46.57
± 4.12 %, p < 0.05).
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Figure 3.10: Percentage change in central widths of constructs at day 21 compared to
day 0 (n = 6 per case). * indicates significance of differences compared to control
cultures, deemed for p < 0.05

Tensile testing of constructs (Figure 3.11) revealed non-linear stress strain
curves, typical of collagenous tissues. Addition of factors did not significantly alter the
modulus of the constructs, in both the elastic toe region, as well as the plastic region. The
highest elastic moduli were observed in untreated control constructs (740.7 ± 81.2 kPa),
and the lowest in constructs with 0.1 ng/ml TGF–β1 and 0.2 µg/ml HA-o (632.6 ± 61.3
kPa). However, these differences were not statistically significant, compared to control or
between constructs. The toe region of the constructs at the start of load to failure test
phase was inconsistent. Therefore tensile modulus at this region was not calculated.
Almost all constructs failed at the grips, and therefore the yield properties could not be
accurately and consistently determined.

3.3.5. Visualization of Elastic Matrix
VVG staining for elastin (Figure 3.12) and immuno–fluorescence labeling after
Pontamine sky–blue quenching (Figure 3.13) showed the presence of elastic fibers in all
the constructs treated with factors, although due to the limited thickness of the sections,
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Figure 3.11: Effect of select doses of treatment conditions on tensile properties of
constructs. (A) Representative stress vs. strain curves of constructs at the 4 treatment
doses. Toe regions were not consisently seen in all constructs. All constructs failed at
the grips. Tensile modulus calculated between 15%-30% strains were not statiscally
different between cases (B).
the continuity and total length of individual fibers could not be ascertained. Elastic fibers
were more abundant and appeared more complete towards the edges of the constructs.
Elastic fiber alignment, calculated in terms of angular standard deviation, did not
differ between the various culture conditions (Figure 3.14 A). However, there were a
significantly greater number of elastic fibers (Figure 3.14 B) present in all cultures that
received the elastogenic factors, (except cultures that received 1 ng/ml of TGF–β1 and 2
µg/ml of HA–o).

Von Kossa staining (Figure 3.15) for calcific deposits indicated lack

of matrix mineralization in all constructs.
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Figure 3.12: Representative images of 5 µm sections stained for elastin with modified
VVG at 20 × magnification (scale bar = 200 µm). Elastic fibers are stained purple and
surrounding collagen is stained pink

Figure 3.13: Representative fluorescence micrographs of construct sections
showing distribution of nuclei in green (A), elastin/elastic fibers in red (B), and the
overlay of the two (C). Paraffin embedded sections were treated with Pontamine sky
blue to quench autofluorescence of collagen and shift that of elastin to the red
wavelengths. Nuclei were stained with DAPI. Magnification: 20 × (scale bar = 100
µm)
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Figure 3.14: Elastic fiber alignment in collagen gel constructs represented by
angular standard deviation in degrees (A) and no. of aligned fibers (B). ‘*’ represents
significance in difference from control cultures

Figure 3.15: Von Kossa staining for mineral deposits. The absence of any black
spots/deposits indicates lack of TGF–β1–induced matrix mineralization in the dose
range studied. The kit used stains nuclei red. Magnification: 10 × (scale bar = 500
µm)

3.4. DISCUSSION
Attempts at engineering elastic tissue constructs, such as vascular replacements,
thus far, have been challenged by poor ability of post–neonatal cell types to synthesize
tropoelastin and crosslink the precursors into a fibrous matrix227-228. It is also evident
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from literature that the extracellular microenvironment critically influences cell
phenotype and behavior. In this context, a large body of work attests to the contractile
phenotype of SMCs within the intact vessel wall, and the switch to a more synthetic (i.e.
proliferative and ECM–generating) phenotype, when these SMCs are isolated and
cultured in vitro56, 141, either on tissue culture polystyrene (TCPS), or within scaffolds
created from one of the many natural (e.g. fibrin227) or synthetic (e.g. Polyglycolic acid
(PGA)52) polymers. From the standpoint of elastin regeneration, vascular SMCs in
contact with these scaffolds have been found to enhance tropoelastin synthesis. Although
the cellular scaffolds may provide the initial framework for cell adherence and
proliferation, the expectation is that the scaffold would gradually biodegrade, and cell–
synthesized ECM would accumulate and assume primary load–bearing roles. Key among
these ECM proteins is collagen, which cells are able to abundantly and preferentially
synthesize and deposit, beginning at a fairly early stage in culture. While such collagen
fiber deposition is favorable from the standpoint of replicating the 3–D collagenous
matrix within the aorta, there is also significant and irrefutable evidence that this
microenvironment promotes a more quiescent, contractile phenotype amongst SMCs
(compared to other scaffolding materials like PGA and fibrin), which is not particularly
conducive to their ability to synthesize elastin and lay down elastic matrix structures49, 5253, 229

.

Thus, efforts to engineer soft elastic tissues, such as vascular tissues, will

tremendously benefit from an elastin–regenerative stimulus that can overcome the
unfavorable microenvironment for elastin synthesis imposed by a collagenous matrix,
standard to most applications.
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Previously, our lab established the elastogenic benefits of TGF–β1and HA–o
towards increasing tropoelastin precursor production and crosslinked–matrix deposition
by RASMCs37,

148, 217, 230

. However these studies were performed on RASMC layers

cultured on 2–D TCPS surfaces, on which SMCs are known to assume a more
proliferative, synthetic phenotype than what they exhibit within intact vessels. In order to
translate the specific benefits of the above mentioned factors to a culture model more
closely evocative of a collagenous 3–D matrix microenvironment, naturally present
within decellularized vascular tissue–based scaffolds, and that generated by cells seeded
on other scaffolds, we studied the effect of the above mentioned factors on adult
RASMCs seeded within 3–D collagen constructs maintained under static tension.
Relative to untreated control constructs, cell numbers within constructs cultured
with HA–o and TGF–β1 were in general slightly greater, with the significant differences
being only for the intermediate factor doses. A significant attenuation in the increase in
cell count was noted only at the highest provided dose (i.e. 10 ng/ml of TGF–β1 and 2
µg/ml of HA–o). While these results are consistent with observations of other groups,
wherein increasing TGF–β1 concentrations was found to lower cell densities231, the
results contrast substantially from our previous observations of a dose–dependent
inhibition of SMC proliferation on TCPS surfaces184. The present results suggest that (a)
interaction with the collagenous ECM alters SMC behavior compared to 2–D cultures,
and (b) such collagen–SMC interaction de–sensitizes the cells to TGF–β1 and HA–o,
attested to by a significant decrease in cell number only at the highest provided doses. It
is also apparent from our results that similar to our recently published observations in 2–
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D cultures, TGF–β1 effects dominate with a biphasic dose–dependent proliferative
response to TGF–β1 at both HA–o doses232. However, from the standpoint of a tissue
engineering application, wherein growth in tissue mass is contingent on increased
availability of ECM–generating cells, the HA–o/TGF–β1 dose combination that provides
greater impetus to SMC proliferation (i.e. 0.1 ng/ml of TGF–β1 and 0.2 or 2 µg/ml of
HA–o), is most desirable.
Within a collagenous 3–D matrix, SMCs are likely to switch to a more contractile
phenotype characterized by reduced ECM synthesis, which has been previously
reported49,

52-53, 229

. Concurrently, our results indicated that within 3–D collagen

constructs, HA–o and TGF–β1 together had mostly no effects on tropoelastin synthesis.
The sole exception was the highest factor dose which induced a moderate, but significant
increase. While this lies in complete contrast with our prior published studies in 2-D
culture, wherein we noted even the lowest dose combination of factors we test here, to
induce multi–fold increase in tropoelastin synthesis compared to non–additive controls,
and the differences could be attributed to a switch in SMC phenotype between 2-D and 3D cultures.
HA–o and TGF–β1 in this study appear to influence the process of tropoelastin
crosslinking and matrix deposition to a greater extent than tropoelastin synthesis itself;
the enhancement of elastic matrix deposition appears to be the predominant effect of the
factors, though in the absence of information as to an exact mechanism by which the
factors elastogenically induce the cells, this currently remains an unsubstantiated
observation. As seen in Figures 4A and 4B, at both HA–o doses (i.e. 0.2 and 2 µg/ml), a
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classic biphasic TGF–β1 dose response is seen with regard to elastic matrix deposition,
with significant (~ 5 fold) increases noted at the lowest tested TGF–β1 dose (0.1 ng/ml)
and much smaller increases noted at higher TGF–β1 doses. Our results also suggest that
at higher doses, HA–o reduces this biphasic elastic matrix synthesis response to TGF–β1;
especially at higher TGF–β1 doses (i.e. 1 and 10 ng/ml), increasing HA–o dose led to a
significant increase in elastic matrix deposition. Matrix elastin increases were primarily
associated with enhanced deposition of the less crosslinked alkali–soluble fraction.
In the majority of cases, we found the factors to enhance significantly relative to
controls, the synthesis of LOX enzyme, which is believed to play a central role in
crosslinking tropoelastin into a mature elastic matrix. This is in agreement with our prior
published findings37, 233 where we showed HA–o/TGF–β1 to enhance mRNA expression,
protein synthesis and activity of the elastin crosslinking enzyme. However, the most
significant increase in LOX synthesis was observed in cell cultures treated with 0.2 μg/ml
of HA-o and 10 ng/ml of TGF-β1 (see Figures 3.6 and 3.7). Likewise, in comparing
ratios of amounts of alkali-insoluble (i.e., highly crosslinked) matrix elastin to amounts of
the alkali-soluble fraction (see Figure 3.4), we find that the ratios are far less than 1, for
all cases, especially for cultures treated with the lower doses of the factors, but greater
than 1 in the singular case wherein LOX synthesis was most significantly enhanced (i.e.,
0.2 µg/ml of HA-o and 10 ng/ml of TGF-β1). We thus hypothesize that the increases in
amounts of LOX protein contribute to more efficient crosslinking of elastic matrix into an
alkali-insoluble form.
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A very interesting observation is that the matrix yield (i.e. mass % of total elastin
output crosslinked into a matrix) in control collagen constructs is much lower (~ 0.2%)
than what we have observed with the same cell type in 2–D cultures on non-collagenous
substrates (10–15%). While we have shown a multi-fold increase in matrix yields in the
presence of TGF–β1 and HA–o factors, most significantly at the lowest tested doses, the
yields remain < 1%. One possible reason for the low levels of elastic matrix deposited,
which will confirm in a future study, might be over-production of GAGs such as
chondroitin sulfate by the SMCs, which as studies by Hwang et al.38 and Allison et al.39
have shown, to inhibit elastin synthesis and assembly, and shown to correlate with
increased collagen matrix deposition.

Regardless, despite the likely LOX–mediated

crosslinking of tropoelastin in the presence of HA-o and TGF-β1, the poor elastic matrix
yields obtained in this study indicate that there is room for improvement in terms of
enhancing the deposition of the more robustly crosslinked, and hence the more stable
alkali–insoluble elastic matrix fraction.
In the context of enhancing elastin matrix within 3–D collagenous constructs,
leading to tissue engineering of a clinically sufficient, implantable tissue, it might thus be
necessary to seed the scaffolds at much higher cell densities to overcome the poor matrix
yield obtained per cell (even when elastogenically induced) or alternatively co–deliver
elastin–crosslink–promoting factors (e.g. LOX or LOX–activity enhancing copper
nanoparticles), which we have shown to be very useful for the purpose148-149.
MMPs –2 and –9 represent a class of Zn2+ dependent gelatinases that degrade
matrix proteins, specifically elastin12. Since intact elastic fibers serve as nucleation sites
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for organization of new elastic matrix structures, and since net accumulation of elastic
matrix is dependent on much attenuated matrix degradation relative to its regeneration,
minimizing MMP production/activity is desirable83. In this context, our study showed
that the lowest, but the most elastogenic dose combination of TGF–β1 and HA–o
significantly attenuate MMP–9 synthesis, but enhance MMP–2 production by SMCs. At
the highest provided dose, also deemed to be elastogenic, but less so, MMP–9 production
was negligible and MMP–2 levels were similar to untreated controls. Likewise, active
forms of MMP–2 protein was enhanced at the lowest TGF–β1 and HA–o dose
combinations, and remained unaffected at higher doses. While it is yet undetermined as
to whether the above mentioned increases in synthesis of MMP–2 protein quantities (both
zymogen and active forms) at the lowest tested TGF–β1 and HA–o doses are significant
enough on absolute terms to actually compromise the matrix; if it is so, providing MMP–
inhibiting culture conditions, or alternatively, providing the higher, non–MMP–
enhancing factor dose might be a desirable approach.
Another favorable observation of culturing SMCs within statically loaded
collagen gels was the high degree of alignment in the synthesized elastic fibers, as seen in
Figure 3.14. While the degree of alignment was more or less uniform irrespective of the
culture conditions, all cultures that received the elastogenic factors, except those with 1
ng/ml of TGF–β1 and 2 µg/ml of HA–o, consisted of significantly larger number of
aligned fibers compared to non-additive control cultures.
TGF–β1, when over–expressed, especially in a sustained manner, can induce
SMCs to assume a more osteogenic phenotype, and enhance matrix calcification139.
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However, our study did not show any calcification, even in constructs cultured with the
highest dose of 10 ng/ml TGF–β1.

3.5. CONCLUSIONS
This study demonstrates elastogenic induction of RASMCs with HA–o
and TGF–β1 factors within non-elastogenic 3-D constructs of statically loaded collagen
gel constructs. While a much higher dose combination than that shown useful in earlier
studies within 2-D cultures is necessary to enhance both tropoelastin and matrix synthesis,
compared to other studies performed on SMCs in collagen gels, we have demonstrated
that synthesis of significant amounts of matrix elastin is possible in the presence of these
factors. A major challenge to our ability to obtain the optimum amount of elastin, that
engineering of tissue constructs for human use demand, is the rather poor elastic matrix
yield (< 1%), and requires addressing.
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CHAPTER FOUR
IMPACT OF DYNAMIC CONDITIONING ON INDUCED ELASTOGENESIS BY
CELLS IN 3D COLLAGENOUS MICROENVIRONMENTS

4.1. INTRODUCTION
In the previous chapter we demonstrated that EF-stimulation of adult vascular
cells towards de novo synthesis of elastic matrix components can be achieved even in a
quiescent 3D collagenous microenvironment not particularly conducive to elastogenesis.
We also showed that cell alignment achieved in the predominant direction of applied
static strain, positively influenced orientation and alignment of both the pre-existing
collagen matrix, and the cell-synthesized elastic matrix. However, due to the particular
design of the 3D collagen gel system that applies strain along the longitudinal axis, the
orientation of the synthesized matrix is tangential to the circumferential orientation
exhibited in vivo by the elastic arteries. In this study, we therefore wanted to further
modify this 3D model system such that the orientation of cells, and as a result, the
synthesized elastic matrix would mimic that contained in vascular tissues. Several studies
have demonstrated the benefits of cyclic mechanical stretch towards inducing orientation
of SMCs. Studies have also demonstrated that cells behave differently under uniaxial
tension within 3D constructs similar to that incorporated in our previous study57,

234

,

compared to when they are cultured within tubular constructs. While cells are shown to
orient in the direction of uniaxial tension, cells within tubular constructs experience radial
and circumferential stretch, and orient in a direction perpendicular to stretch, therefore
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conforming to circumferential alignment, similar to that seen in vivo. We therefore chose
to use a tubular collagen gel model to which cyclic distension could be applied with the
aim of achieving circumferential orientation of cells and thereby, enabling deposition of
newly synthesized elastic matrix in a circumferential orientation as in intact blood
vessels.
The three important factors that influence mechano-transductive response by
cells, and as a result, cell phenotype and final matrix output, are strain amplitude,
frequency and duration of cyclic stretch164,

235

. To date, most studies utilizing cyclic

stretch parameters have primarily used strain levels of > 2.5%, and a majority of them
have used 10% strains57, 59, 166, 236. However, most of these studies were also targeted
towards generating small diameter vascular tissue equivalents that typically respond to
much higher strains than do elastic arteries5. Moreover, the synthesis and enzymatic
activity of the predominant elastolytic protease MMP-2, has been reported to increase at
higher strains237-238. While it is argued that MMP-2 is important for matrix
reorganization237, its enzymatic activity can at the same time however, also degrade
newly synthesized elastic matrix, and prevent its maturation and assembly within the
scaffolds10,
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. Another limitation of applying these higher strains, especially in a

collagenous hydrogel environment that has not yet completely been remodeled to have
sufficient fibrillar matrix, is the irrecoverable creep that the scaffold would experience
under repeated cyclic loading59. This would also lead to the cells perceiving constantly
changing levels of strains, and not the set strain levels intended to transduce the cells.
Alternatively, studies have also demonstrated the importance of frequency of strain
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perceived by cells, and that changing the frequency of cyclic strains was found to play a
significant role in regulating the alignment of vascular SMCs in an intact actin filamentdependent manner167-168. In order to minimize the detrimental effects of high strain levels,
and at the same time promote cell and matrix alignment, we therefore chose to subject
SMC-seeded tubular collagen constructs to 2.5% cyclic strain applied at frequencies of
0.5 Hz, 1.5 Hz and 3 Hz for 21 days of culture. The doses of the EFs used to
elastogenically stimulate cells in this study, were based on the results obtained in Chapter
1, where the dose combination of 0.1 ng/ml TGF-β1 and 0.2 μg/ml HA-o was concluded
to be most elastogenic. In light of results of other studies in our lab that human aortic
SMCs (HASMCs) respond to elastogenic stimulation by EFs239, we transitioned to study
of these cell types to render our outcomes more clinically relevant.

4.2. MATERIALS AND METHODS
4.2.1. Design, Construction and Principle of Operation of Bioreactor for Dynamic
Cell Culture
A bioreactor was constructed to deliver cyclic, tangential strains to the tubular
collagen gel constructs and the SMCs seeded within it. The set up (Figure 4.1.) consisted
of (a) tubular tissue-culture-chambers with centrally placed silicone tubing (around which
the collagen gel constructs would compact) connected to (b) compressible metallic
bellows distended cyclically by (c) a stepper motor whose motion was controlled by (d) a
custom-programmed motor-controller. The motor and controller were powered by a
standard 3 amp power supply. The system was fabricated at the Device Prototype Core
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(Design, Electronics and Polymer cores) at the Cleveland Clinic. All bioreactor parts
were either made in house at the Device Prototype Core, or purchased from Cole Parmer
(Vernon Hills, IL) or McMaster Carr (Aurora, OH).

Principle of Operation: The segment of the bioreactor that was filled with water (from
the sealed end of the bellows to the sealed ends of silicone tubes within the culture
chamber in Figure 4.1) was a closed, air-tight unit, within which the inner silicone tubes
are the only compliant parts.

Figure 4.1: Bioreactor set-up for applying 2.5 % stains. The tissue culture chamber with
inner silicone tubing (a), is connected via a manifold to the bellows (b), which are in turn
coupled to the shaft (c) of the DC motor (d). The forward and backward movement of the
shaft of the motor is controlled by the motor controller (e), powered by an external power
supply (f). The volume spanning the region within the silicone tubing starting from the
tissue culture chamber, to the end of the bellow is a closed loop into which sterile water is
purged in via a leur lock inlet.
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The system therefore worked on the principle that when the bellows are
compressed by the motor shaft, the change in volume will be experienced only by the
elastic silicone tubes and compensated by a resultant change in diameter of the tube. This
cyclic change in diameter therefore induced circumferential strains on the SMCs cultured
within the collagen-gel constructs surrounding the tube.
The increase in volume within the silicone tubes in order to deliver the required
strains is proportional to distance travelled by motor shaft to compress the bellows which
will displace that same change in volume, resulting in generation of strains at the silicone
tube. It was crucial to ensure that the system was completely devoid of any air bubbles
and maintained airtight throughout the culture duration in order to deliver accurate strains
to the constructs.

Tissue Culture Chamber: The tissue culture chamber of the bioreactor (Figure 4.2)
consisted of tubular compartments, 5 cm length, 8 mm diameter each, cast out of silicone
rubber. Silicone rubber tubes (4 cm length, 4 mm outer diameter, 1 mm thickness) were
inserted across the length of each compartment, and held taut in place by friction.
Silicone rubber is easy to sterilize and provides a non-adherent surface to prevent cellattachment. The collagen gel constructs were polymerized and contracted within these
chambers such that a 5 ml volume of the collagen-cell mixture would be equally
distributed around the circumference of central silicone tubing. The compartments with
the silicone tubes were sealed at one end with lour fittings, and connected to a 6-channel
polycarbonate manifold at the other end, which was in-turn connected to the bellows of
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the bioreactor. A leur-lock was fitted to either ends of the manifold to remove air and fill
the circuit with sterile water. All parts of the system directly in contact with the culture
chamber were either constructed out of autoclavable polypropylene or silicone rubber.

Figure 4.2: Tissue culture chamber of the bioreactor showing 6 parallel culture chambers
with central silicone tubing around which the sell-seeded collagen gels would contract

Motor Controller and Generation of Strains: Stainless steel bellows were mechanically
coupled to the shaft of the stepper motor (EZStepper, All Motion, Union City, CA), such
that as the shaft rotates clock-wise or anti-clockwise, the bellows compress or expanded
proportionately. The speed of rotation, number of steps moved forward or backward by
the shaft, and the minimum and maximum limits (of shaft movement and current drawn)
were controlled by the stepper motor-controller supplied with the motor, customprogrammed to deliver the required strains and frequencies. The compressibility of
bellows and the stepper motor specifications were set such that the system would deliver
a maximum of 5% strain at 5 Hz frequency, sufficient to meet the requirements of our
study. The motor was first programmed to generate linear motion according to the
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manufacturer’s instructions. The parameters in the program were then set up in order to
deliver the 2.5 % strains at the three chosen frequencies of 0.5 Hz, 1.5 Hz and 3 Hz. Each
bioreactor set up delivered cyclic strains to 6 collagen gel constructs cultured in parallel
(as seen in Figure 4.2). In order to confirm the settings and optimize the parameters, test
runs of the strain delivery in the chambers were performed under a stereoscope (Olympus
SZ61; Olympus, Center Valley, PA) connected to a CCD camera (Infinity-2, Electron
Microscopy Sciences, Hatfield, PA). The strain in the silicone tubes were recorded,
calculated using Image J software (NIH, Bethesda, MD) and confirmed based on the
difference in outer diameter per cycle for the three frequencies.
The motor, shaft and the bellows were enclosed in a plastic casing for ease of
handling. The controller was connected to a PC with its software via a USB cable and to
start and stop the program alone, but not at other times. Each bioreactor was individually
connected to an external power supply (0-30 V, 1-3 amps). The system drew less than 0.3
amps and its running voltage was ~ 20 V. During tissue culture, only the tissue culture
chamber with its connections to the bellows and motor were placed inside a sterile CO2
incubator maintained at 37 °C, while the controllers and power supplies were placed
outside.

4.2.2. Fabrication of Tubular Collagen Gel Constructs
Before starting the cultures, the single-use central silicone tubing within each
tissue culture chamber (Figure 4.2) was first inserted and held taut in place to prevent
sagging. A leak test was then performed to ensure that there were no holes in the tubing
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and it did not pop out of the chamber at the strains delivered. The chambers containing
the silicone tubes were then steam sterilized (121 °C, 45 minutes). Parts (b) and (c)
(mentioned in Section 4.2.1) were then assembled and attached to the polypropylene
manifold. A leak test was separately performed for these parts to ensure a tight seal. Even
though the closed circuit (containing bellows, manifold, silicone tubing and the
connecting parts, Figure 4.1) in which water is stored to deliver the strains, is isolated
from the cultures, it was ensured that they were maintained relatively clean as well. To do
this, after the leak test, the entire circuit was incubated with 70% v/v ethanol (10 minute
 3 change) and then rinsed in sterile water (3 ) . These parts were then attached to the
tissue culture chamber inside a sterile hood. Sterile water was then slowly pumped into
the closed circuit via the leur locks using a syringe to completely fill the volume with
water. A leak test was again performed to ensure a tight, closed loop to remove any
residual air bubbles. The set up was positioned upright overnight in the sterile hood,
during which time any residual air bubbles from the circuit arose, to be easily removed by
slowly pumping in more sterile water into the circuit.
Acid solubilized rat tail collagen-I was brought to neutral pH and kept on ice as
described in Section 3.2.2. Adult healthy human aortic SMCs (HASMCs) (Cell
Applications, San Diego, CA) were trypsinized at passage 4 and mixed with the collagen
solution at a final concentration of 0.5  106 cells/ml and 2 mg/ml collagen. Due to the
high collagen gel volumes and number of replicates, cell seeding density used in this
study was 50% of that used in the experiments using rat cells detailed Chapter 3.
Preliminary studies performed to test the extent of contraction between 1  106 cells and
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0.5  106 HASMC/ml indicated comparable degrees of contraction when evaluated 5
days after seeding. The lower cell seeding density is also relevant in the context of our
studies since prior studies have suggested that tropoelastin synthesis tends to be higher on
a per cell basis with lower cell densities28. An aliquot of the cell-collagen mixture (5 ml)
was then added slowly to each culture chamber such that the mixture uniformly
distributed itself around the circumference of the tube. Culture medium was changed
after 24 hours. At 48 hours, the medium was changed yet again and fresh medium with
the stated EF doses (Table 4.1), and dynamic culture conditions were provided. Day one
of the culture was therefore corresponding to 72 hours post-seeding of the constructs.
Optimized EF doses of 0.1 ng/ml TGF-β1 and 0.2 μg/ml HA-o were added exogenously
to the culture medium, similar to that described in Chapter 3. The five experimental and
control conditions are listed in Table 4.1. Constructs that did not receive EFs and were
cultured under static conditions (no EFs, static) were considered to be biological controls
for all normalization purposes. Culture medium was changed every two days and spent
medium was removed, pooled with prior aliquots from the same well, and frozen at -20
°C for later analysis.
After 21 days of treatment, i.e., 24 days post-seeding, the constructs were
harvested for analysis. The constructs were first rinsed in three quick changes of sterile
PBS. Each construct was then cut with the silicone tube, removed from the chamber, and
placed into a dish containing sterile PBS. Constructs were transversely cut into four equal
parts to be further processed for the various biochemical assays listed below.
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Mechanical testing and PCR were performed on a different set of constructs, than
those cultured for biochemical analysis discussed in the following sections. RT-PCR was
performed on approximately

0.8 cm segments of the same constructs seeded for

mechanical testing. In the procedure followed for other assays, for each batch of
trypsinized cells, an equal number of constructs were seeded for each culture condition,
including treatment controls. However, for these analyses, we staggered seeding and
harvesting of constructs corresponding to individual test cases by a few days. All factors
related to initial seeding that may contribute to any variability of construct outcomes such
as cell count, final pH, volumes pipetted etc., were however maintained the same.

Group

0.1 ng/ml TGF–β1+ 0.2
μg/ml HA-o

Frequency of 2.5%
Cyclic strain (Hz)

No EFs, static (control)

-

Static

EFs, static

+

Static

EFs + 0.5 Hz

+

0.5

EFs + 1.5 Hz

+

1.5

EFs + 3 Hz

+

3

Table 4.1: Experimental conditions: impact of dynamic conditioning on induced
elastogenesis in 3D tubular collagen gel constructs
4.2.3. Compaction of Tissue Constructs
All constructs were photographed weekly and their lengths and central widths
measured using Image J software (NIH, Bethesda, MD). At least 5 measurements for
central width and 3 measurements for the length were made per construct. Construct
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compaction was measured and reported as the aspect ratio (length : outer diameter) on the
day of harvest.

4.2.4. DNA Assay for Cell Quantification
One segment of each construct was snap-frozen in liquid nitrogen and lyophilized
for 24 hours, following which dry weights of the segments were measured. The segments
were then digested in 750 μl of 5mg/ml proteinase-K (Gibco–Invitrogen, Carlsbad, CA)
in a 65 °C water bath for 10 hours. The samples were then boiled for 10 minutes above
75 °C to neutralize the enzyme. After cooling the samples down to room temperature (~
25 °C), they were sonicated on ice 5 second cycles for 45 seconds, with a 10 second lag
between each sonication cycle. DNA content was then measured in these samples using a
Hoechst-dye based flourometric assay as described in Section 3.2.4221. Cell count was
measured based on the estimate of 6 pg DNA/cell, and was normalized to mg weights of
constructs (n = 6/case).

4.2.5. RT-PCR for mRNA Expression of SMC Phenotypic Markers and Matrix
Proteins
One segment of each construct (n = 6/case) was cut into 1 mm thick pieces and
snap frozen until processing. Samples were reconstituted in RLT buffer provided with the
RNeasy mRNA isolation kit (Qiagen, Valencia, CA) with 1% v/v 2-mercaptoethanol and
homogenized using

a 21-guage needle and syringe. mRNA was isolated from the

homogenized samples as per the instructions provided in the RNeasy kit manual. Isolated
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Primer Sequence (5’-3’)

Gene
Forward

Tm
(°C)

Size
(bp)

Accession
no. (Source)

58

488

NR_003286
(Real Time
Primers)

58

158

NM_000501
(Real Time
Primers)

145

NG_008805.
2 (Applied
Biosystems)

58

207

NM_06329
(Real Time
Primers)

58

223

NM_002317
(Real Time
Primers)

189

NG_007400.
1 (Applied
Biosystems)

60

153

NM_004530
(Real Time
Primers)

58

183

NM_00994
(Real Time
Primers)

58

165

NM_001613
(Real Time
Primers)

162

NG_029186.1
(Applied
Biosystems)

147

NG_030362.1
(Applied
Biosystems)

TCAAGAACGAAAGTCGGAGG

18S
Reverse

GGACATCTAAGGGCATCACA

Elastin
(ELN)

Forward

CAGTTGGTACCCAAGCACCT

Reverse

AGGTGGCTATTCCCAGTGTG

Fibrillin- 1
(FBLN1)

Forward

GCTCCAGATCCATACAACAC

Reverse

ACACCTTCCTCCATTGAGAC

Fibulin-5
(FBLN5)

Forward

CATTGCAGTGATATGGACGA

Reverse

GAAGCCCCCTTGTAAATTGT

Lysyl
Oxidase
(LOX)

Forward

CAGAGGAGAGTGGCTGAAGG

Reverse

CCAGGTAGCTGGGGTTTACA

Collagen-1
(COL1A1)

Forward

AAGGGACACAGAGGTTTCAG

Reverse

TAGCACCATCATTTCCACGA

Matrix
Metalliprot
einase-2
(MMP2)
Matrix
Metalliprot
einase-9
(MMP9)
α-Smooth
Muscle
Actin-2
(ACT2)

Forward

TTGACGGTAAGGACGGACTC

Reverse

GAGGTCCTTCCTGATGTCAA

Caldesmon
(CALD1)

Forward

CCCAAACCTTCTGACTTGAG

Reverse

ACTTGCCGTACTCCCCATCG

Forward

CTCTGGAGGTTCGACGTG

Reverse

GTCCACCTGGTTCAACTCAC

Forward

AGTTACGAGTTGCCTGATGG

58.5
59.5

59.7
59.5

58.6

Reverse

CGAATTAGCCCTCTACAACTG

59.7

Osteopontin-1 Forward
(OPN1)
Reverse

TGTGCCATACCAGTTAAACAG

58.7

ACTTACTTGGAAGGGTCTGTG

59.8

Table 4.2: Forward and reverse primer sequences for genes analyzed in this study
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RNA (120 ng) was converted into cDNA using iScript cDNA synthesis kit (Biorad,
Hercules, CA), as outlined in Section 3.2.8. Gene expressions of various SMC markers
such as SMA, caldesmon and osteopontin, elastic matrix proteins such as elastin,
fibrillin-1, fibulin-5 and LOX, and MMPs -2 and -9, were estimated in 1 μl cDNA (in
duplicates), using the comparative threshold method with 18 s as the normalizing gene, as
described in the previous chapter. Primers for all genes were either purchased as
optimized primer sets from Real Time Primers (Elkins Park, PA), or designed using the
NIH software PerlPrimer®, as listed in Table 4.2.

4.2.6. Fastin Assay for Elastin Content
One segment from each construct was lyophilized for 24 hours and their dry
weights were measured. Lyophilized constructs were first digested in 1 ml of 0.1 N
NaOH for 1 hr in a 98 °C water bath to convert alkali-soluble matrix elastin into an αelastin form in order to be measured using the Fastin assay kit (Accurate Scientific and
Chemical Corporation, Westbury, NY). The samples were then centrifuged at 5000 rpm
for 10 minutes, and supernatants collected to analyze for alkali-soluble elastin content
(200 µl per sample in duplicates). The pellets were resuspended in 500 μl of 0.25 M
oxalic acid and digested for 1 hr in a 98 °C water bath to convert alkali-insoluble matrix
elastin into the α-elastin form. Digested samples were then filter–centrifuged with 10 kDa
cut–off membranes (Millipore, Billerica, MA) at maximum speed for 10 minutes. The
solubilized matrix elastin retained above the filters (40–50 µl) were then reconstituted to
a total volume of 1000 μl and then quantified with the assay kit (300 µl per sample in
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duplicates). Matrix elastin content measured as alkali-soluble and –insoluble elastin was
reported after normalizing to mg dry weights of construct (duplicate readings, n =
6/case).

4.2.7. Western Blotting for Cellular and Matrix Proteins
One segment from n = 3 constructs from each case were lyophilized, and the cut
into small pieces to speed up homogenization. Cold RIPA lysis buffer (750 µl,
Invitrogen, Carlsbad, CA) with a protease inhibitor cocktail (Thermo Scientific,
Rockford, IL) was then added to each of the samples, following which they were
homogenized on ice for 10–15 minutes (until the pieces appeared to have been
homogenized). The samples were then agitated at 4 °C for 2 hours to completely
homogenize and solubilize the proteins. The digested samples were then centrifuged at
10,000 rpm for 20 minutes, and supernatants collected for further analysis. A BCA assay
was performed to measure total protein concentration in each sample using a
commercially available kit (Thermo Scientific, Rockford, IL).
Western blotting was performed to compare expression of phenotypic markers of
contractile SMCs such as smooth muscle α-actin (SMA; an early-stage marker), Smooth
muscle-22-α (SM22; a mid-stage marker), myosin heavy chain (MHC; a late-stage
marker), and calponin and caldesmon (both mid-stage markers), elastic matrix proteins
such as LOX, fibrillin-1 and fibulins -4 and -5, and matrix proteases MMPs-2 and -9.
Volumes equivalent to 5 μg protein were loaded under reduced conditions into 4–12%
SDS PAGE gels for LOX, fibulin, SMA, SM22, calponin and caldesmon, with MES
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running buffer, and 10% SDS PAGE gels for MMPs, fibrillin and MHC with MOPS
running buffer, along with a pre–stained molecular weight ladder (either 3.5 kDa–250
kDa, or 10 kDa–190 kDa). The gels were then transferred onto nitrocellulose membranes
using an iBlot® Transfer system according to the manufacturer’s instructions. Blots were
then blocked for one hour using a commercially available blocking solution (Li-Cor,
Lincoln, NE), then incubated overnight in primary antibodies, and one hour in secondary
antibody solutions (Li-Cor). Blots were imaged using an Odyssey® Imaging System (LiCor) which enabled the simultaneous measurement of 2 proteins in the same blot. β-actin
was used as a normalizing protein for every blot. All primary antibodies were purchased
from Abcam (Cambridge, MA), except LOX, fibrillin-1 and fibulin-5 (Santa Cruz, CA),
and MMP-9 (Millipore, Billerica, MA), and all western blotting supplies purchased from
Invitrogen (Carlsbad, CA), unless otherwise mentioned.
Protein band intensities were measured using Image-J (NIH, Bethesda, MD)
software in terms of RDU, normalized to the corresponding β-actin bands in the same
blots and reported as a fold change in normalized RDU values relative to treatment
control samples. Samples from three biological replicates were analyzed for each protein,
except for the SMC markers (n = 1 blot each), whose bands were not quantified.

4.2.8. Gelatin Zymography for Detection of Enzyme Activities of MMPs -2 and -9
Gelatin zymography (as described in Section 3.2.8) in was performed on the
RIPA buffer lysed samples as described in Section 3.2.7. Volumes equivalent to 6 μg
protein were loaded into each lane of a 10 % gelatin zymogram (Invitrogen, Carlsbad,
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CA), alongside a pre-stained protein ladder (10 kDa–190 kDa; Invitrogen, Carlsbad, CA),
and purified protein standards of MMPs -2 and -9 (Anaspec, Fremont, CA). Gels were
developed and destained to estimate the activity of MMPs-2 and -9 proportional to the
extent of gelatin digestion bands in the gels. Band intensities were quantified and
reported as outlined in Sections 3.2.8 and 4.2.7. Band intensities of samples from n = 3
biological replicates were used to analyze results.

4.2.9. Visualization of Elastic Matrix
One segment from each experimental case was fixed and paraffin-embedded as
detailed in Section 3.2.9., at the Imaging Core of the Cleveland Clinic. Sections (10 µm
thick) were deparaffinized, epitope-retrieved in 10 mM citrate buffer in a 100 °C water
bath for 40 minutes. Sections were then blocked in 5% v/v goat serum for 30 min,
immunolabeled for elastin (1:100 primary, overnight, 4 °C) and fibrillin-1 (1:50 primary,
overnight, 4 °C), with Alexa Flour®-633 (Invitrogen, Carlsbad, CA) secondary antibody
(1:1000, 1 hour RT). The labeled sections were mounted in Vectashield with DAPI
(Vector Laboratories, INC. Burlingame, CA) to stain for nuclei, cover-slipped and
visualized under a Cy5 filter for elastin and fibrillin. Both cross-sections and
longitudinal-sections of the constructs were labeled and imaged.
Additionally, 30─µm cross- and longitudinal-sections were stained using a
commercially available VVG-based staining kit (ScyTek Laboratories Inc., Cache, UT)
to visualize elastic fibers.
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Longitudinal and cross section of one construct from each treatment condition
were also processed for Transmission Electron Microscopy (TEM). Constructs harvested
at 21 days of culture were fixed in 2.5% v/v gluteraldehyde and 4% v/v
paraformaldehyde in 2% w/v sodium cacodylate buffer for 6 hours at RT and 6 hours at 4
°C, and stored in cacodylate buffer until further processing . Samples were then post–
fixed in 1% w/v osmium tetroxide and 1% uranyl acetate (1 hour), and dehydrated in a
graded ethanol series (50–100 % v/v). Fixed cell layers were embedded in Epon 812 resin
and placed on copper grids embedded in pure Eponate for sectioning. Sections (85 nm
thickness) were cut using a diamond knife, and stained with uranyl acetate and lead
citrate. Sections were imaged using a Philips CM12 electron microscope operated at 60
kV.

4.2.10. Mechanical Testing of Constructs
Tensile properties of the tubular collagen constructs were analyzed on 0.8 cm wide ring
sections of the constructs as outlined by Isenberg. et.al.59 and Lee. et.al.169. Segments (23) from each of the 6 biological replicates per case were harvested. The initial diameter
and thickness of specimens were measured on smaller ring sections (2-3 mm width)
flanking each test specimen using an upright Olympus histology microscope (Pittsburgh,
PA) and its accompanying imaging software, DP2. Multiple specimens (3-4) were
imaged to take these measurements per biological replicate. Tensile testing was
performed using an Instron BioPuls 5988 system (Norwood, MA) with a 10 N load cell,
and in a 37 °C PBS bath. The ring specimens were held in place for the testing via 2
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stainless steel hooks, which were placed between the metal grips of the instrument. The
initial runs performed on test samples indicated that the constructs began to show plastic
deformation and failure at very low loads, i.e., < 1 N. Therefore, unlike the method
outlined in the Nerem study, pre-conditioning was not performed on these constructs.
Load to failure tests were performed at rate of 10 mm/min. The gauge was calculated
when the construct was truly in tension. This was done by dividing the circumference of
the construct by 2, and then subtracting the circumference of the stainless steel hooks
(half of the top and the bottom, equating to the full circumference of one hook). The
thickness was considered to be twice the thickness of the construct, since the stresses
were experienced by both sides of the ring. Tensile modulus and yield properties were
determined from the engineering stress and strain values, plotted from the load vs.
displacement data generated by the instrument. Modulus was calculated as the linear
slope of the stress-strain curve, i.e., the section spanning a 20%-30% strain range with the
highest modulus. A 10%-15% (i.e., 0.32 mm displacement) offset was used to calculate
the yield point to determine the stress strain values.

4.2.11. Statistical Analysis
All quantitative results were analyzed from n = 6 independent biological replicate
cultures and measurements made in triplicates, unless otherwise indicated, and reported
as mean ± standard deviation. Statistics was performed with the help of SPSS software
using a one-way ANOVA, and results were deemed significant for p values ≤ 0.05.
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4.3. RESULTS
4.3.1. Compaction of Tissue Constructs
The aspect ratios (length : O.D.) of constructs in all treatment and control
conditions were ~ 11 (Figure 4.3). No significant differences were found between
groups. It should be noted that there were 1-2 constructs that exhibited aspect ratios
between 8 and 9, indicating higher degrees of longitudinal contraction, but these
observations were not particular to any given condition.

Figure 4.3: Effect of application of cyclic stretch with EFs on construct compaction.
Constructs in different treatment conditions were contracted to similar levels

4.3.2. Cell Quantification
DNA assay performed on tubular collagen constructs (n = 6) indicated all
constructs to have similar cell densities 21 days after treatment (Figure 4.4). Cell
densities per mg dry weight of construct was found to range between (1.2 ± 0.6)  105
cells for cases with mechanical strains at 1.5 Hz, to (2 ± 0.8)  105 for cases at 0.5 Hz.
Differences in cell counts between different treatment conditions were found not to be
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statistically significant. Application of strains did not seem to have a positive or a
negative effect on cell proliferation.

Figure 4.4: Effect of addition of EFs and dynamic conditioning on cell density after 21
days of treatment. No significant differences were observed between different treatment
conditions

4.3.3. Analysis of SMC Phenotypic Markers
RT-PCR of SMC phenotypic markers SMA, caldesmon and osteopontin was
performed to evaluate the effects of treatment with EFs under static and dynamic
conditioning (Figure 4.5). While the addition of EFs did not seem to affect the
expression of early-stage contractile marker within static constructs, SMA within static
constructs (1.21 ± 0.3 –fold,  = 0.97, relative to control), a bimodal increase was
observed with the addition of cyclic strains with increasing frequencies. A 2.23 ± 0.4 fold increase from control was noted for constructs treated with EFs + 0.5 Hz ( = 0.004,
relative to control, and 0.02 to static EFs). This was further increased to 4.13 ± 1 -fold in
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constructs treated with EFs at 1.5 Hz, relative to control and static EFs constructs (ρ <
0.001 for both). However, increasing frequency to 3 Hz brought this expression down to
levels similar to that in control (1.93 ± 0.23 -fold, ρ = 0.06), and static constructs with
EFs (ρ = 0.19). SMA gene expression was significantly higher in constructs with EFs
under 1.5 Hz relative to all treatment conditions ( < 0.001).
mRNA expression of caldesmon in static constructs with or without EFs remained
unchanged (1.17 ± 0.28 –fold,  = 0.9). Relative to control, its gene expression was
increased to similar extents in constructs with EFs under frequencies of 0.5 Hz (1.9 ± 0.4
–fold) and 1.5 Hz (2.2 ± 0.3 –fold), ρ < 0.001. This increase was statistically significant
compared to static EFs constructs as well (ρ ≤ 0.003). Similar to the trend seen in SMA
gene expression, caldesmon gene expression in constructs with EFs under 3 Hz was again
brought down to levels similar to static constructs with or without EFs (1.13 ± 0.34,
relative to control, ρ > 0.95).
Expression of osteopontin remained relatively unchanged among both sets of
static constructs, and dynamic constructs with EFs under 0.5 Hz and 1.5 Hz (ρ > 0.72).
On the other hand, it was elevated significantly in constructs with EFs under 3 Hz
frequency (2.6 ± 0.7 –fold, ρ < 0.001, relative to control). This increase was statistically
significant compared to all other treatment conditions tested in this study (ρ < 0.001).
Western blotting was performed to detect protein quantities of contractile SMC
phenotypic markers (Figure 4.6). Similar to that seen with RT-PCR, band intensities of
SMA, calponin and SM22 were highly pronounced in all cases that received dynamic
stimulation, and appeared similar in both static constructs. Those of MHC appeared more
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elevated only in case with 0.5 Hz frequency and seemed similar within all other treatment
conditions.

Figure 4.5: Change in mRNA expressions of SMC phenotypic markers with addition of
EFs and cyclic strains relative to control. Frequency-dependent regulation of gene
expressions of SMA, caldesmon and osteopontin were observed. ‘*’ represents
significant difference from control, ‘#’ from static EFs, ‘+’ from EFs + 3 Hz, and ‘$’
relative to every condition, for p ≤ 0.05

Figure 4.6: Representative western blots of contractile SMC phenotypic markers, along
with normalizing protein, β-actin. Contractile marker band intensities appeared to be
higher in the three stretched constructs relative to static constructs
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4.3.4. Elastic Matrix Synthesis
RT-PCR was performed to evaluate the effects of EFs and cyclic strains applied at
different frequencies on mRNA expressions of genes encoding various elastic matrix
proteins such as elastin, fibrillin-1, fibulin-5 and LOX (Figure 4.7). mRNA expression of
elastin was greatly influenced with the addition of EFs as well as by change in cyclic
strain frequencies. Within static constructs, addition of EFs significantly increased elastin
gene expression to 4.8 ± 0.4 –fold ( < 0.001), relative to control. Application of cyclic
strains in addition to EFs showed a bimodal behavior in elastin gene expression with
increasing frequencies. Constructs stretched at 0.5 Hz showed an increase of 3.1 ± 0.5 –
fold relative to control ( = 0.001). While this increase with 0.5 Hz was lower than that
seen with static constructs treated with EFs ( = 0.003), application of strain at 1.5 Hz
significantly increased elastin gene expression further to 6.67 ± 1.5 –fold relative to
control ( ≤ 0.002 relative to all treatment conditions). On the other hand, at 3 Hz,
elastin gene expression was brought down to levels similar to that with untreated controls
(1.3 ± 0.2 -fold,  = 0.97, relative to control).
mRNA expression of fibrillin-1 was also influenced by the frequency of applied
strain. Relative to control, while a 2 ± 0.6 –fold increase was observed in static constructs
with EFs ( = 0.007), this was not mirrored under cyclic strain frequencies of 0.5 Hz
(1.38 ± 0.41 –fold,  = 0.7) and 3 Hz (1.7 ± 0.32 –fold,  = 0.1). However, at 1.5 Hz
stretch frequency, fibrillin-1 gene expression was increased to 1.8 ± 0.5 –fold relative to
control, which was deemed statistically significant ( = 0.045). It is important to note that
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among the 4 EF-treated constructs (both static and strained), differences in gene
expression were not statistically significant ( > 0.1).
Addition of EFs or change in cyclic strain frequencies did not appear to influence
mRNA expression of fibulin-5. Its expression levels in all treatment conditions, both
static and dynamic, were similar to that in untreated static control constructs ( > 0.7).
mRNA expression of LOX showed similar trends as that seen with elastin.
Addition of EFs to static constructs increased its gene expression to 2.8 ± 1.1 -fold
relative to control ( = 0.005). Application of strains at 0.5 Hz and 3 Hz did not
significantly alter its expression relative to control ( > 0.7). However at the median
frequency of 1.5 Hz, it was elevated by 2.7 ± 1.2 –fold ( = 0.01), relative to control. The
increase seen with addition of EFs to static constructs and those stretched at 1.5 Hz, were
statistically similar to each other ( = 0.99) and to those stretched at 0.5 Hz ( > 0.07),
but greater than those stretched at 3 Hz ( < 0.02).

Figure 4.7: Effect of addition of EFs and varying cyclic strain frequency on mRNA
expression of genes encoding elastic matrix proteins, elastin, fibrillin-1, fibulin-5 and
LOX. Significant differences represented by '*' from control, '#' from static EFs, '$'
relative to every treatment condition, and ‘@’ between conditions indicated, for p ≤ 0.05
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A

B

Figure 4.8: Effect of EFs treatment under static and stretched conditions on matrix
elastin content. Matrix elastin measured in terms of alkali-soluble and -insoluble elastin
and normalized to cell count (A) and mg dry weight of constructs (B). Significant
differences represented by ‘*’ relative to control, and ‘$’ relative to all treatment
conditions, for p ≤ 0.05

Matrix elastin content was measured using a Fastin assay kit, in terms of alkalisoluble and –insoluble elastin. As seen in Figure 4.8, addition of EFs did not
significantly improve alkali-soluble matrix elastin content in static cultures ( = 0.97).
However, application of cyclic strains in the presence of EFs did significantly improve
alkali-soluble matrix elastin output in a frequency-dependent manner. Relative to control,
constructs treated with EFs and stretched at 0.5 Hz frequency increased alkali-soluble
matrix content up to 2-fold (12.5 ± 3.3 μg/mg, compared to 5.8 ± 2.9 μg/mg in control, 
= 0.4). A significant improvement in alkali-soluble elastin content was seen with EFs
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treatment under at 1.5 Hz cyclic strains. Up to 5-fold increase relative to control, and 3folds relative to static constructs with EFs was seen with application of stretch at 1.5 Hz
(26.2 ± 9.6 μg/mg,  < 0.001 relative to both sets of static treatment). Application of
stretch at 3 Hz however appeared to decrease elastic matrix output (3.8 ± 0.4 μg/mg).
However, it is important to note that the differences in alkali-soluble elastin content were
statistically insignificant among all treatment conditions ( > 0.1), except in constructs
treated with EFs at 1.5 Hz where significantly greater quantities were deposited relative
to all other conditions ( < 0.001). Insoluble matrix elastin content did not appear to
benefit by the addition of cyclic strains despite treatment with EFs. There was a 1.8 fold
increase observed in the static cultures treated with EFs alone (3.9 ± 0.6 μg/mg vs. 2.2 ±
0.4 μg/mg in static controls,  = 0.026). Constructs that received cyclic strains with EFs
synthesized similar quantities of alkali-insoluble elastin under all three frequencies
compared to untreated control ( > 0.9).
Western blotting analysis of other proteins constituting elastic matrix such as
LOX, fibrillin-1 and fibulins -4 and -5 were not reliably detected at the protein
concentrations tested (5 µg). It was found out from the manufacturers of the antibodies,
that for the detection of fibulin in western blots, at least 50 μg protein was required,
which was much higher than the protein yields obtained in our studies.

4.3.5. MMP -2 Production and Activity
RT-PCR, western blotting and zymography were performed to analyze the
expression, synthesis and activity of proteases specific to elastic matrix degradation
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synthesized by SMCs, i.e., MMPs -2 and -9. As seen in Figure 4.9, relative to control,
mRNA expression of MMP-2 remained unchanged within constructs treated with EFs
under static conditions and with cyclic stretch applied at 0.5 Hz and 1.5 Hz ( > 0.5).
However, under EF-treatment with cyclic stretch at 3 Hz, there was a 1.9 ± 0.3 –fold
increase in MMP-2 mRNA expression, relative to control. This increase was statistically
significant relative to all treatment conditions ( ≤ 0.001). However, as seen in Figures
4.10 A and B, western blotting performed to estimate total protein content of zymogen
and active forms of MMP-2 did not reveal any significant differences among the
treatment conditions, both static and dynamic. On the other hand, zymography (Figures
4.11 A and B) performed to estimate activity of secreted MMP-2 enzyme, showed more
than 3-fold increase in band intensities of the zymogen form of the protease in all EFtreated constructs, relative to control ( < 0.02). This increase in zymogen content was
similar in all EF-treated conditions, both static and dynamic ( > 0.4). On the other hand,
no significant differences in zymogram band intensities of the active form of protease
was observed in any of the treatment conditions relative to control ( > 0.1).

Figure 4.9: Effect of varying cyclic strain frequency and addition of EFs on MMP-2
mRNA expression relative to control. Increase in MMP-2 gene expression was significant
($) in constructs stretched at 3 Hz frequency, relative to all other treatment conditions, p
≤ 0.05
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Figure 4.10: Effect of addition of EFs under static and dynamic conditions on MMP-2
protein content. (A) Representative immunoblots showing zymogen and active forms of
MMP-2 protein, with normalizing protein, β-actin. (B) Semi-quantitative analysis of
differences in band intensities of the 2 forms of MMP-2 protein relative to control. No
significant differences were observed between different treatment conditions

Figure 4.11: Effect of addition of EFs and change in cyclic stretch frequency on MMP-2
enzyme activity. (A) Representative zymogram showing MMP-2 band intensities at both
active and zymogen forms. (B) Semi-quantitative analysis of change in MMP-2 enzyme
activity relative to control. ‘*’ indicates significant difference from control for p ≤ 0.05

4.3.6. MMP -9 Production and Activity
mRNA expression of MMP-9 was uniformly low in all constructs, and their Ct
values were at or below the detection limits of the instrument, at the cDNA
concentrations tested. Therefore, it was difficult to discern differences between treatment
conditions, if any existed. Similarly, bands corresponding to either active or inactive
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forms of the protease were undetected by zymography, at the protein concentrations
tested (5 µg/case). However, western blotting analysis of MMP-9 (Figures 4.12 A and B)
showed increase in band intensities of both active and zymogen forms of the protease in
EF-treated constructs subjected to cyclic stretch at frequencies of 1.5 Hz and 3 Hz.
Relative to control, 1.6 ± 0.5 –fold increase in both active and inactive forms of MMP-9
were seen under 1.5 Hz ( < 0.05). With application of stretch at 3 Hz, relative to control,
increase of 1.7 ± 0.5 –fold for zymogen, and 1.4 ± 0.1 –fold for active MMP-9 were seen
( < 0.04). This increase with application of 1.5 Hz and 3 Hz was statistically significant
compared to static EFs and EFs + 0.5

Hz stretch as well ( < 0.04).

Figure 4.12: Effect of change in cyclic strain frequency and addition of EFs on MMP-9
protein content. (A) Representative immunoblot of MMP-9 showing active and zymogen
forms of the enzyme. (B) Semi-quantitative analyssis of fold-change in RDU of band
intensities of both forms of the protein relative to control. Significant differences are
represented by ‘*’ from control, ‘#’ from static EFs, and ‘+ from EFs + 0.5 Hz, for , for p
≤ 0.05
4.3.7. Matrix Ultrastructure
Cross- and longitudinal- sections of all treatment conditions were labeled for
elastin and fibrillin proteins. As seen in Figures 4.13 through 4.15, cells and fibers were
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found be oriented more in the longitudinal direction than in the circumferentially.
A

B

Figure 4.13: Effects of EF-treatment and variation of strain frequency on matrix
assembly and orientation. Representative images of 30 µm-thick longitudinal-sections
(A) and cross-sections (B) of all constructs stained with modified VVG. Elastic fibers,
stained purple to black, within cyclically strained constructs appear oriented more
towards the longitudinal direction, than in the circumferential direction. Alignment in the
longitudinal direction appears more random with increase in strain frequency, indicating
initiation of alignment perpendicular to applied strain. Circumferential alignment can be
seen closer to the lumen (L) within strained constructs, which does not appear to have
uniformly translated across the thickness of the constructs. More number of elastic fibers
appear to be present in constructs treated with EFs compared to those without. Scale bar
(in red) = 100 µm, 10  magnification.
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B

Figure 4.14: Effects of EF-treatment and cyclic strain frequency variation on synthesis
and assembly of fibrillin. Representative images of 10 µm thick longitudinal- (A) and
cross- (B) sections of constructs immunolabeled for elastin (red) and nuclei (blue).
Longer fibers of elastin are seen in the longitudinal direction than circumferentially,
similar seen in Figure 4.13. White arrows indicate longitudinal direction of constructs.
‘L’ = lumen. 10  magnification.
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B

Figure 4.15: Effect of EF-treatment and varying frequency of stretch on fibrillin
assembly and orientation. Representative fluorescent images of 10 µm thick longitudinal(A) and cross- (B) sections of constructs immunolabeled for fibrillin (red) and nuclei
(DAPI). White arrows indicate longitudinal direction of constructs. ‘L’ = lumen. 10 
magnification.
Application of stretch was found to improve orientation in the circumferential
direction in the regions closer to the silicone tubing, and progressively decreased in
regions further away from it. However, in the longitudinal direction, as seen in both in
VVG-stained images (Figure 4.13) and the IF images (Figure 4.14 and 4.15), mature
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elastic fibers were found in all the cases. Another important observation to be made is
that the distribution of these fibers is not uniform across the width or circumference of
the constructs; they appear to be denser in some regions more than others.
Immunolabeling of elastin and fibrillin (Figure 4.14 and 4.15) showed that these proteins
were mostly found associated with each other.
TEM was also performed on both cross- and longitudinal- sections.
Representative images of longitudinal sections from a construct treated with EFs + stretch
at 1.5 Hz are shown in Figure 4.16. Once again, what appears to be elastin assembly on
fibrillin scaffolds (indicated by arrows) are seen in some regions within longitudinalsections, but were hardly observed in the cross-sections. Cell morphology appeared
normal across most regions in the section and cell membranes appeared intact.

Figure 4.16: Representative TEM images of constructs conditioned with EFs and cyclic
stretch at 1.5 Hz. Initiation of elastic matrix deposition (indicated by red arrows) can be
seen between adjacent cells. Collagen is indicated by black arrows. Scale bars = (A) 1
µm, 25,000  magnification, and (B) 500 nm, 40,000  magnification.
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4.3.8. Mechanical Properties of Constructs
As mentioned in Section 4.2.2 of this chapter, mechanical testing was performed
on a different set of samples than that seeded for biochemical assays discussed above.
While all seeding procedures were kept constant, we observed that in the constructs
seeded under the dynamic conditioning at 0.5 Hz and 1.5 Hz, the two constructs located
in wells at each end of the tissue culture chambers, contracted much less than the ones
seeded in the middle. We attribute this to user error that may have arisen either due to
presence of residual ethanol vapors in the chambers or unequal mixing of cell-collagen
solution prior to seeding. While this anomaly resulted in a decrease in mRNA yields, it
did not affect the overall outcomes of our PCR results. However, the mechanical
properties of these constructs cultured on either ends were quite different than the ones
cultured in the three chambers towards the center. We have therefore reported results
both including and excluding these constructs (Figures 4.17 and 4.18). We also observed
a higher degree of circumferential non-homogeneity compared to previous culture sets,
which is likely to have had a significant impact on the mechanical testing outcomes.
Tensile modulus was calculated over 0.873 mm displacement, corresponding to
20% - 30% strain in the constructs (Figure 4.18 A). Prior to excluding the end constructs,
the tensile modulus was calculated to be 1.59 ± 0.97 kPa for constructs cultured at 0.5 Hz
with EFs, and 1.93 ± 1.08 kPa at 1.5 Hz strains with EFs. The static constructs without
EFs showed a modulus of 2.30 ± 0.39 kPa, and 2.12 ± 0.81 kPa for those with EFs. After
eliminating the anomalous end constructs, the modulus was found to be 1.81 ± 1.06 kPa
for 0.5 Hz and 2.48 ± 0.51 kPa for 1.5 Hz, compared to 2.41 ± 0.37 kPa for static
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controls, and 1.67 ± 0.33 kPa for static cultures with EFs. The differences in the tensile
modulus between cases were found to be statistically insignificant both with and without
inclusion of the end constructs.
As seen in Figure 4.18 B, yield properties were found to be lowest in constructs
with EFs at 0.5 Hz. While the yield stress showed significant decrease compared to static
constructs after eliminating the end constructs (1.16 ± 0.54 kPa,  = 0.019), decrease in
yield strain was significant prior to eliminating them (1.41 ± 0.12,  = ). Differences in
yield properties among all other constructs remained statistically insignificant.
Since the testing was started when the constructs were technically not in tensioni.e., in their original diameters, the toe region seen in the stress-strain curves primarily
represent the phase where the constructs are being stretched up to a length at which they
begin to experience true tension. We believe that any elastic properties of the constructs
contributed by the synthesized elastic matrix may be masked by this phenomenon within
this region. Therefore, unlike that reported by the Nerem group, we believe that
calculating the modulus within this toe region does not provide accurate information
regarding the elastic properties of the constructs. We have therefore calculated the tensile
and yield properties beyond the toe region, once the constructs were in true tension.

4.4. Discussion
Among the various hemodynamic forces present in the vasculature, cyclic
circumferential strains are the most prevalent forces perceived by vascular smooth
muscle cells5. Cyclic strains are therefore also most influential in regulating
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mechanotransduction-mediated effects in VSMC phenotypic state, matrix synthesis and
orientation164,

235

. Various cell surface receptors have been identified that respond to

different components of external stimuli. For example, Liu et.al., have shown that strain
frequency-dependent modulation of VSMC alignment is regulated by integrin β-1
receptors that activate a p38-mitogen-activated protein kinase (MAPK) pathway167.
Alignment is elicited first in the cytoskeletal actin filaments, which ultimately results in
cellular orientation. It has also been reported that such alignment is highly frequency
dependent, and maximum alignment is usually obtained in frequencies between 0.5 Hz
and 1.25 Hz167-168.

Figure 4.17: Representative stress vs. strain curves of n = 6 samples per treatment
condition. The initial toe region corresponds to the phase during which constructs are
truly brought under tension. All constructs demonstrated a linear phase, where their
tensile properties were determined. Soon after the constructs started to fail, they
continued to display plastic deformation, until they completely failed. The end constructs
that did not contract as much as the ones centrally placed.
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B

C

Figure 4.18: Effect of EF-treatment and cyclic strain frequencies on mechanical
properties of HASMC-seeded tubular collagen gel constructs. Tensile and yield
properties are represented excluding the anomalous end constructs. (A) Tensile modulus
corresponding to 20%-30% strains, were found to be similar in all treatment conditions.
Yield properties (B) and (C) were not improved by cyclic strains or addition of EFs. ‘*’
represents significant difference from untreated static controls, ‘#’ from static EFs, ‘§’
from EFs+1.5 Hz and ‘+’ from EFs+3 Hz, for p ≤ 0.05

Most studies conducted so far that have explored the role of cyclic stretch to
improve cell alignment and matrix output have utilized physiological levels of 10% strain
at 1 Hz frequencies57, 59, 166, 236. These studies were also aimed towards tissue engineering
small diameter vascular grafts that typically experience higher strains than elastic
arteries5. However, as noted by the Tranquillo group, cells under these conditions in vivo
usually remain in a quiescent, non-proliferative and non-matrix producing states59. In one
of their studies, they have further noted no changes in cell proliferation, alignment or
matrix production between 2.5% and 10% strains59. Moreover, reconstituted collagen
gels, such as that used in this study, behave like viscoelastic fluids prior to forming
mature fibrils. Therefore, when subjected to long-term cyclic loading, they can succumb
to irreversible creep, especially at higher strain amplitudes59. Wernig et.al., have shown
that the same integrin β-1 receptors involved in cell alignment, also mediate stretchinduced apoptosis at strains greater than 10%171. Further, studies have also shown higher
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expression of matrix degrading MMPs such as MMPs-2 with higher strain amplitudes237238

. While it can be argued that the presence of these MMPs might be required to initiate

matrix remodeling, their activity can at the same time also adversely cause the
degradation of newly synthesized elastic matrix10, 83, 172. In the current study, we therefore
utilized lower strain values of 2.5% and varied the frequency rates to evaluate its effects
on cell behavior and induced elastic matrix outcomes.
Cell densities after 21 days of treatment were found to be comparable between the
static and dynamic cultures. This was in accordance with other studies that have reported
similar observations within collagen gel scaffolds28, 236. It has been noted that under 10%
strains, cell proliferation appears to be dictated by the scaffold in which the cells are
grown. For example, while Kim et.al., noted increased cell proliferation at 7% strains in
PGA scaffolds57, Isenberg et.al. noted no changes in cell densities between 2.5% and
10% strains59, or between static and dynamic cultures within tubular collagen scaffolds.
In contrast to the results reported on rat cells in the previous chapter, addition of EFs did
not increase cell numbers in this study.
Several studies have also shown that cyclic stretch can maintain a healthy
contractile phenotype of SMCs. SMCs in culture are known to typically switch to a more
synthetic, proliferative and matrix-producing phenotype, compared to that seen in vivo.
While this phenotypic switch to produce matrix is crucial from the stand point of tissue
engineering and regenerative medicine, excessive expression can also lead to abnormal
proliferation and undesirable matrix output, as seen in a diseased environment such as
that in AAAs. Maintaining a balance between a healthy and a synthetic phenotype is

114

therefore the key to carefully regulate desirable cellular response. Cyclic stretch is known
to improve the expression of various contractile phenotypic markers of SMCs such as
SMA, caldesmon and MHC, while at the same time, also increase matrix output. In our
study, mRNA expressions of the 2 contractile markers tested- SMA and caldesmon
appeared to be influenced more by change in frequency, than with the addition of EFs.
While addition of EFs to static constructs did not significantly change gene expression of
the above contractile markers, a bimodal trend was observed with increase in frequency
of applied strain. This trend was far more pronounced in SMA gene expression, which
showed a moderate 2-fold increase with stretch at 0.5 Hz, increased further up to 4-fold
at 1.5 Hz, and at 3 Hz, dropped down to levels similar to that within static constructs.
Caldesmon expression was moderately increased with stretch at 0.5 Hz and 1.5 Hz, but
not at 3 Hz. On the other hand, gene expression of osteopontin, a marker for osteogenic
differentiation of SMCs suggestive of an activated phenotype, was elevated up to 2-fold
within constructs stretched at 3 Hz alone. However, no differences were noted relative to
control in other constructs treated with EFs, both static and dynamic. This is in contrast to
other studies that have reported that the expression of osteopontin that is generally
increased within 3-D cultures, is down regulated by the addition of cyclic stretch240.
TGF-β1 is known to induce osteogenic differentiation of SMCs at concentrations > 10
ng/ml139. While the doses utilized in our study were a 100-fold lower, it is likely that at
frequencies as high as 3 Hz, the addition of TGF-β1 could induce such osteogenic
expression. mRNA expression of elastin appeared to be influenced both by the addition
of EFs and changing frequencies of cyclic stretch. While addition of EFs increased elastin
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mRNA expression up to 5-fold within static constructs, a bimodal frequency-dependent
change was seen under cyclic stretch. Up to a 3-fold increase was seen with stretch at 0.5
Hz, which was significantly elevated up to 6-fold at 1.5 Hz, but lowered to levels
comparable to static constructs without EFs at 3Hz. Similarly, the 2-fold increase mRNA
expressions of fibrillin-1 and LOX within EFs-treated static constructs, relative to
control, were mirrored in stretched constructs under 1.5 Hz frequencies alone. This trend,
together with that seen with variation in gene expressions of SMC markers, suggests that
EF-mediated alternations in gene expressions are closely regulated under varying
dynamic environments. This is further substantiated with observations made in elastic
matrix output within different treatment conditions in this study. Within static constructs
treated with EFs, despite the up-regulation in elastin gene expression, alkali-soluble
matrix elastin content was not significantly greater than untreated controls. However, EFtreatment under cyclic strains at 1.5 Hz, significantly improved alkali-soluble matrix
elastin output up to 5-fold, relative to static constructs with or without EFs. Further, while
mRNA expression of elastin and genes encoding other elastic matrix proteins were lower
in EF-treated constructs stretched at 0.5 Hz and 3 Hz relative to static EFs, alkali-soluble
elastin content between the three groups were comparable. Moreover, despite the 2-fold
increase in LOX and fibrillin-1 gene expressions seen relative to control within static EFs
and EFs + 1.5 Hz constructs, we could not detect their presence at the protein levels.
Fibrillin-1 is an important component of the microfibrillar scaffolds on which
tropoelastin units are coecervated, and LOX is a Cu2+ dependent enzyme that crosslinks
tropoelastin molecules. Their synthesis and activity are therefore important determinants
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in generating a mature, crosslinked elastic matrix. In the light of limited synthesis of
these proteins, despite increase in their gene expressions, crosslinking new elastin
precursors were likely limited. This could potentially have contributed to the low levels
of alkali-insoluble elastin measured in all treatment conditions.
Analysis of elastic matrix degrading gelatinases, MMPs -2 and -9, showed
different trends at the gene expression level compared to that at the enzyme level. MMP2 gene expression was up-regulated up to 2-fold relative to control in EF-treated
constructs stretched at 3 Hz alone, and was comparable to static controls within all other
constructs. However, both the total protein content as well as enzyme activity of MMP-2
were comparable among all treatment conditions. This finding is in contrast to that
observed by other groups, wherein both gene expression and enzyme activity of MMP-2
have been reported to increase under cyclic stretch relative to static controls237-238. This
difference could be attributed to the use of low strains of 2.5% in our studies, compared
to the 10% strains used in other studies. It is also likely that at these strains, EFs-mediated
decrease in MMP-2 enzyme activity is being facilitated. While the differences in protein
content and enzyme activity remained insignificant, it is important to note that the thick
bands corresponding to active enzyme in the zymograms indicated high levels of enzyme
activity for protein concentrations as low as 5 μg/lane. On the other hand, mRNA
expression of MMP-9 was uniformly low in all treatment conditions. However, moderate
increase (~ 1.5 –fold) in its protein content, both zymogen and active forms, were seen in
constructs treated with EFs and stretched at 1.5 Hz and 3 Hz.
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The matrix ultrastructure and orientation of cells in the scaffolds were contrary to
what we had hypothesized. As noted in the VVG stained slides and IF images, at the
strain and frequencies provided, the cells and elastic fibers all appear to be oriented more
in the longitudinal direction, than in the circumferential direction. Several studies have
reported lower degrees of orientation and random alignment at 2.5% strains, compared to
higher strains of 10%. However, what we note in this study is a uniform orientation in the
longitudinal direction. Further, the longitudinal orientation closely resembles what was
observed in the static cultures reported in Chapter 3. The increase in expression of
various SMC contractile markers and changes in levels of matrix elastin however indicate
that the cells have responded to the presence of external mechanical stimuli. The cross
sectional views of constructs treated with stretch do indicate higher levels of
circumferential orientation on the surface closest to the silicone tubing, compared to the
regions further away from it. This indicated preliminary levels of orientation, not
completely transferred to the entire thickness of the collagen gel. As a result of this
orientation, the mechanical tests that were performed on ring sections of the constructs
also did not show significant differences in tensile or yield properties. The low modulus
of ~ 2 kPa seen in all test conditions could also be explained by the apparent influence of
treatment conditions on matrix orientation more in the longitudinal direction and less in
the circumferential direction.

118

4.5. Conclusions
In this study we have demonstrated a positive influence of application of dynamic
stimulation along with EFs up to 1.5 Hz frequency. Both increases in mRNA expression
of proteins involved in elastic matrix assembly as well as increase in alkali-insoluble
matrix elastin content was observed and found to be highest in the constructs treated with
EFs and stretched at frequency of 1.5 Hz. Alkali-insoluble matrix elastin remained
unchanged with the addition of EFs along with dynamic stimulation. While a
circumferential orientation was not obtained as expected, a high degree of longitudinal
orientation was obtained.
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CHAPTER FIVE
IMPACT OF MMP─INHIBITION ON OUTCOMES OF INDUCED
ELASTOGENESIS IN STATICALLY AND DYNAMICALLY CULTURED
TISSUES

5.1. INTRODUCTION
In the studies described in the previous chapters, we reported on the elastogenic
benefits of TGF–β1 and HA-o to adult SMCs, both rat and human, cultured under static
and dynamic conditions. In these studies, however, it was noted that the fraction of
matrix elastin deposited in the highly crosslinked alkali-insoluble elastin form was low,
and the expression and activity of the elastolytic enzyme MMP-2 continued to be high,
regardless of the treatment condition. In an attempt to improve deposition of crosslinked
mature elastic matrix and reduce its degradation, critical to enhancing accumulation and
fiber formation, in this study, we sought to evaluate if suppression of MMP-2 activity in
the cultured constructs improves the above mentioned synthesis.
Doxycycline (DOX) is a modified tetracycline compound that has been widely
administered as a broad-spectrum antibiotic126. Known to be a non-specific MMP
inhibitor, systemic delivery of DOX has been clinically shown to reduce the rate of AAA
growth and progression of disease45-47. Studies exploring the mechanisms of MMP
inhibition have found DOX to significantly reduce activity of both elastolytic (MMPs -2,
-9) and non-elastolytic (MMPs -1,-3,-8,-12) proteases, both at the transcription and
translation steps of protein synthesis127-128. Several groups have also specifically
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evaluated its effects on gelatinases, i.e., MMPs -2 and -9, proteases that are up-regulated
most in the AAA walls and are primarily responsible for elastolytic activity, both in vivo
and in vitro129-130.
Preliminary studies conducted in our lab tested effects of DOX on SMCs isolated
from a CaCl2 model of rat AAA, over a dose range of 0.1 μM–10 μM. The DOX was
added exogenously with culture medium. Of these, the highest dose of 10 μM was found
to be highly cytotoxic, while the lower doses of 0.1 μM and 1 μM did not impede cell
proliferation over 21 days of culture. For this study, we therefore delivered the lower
DOX doses of 0.1 μM and 1 μM, and exogenously supplemented it to the culture medium
along with previously determined, effective dose combination of EFs (see Chapter 3). In
the study described in Chapter 4, the dynamic conditioning regime found to promote
highest elastogenic activity was 2.5% cyclic strain applied at a frequency of 1.5 Hz. The
two DOX doses with EFs were therefore provided to both static HASMC-seeded tubular
collagen gel constructs, and constructs stretched cyclically to 2.5% strains at 1.5 Hz for
21 days.

5.2. MATERIALS AND METHODS
All steps involved in fabrication and culture of constructs, assay time points and
methods of construct harvest, methods of biochemical analysis, imaging, and statistical
analysis were performed in a manner similar to that described in Section 4.2 of Chapter
4. Doxycycline solutions were prepared fresh prior to each media change. Mechanical
testing was not performed on these constructs.
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The different treatment conditions are listed in Table 5.1. Of these, the static
controls, static + EFs and EFs + 1.5 Hz construct samples were reused from those
cultured for the study in Chapter 4. These samples were either 1) re-assayed along with
the samples obtained from those cultured with DOX in this study (DNA assay, Fastin
assay, zymography western blotting of MMPs -2 and 9), or 2) experiments for both
studies were performed simultaneously (RT-PCR and western blotting for SMC
phenotypic markers, fibrillin and fibulins), in order to enable direct statistical comparison.

Group

Doxycycline
(µM)

TGFβ1 (0.1 ng/ml)/
HA-o (0.2 µg/ml)

Cyclic Stretch
(2.5% strain,
1.5 Hz)

No EFs (Control)

-

-

-

EFs, static

-

+

-

+

-

EFs + DOX, static (1)
EFs + DOX, static (2)

0.1

+

-

EF, dynamic

1

+

+

EFs + DOX, dynamic (1)

0.1

+

+

EFs + DOX, dynamic (2)

1

+

+

Table 5.1: Experimental conditions- effect of MMP-inhibition on outcomes of induced
elastogenesis

5.3. RESULTS
5.3.1. Construct Compaction
As shown in Figure 5.1, the aspect ratios of constructs (length : O.D) at 21 days
after treatment with DOX and EFs were found to be 11 ± 2.3, similar to that seen in
constructs without DOX and in no EF controls. This indicates that the degree of
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contraction was higher in the transverse direction than longitudinally (as length/O.D is ~
11, which indicates length >> O.D).

5.3.2. Cell Quantification
After 21 days of treatment, cell numbers were normalized to mg dry weights of
lyophilized constructs. While cell numbers appeared to increase under dynamic
stimulation in constructs with or without DOX, this increase was statistically significant
only in constructs with 0.1 μM DOX (2.01 ± 0.62  106 ) and EFs compared to static
controls without DOX or EFs ( = 0.006) (Figure 5.2). Differences were statistically
insignificant between all other treatment conditions. This indicates that the addition of
DOX with EFs under static or stretched conditions did not adversely affect cell growth,
either in terms of cell proliferation or cell death, compared to untreated static controls.

5.3.3. Analysis of SMC Markers
RT-PCR (n = 6) and western blotting (n = 1) of SMC phenotypic markers were
performed to analyze the effect of treatment conditions on phenotypic changes to SMC
(Figure 5.3). mRNA expressions of contractile phenotypic markers of SMCs – SMA
(early-stage marker) and caldesmon (mid-stage marker), and synthetic, activated marker,
osteopontin, were analyzed in the different treatment conditions.
Figure 5.3 A shows the fold change in mRNA expression of SMA in the different
treatment conditions compared to static constructs without EFs (control). Compared to
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Figure 5.1: Effect of treatment conditions on construct compaction after 21 days.
Graph above shows similar extents of contraction among all treated conditions,
under both static and dynamic conditions

Figure 5.2: Effect of DOX + EFs on cell densities after 21 days of treatment,
under static and stretched conditions. Plot above shows addition of DOX + EFs
under
both static and dynamic conditions did not significantly alter cell densities
c
ontrols, SMA mRNA expression remained unchanged in all static constructs treated with
or without DOX. Addition or increasing concentration of DOX did not alter this
expression ( > 0.06). On the other hand, cyclic stretch significantly increased its
expression in all treatment conditions ( < 0.001 compared to static controls). This
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increase was highest in dynamic constructs with EFs alone, where 4.13 ± 1 –fold increase
was seen compared to controls ( < 0.001). This increase was also mirrored in all
dynamic constructs treated with EFs or EFs + DOX, compared to their corresponding
static constructs treated with similar concentrations of the same factors ( < 0.001).
Addition of 0.1 μM DOX with EFs to stretched constructs appeared to slightly lower
SMA expression compared to stretched constructs with EFs alone ( = 0.003). However,
as was seen with static constructs, increasing concentration of DOX in stretched
constructs did not alter SMA mRNA expression ( = 0.27).

Figure 5.3: Effect of stretch on SMC phenotypic markers compared to static cultures
in the presence of DOX + EFs. (A) mRNA expression of SMA significantly increased
with application of stretch compared to static constructs. (B) mRNA expression of
caldesmon similarly increased within cyclically stretched constructs. (C) mRNA
expression of osteopontin remained unaffected in all treatment conditions, except in
stretched EFs constructs alone. (D) Representative immunoblots of SMC contractile
phenotypic markers showing increase in protein content with addition of stretch.
Significant differences for p ≤ 0.05 are indicated by ‘*’ relative to control, ‘#’ from
static EFs, ‘&’ between the groups indicated, and ‘+’ from all DOX + EFs –treated
constructs, both static and dynamic
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Figure 5.3 B shows fold changes in mRNA expression of caldesmon compared to
controls. Similar to the trends observed with mRNA expression of SMA, that of
caldesmon remained unchanged within all statically treated constructs ( > 0.49), but
increased to 2.2 ± 0.45 -fold with incorporation of stretch ( < 0.001), compared to
controls. Addition or increasing concentration of DOX did not alter its expression
between conditions within both static ( > 0.93) and stretched constructs ( > 0.98).
However, addition of stretch to constructs treated with similar concentrations of EFs or
EFs + DOX significantly increased its expression compared to corresponding static
constructs ( < 0.02).
As seen in Figure 5.3 C, mRNA expression of the synthetic, activated SMC
phenotype marker, osteopontin, was not significantly increased or decreased compared to
control in any of the treatment conditions ( > 0.2). While addition of EFs alone (both
static and stretched) appeared to slightly increase this expression, the differences were
statistically insignificant ( > 0.2). However, compared to stretched constructs with EFs
alone, addition of DOX at both doses, appeared to lower this expression, in both static (
< 0.02) as well as stretched ( < 0.005) constructs. Differences with increase in DOX
concentration (both static and stretched) were insignificant ( > 0.8).
Western blotting (Figure 5.3 D) of contractile phenotypic markers SMA, SM22α,
calponin and MHC showed an increase in band intensities in all stretched constructs
compared to the static constructs. Bands for caldesmon were undetected at the protein
concentrations tested (5 μg).
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5.3.4. Elastic Matrix Content
RT-PCR for gene expressions of elastin, fibrillin-1, fibulin-4 and LOX, Fastin
assay for quantifying matrix elastin (alkali -soluble and –insoluble), and western blotting
of fibrillin-1, fibulin, and LOX were performed to evaluate the effects of the treatment
conditions on elastic matrix output.
As seen in Figure 5.4 A, mRNA expression of elastin was significantly increased
in all treatment conditions compared to control ( < 0.01). Among the static constructs,
the highest increase was seen in those with 1 µM DOX + EFs (6.1 ± 0.97,  < 0.001),
compared to control. However, among the 3 sets of static cultures treated with or without
DOX, no statistical difference was observed ( > 0.15). The mRNA expression was
pronounced to a greater extent among the stretched constructs than their static
counterparts (6.7 ± 1-fold compared to control,  < 0.001). Similar to that seen with the
static constructs, addition of DOX + EFs at the 2 doses to stretched constructs induced
similar increases in mRNA elastin expression compared to stretched constructs with EFs
alone ( = 1). As seen in Chapter 4, with respect to control, addition of stretch to
constructs treated with EFs alone resulted in a 6.7 ± 1.5 –fold increase in elastin mRNA
expression, which was significantly higher than the 4.8 ± 0.4 –fold among static EFs
constructs ( = 0.006). However, addition of stretch did not improve the already high
mRNA expression among the DOX-treated cultures at either doses ( > 0.15).
The mRNA expression of fibrillin-1, the microfibrillar scaffolding protein of
elastic matrix, was increased to similar extents of approximately 2-fold in almost all
treatment conditions compared to controls ( > 0.12), as seen in Figure 5.4 B. However,
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this increase was statistically significant only in 3 treatment conditions compared to
control- static EFs (2 ± 0.6 –fold,  = 0.02), and 0.1 µM DOX + EFs –treated constructs,
both static (2.1 ± 0.6,  = 0.01) and stretched (2 ± 0.6,  = 0.04). No significant
differences in expression were observed between all other treatment conditions. The
mRNA expression of fibulin-4 (Figure 5.4 C) also remained unchanged in all treatment
conditions compared to control ( > 0.85). mRNA expression of LOX appeared to be
elevated in all treatment conditions (Figure 5.4 D). However, this increase was also
significant only in 3 treatment conditions- static constructs with EFs alone (2.82 ± 1.1, 
= 0.004), stretched constructs with EFs alone (2.68 ± 0.42,  = 0.01), and stretched
constructs with 1 µM DOX + EFs (2.43 ± 0.42,  = 0.047). Like that observed in
expressions of fibrillin-1 and fibulin-5, differences in mRNA expression of LOX between
treatment conditions, both static and stretched, were insignificant ( > 0.098).
Matrix elastin content was measured in terms of the less crosslinked alkali-soluble
elastin, and the highly crosslinked alkali-insoluble elastin, as seen in Figure 5.5.
Compared to control, alkali-soluble matrix elastin content was significantly elevated in
all treatment conditions, both static ( < 0.047) and stretched ( < 0.001). Within static
constructs, the addition of DOX + EFs at both doses resulted in further increase in alkalisoluble elastin content compared to those with EFs alone (26.2 ± 9.5 µg/mg,  = 0.05
with 0.1 µM DOX + EFs, and 30.6 ± 9.3,  = 0.001 with 1 µM DOX + EFs). Addition of
stretch further increased alkali-soluble elastin content. Up to 2-fold increase was noted in
constructs treated with EFs alone (15.5 ± 1.7 µg/mg in static, compared to 32 ± 5.8 µg/ml
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Figure 5.4: Evaluation of changes in mRNA expression of different elastic matrix
proteins under static and dynamic conditions with the addition of DOX and EFs
(A) elastin, (B) fibrillin-1, (C) fibulin-5, and (D) LOX. '*' represents significant
difference from control and '#' from static EFs, for p ≤ 0.05

in not improve the already high levels of alkali-soluble elastin content (> 26 µg/mg in all
cases,  > 0.47 between the 4 DOX + EF –treated constructs). Similarly, among the 3 sets
of stretched constructs, with or without DOX, differences were insignificant ( > 0.46).
The presence of the highly crosslinked, alkali-insoluble matrix elastin content was found
to be similar in almost all treatment conditions (1.9 ± 0.8 µg/mg,  > 0.19), with or
without DOX or stretch. Stretched constructs with 0.1 µg/mg DOX + EFs, were the only
condition that showed a significant increase in alkali-insoluble elastin content compared
to all other constructs (3.8 ± 1.9,  < 0.04).
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Figure 5.5: Effects of addition of DOX and EFs on elastic matrix content under static
and dynamic conditions. Alkali -soluble elastin elevated in all treatment conditions
compared to control. Alkali-insoluble matrix elastin remained unchanged in almost all
cases, except in 0.1 M DOX + EFs. '*' represents significant difference from control,
‘#’ from static EFs, and ‘$’ with respect to every treatment condition, for p ≤ 0.05)
Western blotting of the elastic matrix proteins fibrillin-1, fibulins -4 and -5, and
LOX did not result in consistently detectable or quantifiable bands. This is likely due to
the low protein concentrations (5 µg) that these were tested with.

5.3.5. MMP-2 Production and Activity
RT-PCR, western blotting and zymography were performed to analyze the effects
of DOX + EFs under static and stretched conditions. As seen in Figure 5.6, constructs
treated with DOX + EFs significantly decreased MMP-2 mRNA expression under both
static and stretched conditions, compared to those without DOX ( < 0.01), at both the
doses provided. Within static constructs, compared to control, MMP-2 mRNA expression
was significantly decreased to 0.24 ± 0.05 –fold and 0.22 ± 0.1 –fold with 0.1 µM DOX
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+ EFs and 1 µM DOX + EFs respectively ( < 0.001 for both). This decrease was also
significant compared to static constructs treated with EFs alone ( < 0.01), whose MMP2 mRNA expression was 0.7 ± 0.18 –fold compared to control ( = 0.02). The difference
in expression between DOX-treated and –untreated constructs was significant under
dynamic stimulation as well ( < 0.001 for stretched EFs compared to both doses of
stretched DOX + EFs). MMP-2 mRNA expression within stretched constructs with EFs
alone were comparable to control (0.98 ± 1.8 –fold,  = 1). However, with the addition of
0.1 µM DOX + EFs and 1 µM DOX + EFs, this was brought down to 0.36 ± 0.08 –fold
and 0.31 ± 0.07 –fold respectively ( < 0.001 for both). While MMP-2 mRNA expression
appeared to increase with stretch, this increase was significant in constructs treated with
EFs alone ( = 0.03). Differences in its expression between static and dynamic constructs
treated with DOX + EFs, at both DOX doses, were statistically insignificant ( > 0.25).

Figure 5.6: Changes in mRNA expressions of MMP-2 under static and dynamic
conditions, with DOX + EFs, and EFs alone, relative to control. Significant decrease
observed with addition of DOX + EFs under both static and dynamic conditions. '*'
represents fold change from control, '#' from static EFs, and '&' from dynamic EFs
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Figure 5.7: Effect of addition of DOX + EFs on MMP-2 protein content under static
and dynamic conditions relative to control. (A) Representative immunoblots of active
and zymogen forms of MMP-2 in all treatment conditions. (B) Semi-quantitative
analysis of MMP-2 protein represented as fold change in RDU relative to control. No
significant differences noted between different treatment conditions
Western blotting of MMP-2 (Figures 5.7 A and B) did not show any significant,
treatment-specific differences in intensities of bands corresponding to both zymogen and
active forms of the protein ( > 0.63). However, zymography (Figures 5.8 A and B)
showed significant decrease in enzyme activity of MMP-2 as a function of DOX dose,
under both static and stretched conditions. Within static constructs, fold-change in RDU
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Figure 5.8: Change in MMP-2 enzyme activity with addition of DOX and EFs under
static and stretched conditions relative to control. (A) Representative zymogram
showing bands corresponding to active MMP-2 enzyme. Bands corresponding to
zymogen form of the enzyme were undetected. (B) Fold change in MMP-2 active
enzyme compared to control. Significant decrease observed proportional to increase
in DOX concentration in both static and dynamic constructs. ‘*’ represents significant
difference from control, ‘#’ from static EFs, ‘@’ from 0.1 µM DOX + EFs static, ‘&’
from dynamic EFs and ‘$’ compared to every treatment condition, for p ≤ 0.05
values of active MMP-2 enzyme bands relative to control, were significantly decreased to
0.45 ± 0.18 –fold with 0.1 µM DOX + EFs, and further decreased to 0.25 ± 0.13 –fold
with 1 µM DOX + EFs ( < 0.001 for both). This decrease in MMP-2 enzyme activity
under both DOX doses tested was significant relative to static constructs treated with EFs
alone as well ( < 0.001). Increase in DOX dose (with EFs) to 1 µM significantly
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decreased enzyme activity compared to 0.1 µM DOX + EFs ( = 0.008). Similarly, while
application of stretch did appear to increase MMP-2 enzyme activity, this trend was
mirrored under dynamic conditioning as well. Within stretched constructs, relative to
control, the active enzyme band intensities were significantly decreased to 0.81 ± 0.1 –
fold with 0.1 µM DOX + EFs ( = 0.048), and 0.59 ± 0.2 with 1 µM DOX + EFs ( =
0.001). Again, this decrease was significant compared to stretched constructs treated with
EFs alone ( < 0.04) whose band intensities were comparable to control (1 ± 0.09 –fold,

 = 0.7, relative to control). Similar to that seen within static constructs, decrease in
enzyme activity within stretched constructs was also proportional to increasing DOX
concentration ( = 0.005 between 0.1 µM and 1 µM DOX + EFs, dynamic constructs).
Zymogen forms of MMP-2 (72 kDa) enzyme were undetected in all treatment conditions
at the protein concentrations tested (5 µg) in both western blots and gelatin zymograms.

5.3.6. MMP-9 Production and Activity
mRNA expressions of MMP-9 for constructs in all groups were extremely low
and barely above the detectable limits of the instrument, at the cDNA concentrations
tested. It was therefore not possible to discern differences in its gene expression between
different groups, if any existed. Western blotting of MMP-9 (Figures 5.9 A and B)
showed a dose-dependent decrease in band intensities of active MMP-9 protein, with
decrease in intensity being proportional to increase in DOX concentration (with EFs),
under both static and dynamic conditioning. Within static constructs, relative to control,
RDU values of MMP-9 active protein bands were decreased to 0.64 ± 0.16 –fold ( =
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0.02) with 0.1 µM DOX + EFs, and further down to 0.44 ± 0.07 –fold ( = 0.01) with 1
µM DOX + EFs. Compared to static constructs treated with EFs alone (whose band
intensities were 0.95 ± 0.01 –fold,  = 0.71, relative to control), significant decrease in
MMP-9 active protein band intensity was observed with 1 µM DOX + EFs alone ( =
0.04), and it was comparable to 0.1 µM DOX + EFs ( = 0.1).

Figure 5.9: Effect of addition of DOX and EFs on MMP-9 protein content, under static
and dynamic conditions. (A) Representative immunoblots of MMP-9 active protein in
different treatment conditions. Bands corresponding to zymogen form of protein were
undetected. (B) Semi-quantitative analysis of MMP-9 active protein represented as fold
change in RDU relative to control. Significant decrease seen with addition of DOX +
EFs in both static and dynamic constructs. ‘*’ represents significant difference from
control, ‘#’ from static EFs, and ‘@’ between conditions indicated, for p ≤ 0.05
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Application of stretch appeared to increase MMP-9 active band intensities in all
constructs, relative to the corresponding static constructs treated with similar
concentrations of DOX or EFs. These differences were however statistically significant in
constructs with 1 µM DOX + EFs alone ( = 0.047 between static and dynamic). In all
stretched constructs, MMP-9 intensities remained lower than control; 0.6 ± 0.06 –fold (
= 0.01) for EFs + stretch alone, 0.72 ± 0.15 –fold for 0.1 µM DOX + EFs + stretch ( =
0.048), and 0.66 ± 0.18 –fold for 1 µM DOX + EFs + stretch ( = 0.02). Among the 3
sets of constructs under dynamic conditioning, with or without DOX, MMP-9 band
intensities were comparable ( > 0.8). Bands corresponding to zymogen forms of MMP-9
were undetected in western blots at the protein concentrations tested. Both active and
inactive forms of MMP-9 enzyme were undetected in gelatin zymograms.

5.3.7. Matrix Ultrastructure
Matrix ultrastructure appeared similar to the static and dynamic constructs
evaluated in Chapter 4, as seen in Figures 5.10 through 5.12. Cells and synthesized
matrix were oriented more in the longitudinal direction, than circumferentially. Elastin
and fibrillin appeared to be localized and associated with each other in most regions of all
constructs.

5.4. Discussion
The studies conducted in Chapters 3 demonstrated the elastogenic benefits of
EFs to vascular SMCs cultured under static conditions within collagenous tissue
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A

B

Figure 5.10: Elastic matrix assembly and orientation in response to with DOX and
EFs under static and dynamic conditions. Representative (A) longitudinal- and (B)
cross- sections (30 µm thick) of constructs show more elastic fibers (stained
purple to black) deposited within DOX + EFs- treated constructs. Cells and matrix
appear to be oriented more in the longitudinal direction, than circumferential.
Scale bar denotes 100 µm. 10  magnification
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A
A

B
B

Figure 5.11: Effects of treatment with DOX, EFs and dynamic stimulation towards
elastin synthesis and assembly. Representative fluorescent micrographs of 10 µmthick (A) longitudinal- and (B) cross-sections of constructs immunolabeled with
elastin (red) and nuclei (blue). Longer fibers of elastin are seen in the longitudinal
sections. Addition of DOX, under both static and dynamic conditions appears to
have improved elastic matrix output. White arrows indicate longitudinal direction
of constructs. ‘L’ = lumen. 10  magnification
A
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A

B

B

Figure 5.12: Effects of treatment with DOX, EFs and dynamic stimulation
towards synthesis and assembly of fibrillin. Representative fluorescent
micrographs of 10 µm-thick (A) longitudinal- and (B) cross-sections of constructs
immunolabeled with fibrillin (red) and nuclei (blue). White arrows indicate
longitudinal direction of constructs. ‘L’ = lumen. Magnification = 10 
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serve to enhance net accumulation of newly synthesized elastic matrix and improve its
BB
B
quality, especially in the form of more mature fiber formation. In the current study, we
constructs. In Chapter 4, we were able to replicate these results within adult human SMCs,
and further enhance matrix alignment with the application of cyclic stretch as reported in
Chapter 4. That these observations were made within collagenous microenvironments,
not particularly conducive to elastogenesis, by inducing inherently non-elastogenic adult
SMCs, is highly encouraging. One of the observed shortcomings of the tested methods
was the continued lack of synthesis and organization of highly crosslinked, mature alkaliinsoluble matrix elastin. At the same time, the expression, synthesis and activity of
MMP-2, a major elastolytic protease83, was found to remain consistently high in both
studies. We therefore hypothesized that suppression of MMP-2 can therefore evaluated
the benefits of utilizing DOX, a modified tetracycline reported to be a non-specific MMP
inhibitor130, supplemented with EFs, in improving elastic matrix outcomes via
suppression of MMPs.
Progression of AAA disease appears to be related to two factors, namely, a)
chronically high levels of matrix protease activity, primarily MMPs -2 and -9, initiated by
inflammatory cells infiltrating the site of tissue injury16, 55, 241, and b) the inability of the
native vascular cells to preserve and restore disrupted vascular wall matrix, especially
elastin10, 18, 79. Systemic delivery of Doxycycline has been clinically useful to attenuate
MMP-mediated disruption and loss of elastic matrix46, 126. As a result, progression of
disease is suppressed, and in a few cases even reverted, by preserving the existing elastic
matrix within the AAA wall46, 126. Despite these benefits, systemic delivery of DOX has
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also been linked to likely dose-dependent effects such as frequent gastrointestinal tract
disturbances, cutaneous photosensitivity and irreversible dental discoloration242. Besides,
systemic inhibition of MMPs is not desirable since it plays key roles in normal tissue
remodeling and turnover as well83. Localized delivery of DOX using osmotic pumps in
AAA rodent models has been attempted and showed DOX to retain therapeutic benefits
at concentrations 100-fold lower than that delivered systemically243-244. However, when
we delivered similar concentrations to SMCs in 2D cell culture, we found DOX to be
cytotoxic at concentrations as low as 10 μM, but to promote cell proliferation at lower
concentrations. Other studies have also indicated a dose-dependent inhibition of cell
attachment and proliferation by DOX 245-246. In the current study, at concentrations as low
as 0.1 and 1 μM, we did not observe any changes in cell densities compared to those
without DOX treatment, both static and stretched. These differences may be due to one or
more of the following factors, namely a) reduced DOX dose on a per cell basis within the
current 3D model owing to much higher cell-seeding density, compared to that in 2-D
culture, b) limitation to diffusion of DOX into constructs, effectively reducing doses
perceived by cells, and c) the presence of a collagenous environment that is inherently
deterrent to cell proliferation, potentially normalizing the proliferative capacity of cells
across treatment conditions.
DOX-mediated suppression of gelatinases has shown to be achieved by inhibition
both at the level of mRNA expression of proteases127-128, as well as during protein
synthesis, and inducing irreversible loss of enzyme activity post-synthesis131, 247. Liu et.al.
have shown that DOX destabilized MMP-2 mRNA by reducing its half life from 28 to 4
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hours248. At the concentrations tested in our study, we witnessed a marked suppression in
MMP-2 mRNA expression as well. This suppression was higher in the DOX + EFs
treated cultures, than those treated with EFs alone, both under static and stretched
conditions. In the static cultures, up to a 5-fold decrease in MMP-2 mRNA expression
was found with the addition of 1 μM DOX, and a 4-fold suppression for 0.1 μM. Even
within cyclically stretched constructs, where the stretch-induced increase in MMP-2
mRNA expressions are known to occur170, its gene expression was found to be decreased
to levels statistically similar to that found within static cultures treated with DOX + EFs.
However, this decrease in expression was not found to be dose-dependent, with similar
levels of MMP-2 mRNA suppression seen in both DOX doses tested, with or without
stretch. It is important to note that the DOX doses tested in this study were several orders
of magnitude lower than what has been shown to inhibit MMP-2 gene expression127-128. It
is likely that within a 3D collagenous environment, where cells inherently secrete
proteases for tissue remodeling170, 237, inhibition of MMP at the level of gene expression,
in the presence of such low concentrations of inhibitors, could get normalized. This
normalizing effect is further substantiated by the finding that MMP-2 mRNA expression
was suppressed to similar, and not proportional extents, within static and stretched
constructs. On the other hand, at the protein level, both active and zymogen forms of
MMP-2 were found to be similar under all treatment conditions, indicating that at the
levels tested, DOX did not inhibit protein synthesis, despite the apparent decrease in
MMP-2 mRNA expression. In contrast however, enzyme activity of MMP-2, as
evaluated by zymography, was found to decrease proportionally with increase in DOX
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concentrations, in both static and dynamic constructs. This suppression was however
more pronounced within static constructs (up to 2- and 4- fold decrease with 0.1 µM and
1 µM DOX + EFs respectively), than within stretched constructs (up to 1.5- and 2- fold
with 0.1 µM and 1 µM DOX + EFs respectively), likely due to increase the phenomenon
of tissue remodeling-mediated increase in MMP-2 expression mentioned above. Several
groups, including Liu et.al.,248 have also shown that DOX alters the conformation of both
the zymogen and the active enzyme by binding enzyme-associated Ca++131. This makes
the proteins more susceptible to proteolysis, resulting in their fragmentation into smaller
molecular weight fractions and an irreversible loss of enzyme activity131-132. While we
did not observe MMP-2 fragments in either western blots or the zymograms, our results
nonetheless substantiate the hypothesis that DOX further inhibits MMP-2 activity at the
enzyme-activity level as well. It is likely that the phenomenon of fragmentation occurs at
higher DOX concentrations than that tested here, or that even if the fragments were
formed in our study, their concentrations were too low to be detected. It is important to
note that the MMP-2 gene expression and enzyme activity were far more suppressed in
constructs treated with DOX + EFs, than that within EFs alone, indicating that DOX
significantly enhances the anti-proteolytic activity of the treatment, above what TGF-β140
and HA-o43 have also been reported to also induce.
MMP-9 mRNA expression at concentrations tested were very low to begin with,
which made discerning differences between cases difficult. The low mRNA expression
could also indicate why we did not observe bands corresponding to zymogen form of
MMP-9 at the concentrations tested. However, western blotting did reveal differences in
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total protein content of active MMP-9 enzyme. This was found to be lowered
proportional to increase in DOX concentration, both in static and dynamic constructs.
This further substantiates that the concentrations of DOX tested in this study were
effective in suppressing protease activity.
Addition of DOX also increased mRNA expression of elastin as well as alkalisoluble matrix content, compared to untreated controls as well as constructs treated with
EFs alone, in both static and dynamic constructs. Differences in mRNA expression of
elastin appeared to be more pronounced between static and dynamic constructs, than
between the two doses. mRNA expression of other elastic matrix proteins was found to
be similarly increased (up to 2 fold) in all EF treated cultures, with or without DOX.
Interestingly, unlike that seen in constructs treated with EFs alone, alkali-soluble matrix
elastin content was found to be similar in all EF + DOX-treated constructs, and was not
found to be influenced by varying concentration or application of stretch. This could
likely be due to the similar levels of mRNA expression as well as total protein content of
MMP-2 seen among all DOX + EFs –treated constructs.
Several studies have indicated that DOX-mediated suppression of MMPs
additionally occurs through the suppression of JNK pathway133,

249

. Within AAAs,

suppression of JNK has also been shown increase expression and synthesis of various
matrix proteins, especially LOX, via a TGFβ-1 activated pathway250-253. Thus, it is
pertinent to expect that DOX would enhance LOX bioavailability as well. LOX
expression in our study, while elevated in EF-treated constructs (both static and dynamic)
relative to static control, does not appear to be enhanced further upon addition of DOX.
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TGFβ-1, which is added along with DOX in this study, is also known to enhance LOX
mRNA expression and improve activity of the crosslinking enzyme38. It is possible that
any DOX-mediated regulation of LOX expression may be limited and thus be masked by
the addition of TGFβ-1 in our cultures. It is also important to note that our studies were
conducted on healthy SMCs and in concentrations much lower than that reported in other
studies. The combined suppression of MMP activity and increase in alkali-soluble matrix
elastin was translated into higher quantities of alkali-insoluble matrix elastin only in one
of the treatment conditions- 0.1 μM DOX + EFs with stretch. The levels remained
comparable to static controls in all other cases. It is likely that the formation of the highly
crosslinked alkali-insoluble elastin requires higher expression of elastic matrix
scaffolding proteins i.e., fibrillin-1, fibulins and LOX, than that obtained in our studies.
Matrix ultrastructure also appeared similar to constructs treated with EFs alone. As noted
in Chapter 4 studies, cell and fiber alignment were once again in the longitudinal
direction, and not in the circumferential direction. This is likely due to the low strains of
2.5% applied to the constructs in this study.

5.5. Conclusions
Supplementation of HASMC-collagen constructs with DOX and EFs improved
elastic matrix output in terms of higher quantities of alkali-soluble matrix elastin.
Expression and activity of both MMPs -2 and -9 were found to be suppressed in both the
DOX-doses tested. Improvements in insoluble-elastin content was observed in one of the
DOX treated cultures (0.1 μM DOX + EFs + stretch).
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CHAPTER SIX
EVALUATION OF ELASTOGENIC EFFECTS DUE TO LOCALIZED,
NANOPARTICULATE DELIVERY OF DOX AND TGF-β1 IN 3-D COLLAGEN–
GEL TUBES

6.1. INTRODUCTION
In the previous chapter, we demonstrated that the treatment of adult SMCs within
collagen constructs with EFs and DOX improve outcomes of induced elastogenesis.
While these studies mimic an in vivo tissue microenvironment, the EFs and DOX were
supplemented exogenously to the culture media. There are two limitations to such
delivery. First, the direct translation of such exogenous delivery and its cell-regulatory
outcomes cannot be achieved in vivo at the site of proteolysis and disease, in a manner
similar to that demonstrated in these studies. Second, it is unclear whether diffusional
limitations exist for EF access into the tissue constructs, and to what extent induced
elastogenesis is limited by this factor. In the context of in situ matrix repair, it is thus
important to obtain localized, controlled delivery of therapeutic agents, whose
concentrations and bioavailability can be closely regulated to achieve significant and
predictable cellular response. Nanoparticulate delivery of active agents via polymeric
carriers has been widely used for various in vivo drug delivery applications254-256.
Compared to other delivery modes such as those involving the use of microparticles,
nanoparticles (NPs) offer several advantages such as higher surface area/unit volume,
achieving higher release, better tissue infiltration and interaction at the cellular level due
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to their nano-range sizes comparable to cells, and generation of comparatively lesser
byproducts of polymeric degradation that can adversely impact activity of agents
encapsulated within257-259. In this study, we have utilized the in vitro tubular collagen gel
model, as optimized in the previous chapters, to evaluate the effects of localized delivery
of elastogenic factors from poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs).
It is important to note that in this study, we have evaluated the effects of codelivery of only TGF-β1 and DOX, and excluded HA-o from the study. Nanoparticulate
formulations for HA-o delivery are currently being developed in our lab, and were
therefore not available to be included in this study. Accordingly, a direct comparison of
the results of Chapters 4 and 5 are therefore not possible. We have thus included in this
study, an additional control case in which TGF-β1 and DOX were exogenously delivered
at concentrations similar to that released from the NPs. All other culture conditions were
kept constant among the different treatment cases.

6.2. MATERIALS AND METHODS
6.2.1. Synthesis of TGFβ-1 and DOX loaded Nanoparticles
Two different sets of Poly (dl-lactic-co-glycolic acid) nanoparticles (PLGA; 50:50
lactide : glycolide; inherent viscosity 0.95-1.20 dL/g in hexafluoroisopropanol; Durect
Corporation, Birmingham, AL) nanoparticles were synthesized – one with TGF-β1 (28
kDa) (R & D Systems, Minneapolis, MN) and another with DOX (Sigma, St. Louis, MO).
A double-emulsion/solvent evaporation method was utilized to obtain PLGA NPs loaded
with either of the water soluble factors213-214. Nanoparticles were synthesized with 0.25%
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w/v polyvinyl alcohol (PVA), which acts as an anionic surfactant and a stabilizer213.
Particle size and ζ-potential were evaluated using a NICOMP 380 ZLS analyzer. Size
homogeneity of the synthesized particles was confirmed using TEM. In order to obtain
the target concentration of factors (as optimized in Chapters 4 and 5) released from the
NPs, 2 different drug-loading concentrations for DOX, and 3 for TGF-β1 were tested.
DOX was loaded at 2% and 5% w/v, while TGF-β1 was loaded at 1000 ng, 2000 ng and
5000 ng per mg of PLGA. Blank NPs were synthesized in manner similar to the factorloaded NPs, but without the addition of any factors.

6.2.2. Release Profile of Factors from NPs
Release of DOX and TGF-β1 (agents) from NPs was evaluated in PBS at 37 °C
over 21 days. TGF-β1 NPs were suspended in PBS at a concentration of 10 mg/ml, while
DOX loaded NPs were tested at 0.2 mg/ml and 0.5 mg/ml. In order to measure the
concentration of the agents released from the NPs at each time point, the nanoparticles
were first centrifuged at 14,000 rpm for 30 minutes at 4 °C, and supernatants collected
for analysis. Fresh, 1 ml aliquots of PBS were added post-centrifugation to replenish the
volumes for further study of release. The collected aliquots of supernatant from the TGFβ1- NP preparations were frozen at -20 °C until analysis. The concentration of TGF-β1
was measured in these aliquots using a commercially available enzyme-linked
immunosorbant assay (ELISA) kit (R & D Systems, Minneapolis, MN). Concentration of
DOX in supernatant aliquots similarly obtained by processing DOX NPs, were not frozen
but measured immediately after each centrifugation cycle using UV-spectrophotometry
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(SpectraMax M2, Molecular Devices, Inc., Sunnyvale, CA) at absorbance of λ = 273
nm259-260. Concentrations were determined based on calibration curves of known DOX
concentrations incubated in PBS for similar time points. Based on the cumulative release
curves plotted for all cases, the optimum NP formulation was chosen for each factor, such
that a total of 0.5 mg/ml NPs would be used to release agents within the collagen gel
constructs over 21 days of culture.

6.2.3. Formulation of NP-loaded Collagen Constructs
Acid-solubilized rat-tail collagen was brought to physiological pH as detailed in
Section 4.2.2. Following this, the 2 sets of NPs were added at a final concentration of 0.5
mg/ml. 5  105 HASMCs/ml were then added to this viscous mixture, mixed well by
gentle pipetting, and then added to the culture chambers of the bioreactors. The
bioreactors were sterilized and set up as detailed in Sections 4.2.1 and 4.2.2. Day 1 of
culture was set to 24 hours after seeding the constructs since the factors from NPs were
expected to initiate release of active agents immediately after seeding. The three
treatment conditions tested, i.e. constructs with exogenous delivery (control; EDC), blank
NPs (BNP) and agent-loaded NPs (ANP), and are listed in Table 6.1. Cyclic stretch was
provided to all the 3 conditions at 2.5% strain and 1.5 Hz, as optimized in Chapter 4.
DOX and TGF-β1 were exogenously supplementation to one set of constructs as delivery
mode controls. The concentrations of exogenous delivery were equivalent to that released
by the NPs at similar time points along (determined from their release curves in PBS)
with DMEM/F12 (Media Core, Cleveland Clinic, Cleveland OH), 10 % v/v FBS (PAA
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Scientific, Dartmouth, MA) and 1% v/v PS (Thermo Scientific, Rockford, IL). Constructs
with blank NPs or agent-loaded NPs were cultured in above culture medium with no
exogenous factors. Culture medium was changed every 2 days, and spent media pooled
for each construct and frozen at -20 °C until analysis. Constructs were harvested 21 days
after seeding, rinsed 3  in sterile PBS, and processed for various biochemical assays.

6.2.4. Retention of NPs within Collagen Gels
In order to verify that the NPs were retained in the gels, and not eluted out during
compaction of constructs, a pilot study was performed on PLGA NPs loaded with Cy5tagged bovine serum albumin (BSA; NanoCS, New York, NY). N = 3 constructs were
seeded each with 3 different NP concentrations - 0.1 mg/ml, 0.2 mg/ml and 0.5 mg/ml,
and harvested at 3 time points – day 3, day 7 and day14. Constructs were visualized
under a fluorescence microscope using a Cy5 filter (Olympus, Pittsburgh, PA) to gauge
retention on the day of harvest. Additionally, a DNA assay was also performed at days 3,
7 and 14, to estimate the effect of NPs on cell proliferation. A minor difference between
the NPs used in this pilot study, and the ones used to deliver DOX/TGF-β1, as discussed
in this chapter, concerns the surfactant used to synthesize the NPs. Di-dodecyl-dimethylammonium bromide (DMAB), a cationic amphiphile, that imparts a net positive charge
was used to synthesize NPs in the pilot study. As will be elaborated further in the
Discussion section of this chapter (Section 6.4), although the surfactants may not directly
influence release itself, DMAB, may have associated with released TGF-β1, resulting in
decreased detection with ELISA. Hence, in subsequent experiments, we used PVA,
which provides a net negative charge, as a surfactant. Despite the difference in
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surfactants used, we believe that the pilot study can be used as a reliable indicator to
estimate NP retention within the gels. This is since removal of NPs is likely to occur
either during bulk fluid exclusion during
gel compaction, or subsequently by diffusion.
Table 6.1: Experimental conditions-nanoparticulate delivery of elastogenic agents
Group

Mode of delivery of DOX and TGF-β1

Exogenous Delivery Control (EDC)

Supplemented with culture medium

Blank NPs (BNP)

-

Agent-loaded NPs (ANPs)

0.2 mg/ml DOX-NPs and 0.3 mg/ml TGFβ1-NPs

6.2.5. Compaction of Tissue Constructs
All constructs were photographed at regular intervals and compaction of
constructs was calculated and represented as an aspect ratio of length : O.D. on day 21 of
harvest.

6.2.6. DNA Assay for Cell Quantification
As detailed in Section 4.2.4, 1/4th segment of the each of the harvested constructs
were flash-froze, lyophilized for 24 hrs and digested in 5 mg/ml proteinase-K (Gibco–
Invitrogen, Carlsbad, CA) for 10 hours. Samples were then centrifuged at 14,000 rpm to
pellet any possible NPs, and supernatants sonicated prior to performing the Hoechst
33258 dye (Gibco–Invitrogen, Carlsbad, CA) -based flourometric DNA assay221. Cell
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numbers were calculated based on the estimate of 6 pg DNA/cell, and normalized to mg
tissue weights for comparison, (n = 5/case).

6.2.7. RT-PCR for mRNA Expression of SMA Phenotypic Markers and Matrix
Proteins
Rinsed segments of constructs were cut into small 1–2 mm long pieces and stored
in RNAlater solution until processing, and RNA isolated using RNeasy kit (Qiagen,
Valencia, CA), as detailed in Section 4.2.5. Briefly, samples were transferred to 500 μl
RLT buffer (supplied with the kit) with 1% v/v 2-mercaptoethanol (Sigma, St. Louis,
MO), homogenized using needle and syringe, and manufacturer’s instructions followed to
isolate RNA into 50 μl of RNAase-free water. RNA content was measured using a Ribogreen assay kit (Invitrogen, Carlsbad, CA), and 250 ng total RNA was reverse transcribed
into 40μl cDNA, as detailed in Section 4.2.5. RT-PCR was performed for SMC markers
such as SMA, caldesmon and osteopontin, elastic matrix proteins such as elastin,
fibrillin-1, fibulin-5, LOX and collagen, and MMPs -2 and -9. Gene expressions were
estimated in 1 μl cDNA (duplicate readings, n = 5 per sample), using the comparative
threshold method with 18 s as the normalizing gene, as described in Chapter 1261. Primer
sequences and source for the above genes are listed in Table 4.2 in Chapter 4.

6.2.8. Fastin Assay for Elastin Content
Lyophilized construct segments were digested in 0.1 N NaOH to solubilize alkalisoluble matrix elastin, followed by in 0.25 M oxalic acid to obtain solubilized alkali-
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insoluble matrix elastin, as described in Section 4.2.6. Digested samples were once again
centrifuged at 14,000 rpm for 30 minutes to eliminate any possible contamination from
NPs. Digested aliquots (250 μl) were used to assay for alkali-soluble elastin, and 175 μl
for alkali-insoluble elastin using the Fastin assay kit (Accurate Scientific and Chemical
Corporation, Westbury, NY), as mentioned in Section 4.2.5.

6.2.9. Western Blotting for Cellular and Matrix Proteins
Lyophilized segments of constructs were cut into small 1-2 mm long pieces and
500 μl of RIPA lysis buffer (Invitrogen, Carlsbad, CA) with a protease inhibitor cocktail
(Thermo Scientific, Rockford, IL) was added to homogenize samples and solubilize
proteins, as described in Section 4.2.7. A BCA assay (Thermo Scientific, Rockford, IL)
was performed to measure concentration of total protein in all samples. Western blotting
was performed to detect the phenotypic markers of contractile SMCs (n = 1/case) such as
smooth muscle α-actin (SMA; an early-stage marker), Smooth muscle-22-α (SM22; a
mid-stage marker), myosin heavy chain (MHC; a late-stage marker), and calponin and
caldesmon (both mid-stage markers), elastic matrix proteins (n = 3/case) such as LOX,
fibrillin-1 and fibulins -4 and -5, and matrix proteases (n = 3/case) MMPs-2 and -9. All
blots were simultaneously labeled for the protein of interest and for the normalizing
protein, β-actin. Protein content of 10 μg per sample was used to immunoblot the above
proteins. Antibody concentrations and incubation time points corresponding to different
steps in immunoblotting are detailed in Section 4.2.7. To semi-quantitatively represent
the differences in elastic matrix proteins and proteases content between different
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conditions, samples from n = 3 biological replicates per condition were assayed. Band
intensities of the protein of interest calculated in RDU were first normalized to β-actin
values, then normalized to the condition with exogenous factor delivery (treated as
biological control), and represented as fold change in RDU values compared to the above
condition.

6.2.10. Gelatin Zymography for Detection of Enzyme Activities of MMPs -2 and -9
Gelatin zymography was performed to semi-quantitatively estimate differences
the enzyme activities of the proteases MMPs -2 and -9, between the treatment conditions
(n = 3/case). Protein samples (10 μg) homogenized in RIPA buffer as discussed in
Section 6.2.9., were loaded into each lane of a 10% gelatin zymogram. As described in
Section 4.2.8., zymography was performed on n = 3 biological replicates, and enzyme
activity was represented as a fold change in RDU values relative to EDC constructs
(control).

6.2.11. Visualization of Elastic Matrix
Constructs harvested after 21 days of treatment were rinsed 3 times in PBS, and
0.5 cm long constructs were fixed in 4% w/v paraformaldehyde for 6 hours at RT and 6
hours at 4 °C. Samples were then dehydrated and embedded in paraffin wax as detailed in
Section 4.2.9. Histology was performed on 30 μm-thick cross- and longitudinal- sections
using an Elastic stain kit (Laboratories Inc., Cache, UT) to visualize the ultrastructure of
elastic matrix content in the constructs. IF was performed on 10 μm cross- and
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longitudinal- sections, imaged using an fluorescence microscope under Cy5 filter
(Olympus, Pittsburgh, PA) to detect elastin and fibrillin. The labeled sections were
mounted in Vectashield with DAPI (Vector Laboratories, INC. Burlingame, CA) to stain
for nuclei, and cover-slipped prior to imaging and visualization.
Longitudinal sections (1 mm thick) of harvested constructs were fixed in 2.5%
w/v gluteraldehyde and 4% w/v paraformaldehyde in sodium cacodylate buffer for 24
hours, and then processed for TEM, as described previously in Section 4.2.9.

6.2.12. Statistical Analysis
All experiments were performed on n = 5 biological replicates per treatment
condition, unless mentioned otherwise. Histology, IF and TEM were performed on
segments from n = 1 construct per condition. All quantitative and semi-quantitative
results are represented as mean ± standard deviation per condition. One-way ANOVA
was performed

to calculate statistical significance in differences between treatment

condition. Conditions were deemed to be significantly different for  values ≤ 0.05.

6.3. RESULTS
6.3.1. Nanoparticles Size and Release Profiles
Hydrodynamic diameters of both TGF-β1 and DOX loaded NPs, and blank NPs
synthesized were found to be within 300 ± 30 nm diameter and had a surface charge of
30 ± 5 mV. Figure 6.1 shows the release curves of DOX and TGF-β1 from NPs in PBS
over 21 days. In the studies discussed in Chapters 4 and 5, 0.1 ng/ml of TGF-β1 with
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either of the DOX concentrations of 0.1 μM or 1 μM, were found to promote the most
significant elastogenic outcomes. Based on the release curves of the two agent-loaded
NPs, the formulations that most closely matched these concentrations were 2000 ng/mg
loading of TGF-β1 when added at 0.3 mg/ml, and 5% DOX loading when added at 0.2
mg/ml to the collagen-cell mixture. It is important to note that while the cumulative
release of DOX from NPs over 21 days of treatment was similar to that optimized in
exogenous delivery (5.61 μg/ml over 21 days), TGF-β1 released from the 2000 ng/mg
formulation was ~ 10 fold lower. To account for this, we included exogenous delivery
controls (EDC), to which DOX and TGF-β1 were supplemented exogenously to the
culture medium. Equivalent concentrations corresponding to the release of TGF-β1 from
2000 ng/mg loading (Figure 6.1 A), and DOX from and 5% loading at 0.2 mg/ml
(Figure 6.1 B) were added.

Figure 6.1 A: TGF-β1 Release Profile showing an initial burst phase followed by a
sustained plateau phase. Based on the concentration released from 3 NP formulations,
2000 ng/mg loading condition was used for subsequent studies

6.3.2. Nanoparticle Retention and Effects on Cell Density
Cy5-tagged BSA loaded PLGA NPs were added at concentrations of 0.1 mg/ml,
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Figure 6.1 B: DOX Release Profile. Based on the concentrations released from
the 2 formulations of DOX-loaded PLGA NPs, a 5% w/v loading was chosen for
subsequent studies

Figure 6.2: Cy5-tagged BSA NPs (white specs) retained within collagen gel tubes at
day 14. NPs added at the 3 concentrations - 0.1 mg/ml, 0.2 mg/ml and 0.5 mg/ml

0.2 mg/ml and 0.5 mg/ml to HASMC-seeded collagen gel constructs, and were cultured
for 3, 7 and 14 days. As seen in Figure 6.2, NPs at all three concentrations were retained
within the gels at until day 14. DNA assay was performed to estimate cell densities at the
different time points to estimate the effects of the different NP concentrations on cell
proliferation (Figure 6.3). At day 14, cell proliferation appeared comparable in constructs
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with 0.1 mg/ml and 0.2 mg/ml NPs (1.7 ± 0.05 and 1.6 ± 0.25 –fold compared to day 1 of
seeding). This was slightly less pronounced in constructs with 0.5 mg/ml NPs (1.4 ±
0.16 –fold). However, the increase in cell densities with increasing culture durations in all
treatment conditions indicated that the NPs did not adversely hinder cell proliferation.
Based on these findings, and the results obtained from the release curves of agents from
NPs (Figure 6.1), NP concentration of 0.5 mg/ml was chosen for further studies to test
the effects of nanoparticulate delivery of DOX and TF-β1.

Figure 6.3: Cell density in collagen constructs with different NP concentrations, harvested at 3
time points. None of the 3 concentrations tested ha detrimental effects on proliferation rates

6.3.3. Compaction of Tissue Constructs
After 21 days, constructs in all treatment conditions were found to have a length :
O.D. aspect ratio of 8.4–9.5 (Figure 6.4). No significant differences were observed in the
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extent of compaction between the different treatment conditions ( = 0.91 for both sets of
NP-treated constructs, with and without factors, compared to EDC).

Figure 6.4: Construct compaction after 21 days of treatment. Addition of NPs did
not alter aspect ratios over 21 days of treatment. Compaction was comparable
among the three cases

Figure 6.5: Effects of addition of NPs on cell density. No significant
differences were observed in the cell densities of constructs with or without NPs

159

6.3.4. Cell Quantification
The cell densities after 21 days of culture were found to be similar under all
treatment conditions. Addition of NPs did not seem to adversely impact cell proliferation.
Average cell densities, as represented in Figure 6.5, were found to be around 1.5 ± 0.25
 105 cells/mg construct. No significant differences were observed compared to EDC (
= 0.93 for BNP, and 0.22 for ANP).

6.3.5. Analysis of SMC Markers
RT-PCR was performed to evaluate the mRNA expressions of

SMA and

caldesmon, the contractile SMC markers, and osteopontin, the synthetic/activated SMC
phenotypic marker (Figure 6.6). Expression of the contractile markers was found to be
maintained even with the addition of NPs compared to EDC ( = 0.97 and 0.93 for SMA,
and 0.99 for caldesmon, for BNP and ANP). Osteopontin expression was also not
elevated with the addition of NPs, and was not found to be statistically different from
EDC ( = 0.08 for BNP and 0.07 for ANP).
Western blotting was performed to estimate the differences in synthesis of various
proteins that indicated the maintenance of a contractile, non-activated phenotype of
SMCs over the 21 day period– SMA, calponin, caldesmon, SM22α and MHC (Figure
6.7). For 10 μg protein concentrations, band intensities for all the contractile markers
relative to their β-actin band intensities were found to be similar in all 3 treatment
conditions. This demonstrates that a healthy contractile phenotype of cells was
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maintained despite the addition of NPs, with or without the active agents (DOX and
TGF-β1).

Figure 6.6: Effects of NP addition on SMC phenotypic response. mRNA expressions of
SMC phenotypic markers SMA, caldesmon and osteopontin remained comparable to
EDC constructs

Figure 6.7: SMC phenotypic marker expression in response to NP delivery.
Representative western blots of contractile SMC phenotypic markers indicate that
phenotypic behavior of SMC was not altered by the addition of NPs

6.3.6. Elastic Matrix Content
The mRNA expressions of various genes corresponding to proteins constituting
the elastic matrix were determined using RT-PCR –elastin, fibrillin-1, fibulin-5 and LOX
(Figure 6.8). mRNA expression of elastin was decreased 3 ± 0.1 -fold (   0.001) in
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BNP constructs compared to EDC. This decrease was significantly bridged in ANP
constructs ( = 0.002 compared to BNPs), which showed only a 10% decrease in elastin
expression compared to EDC. Statistical comparison of elastin expression between
exogenous and NP delivery of agents revealed no significant differences ( = 0.512).
Similar trends were seen in differences in mRNA expressions of fibrillin-1 and fibulin-4.
Expression of these genes were decreased up to 4-fold in constructs with Blank NPs ( 
0.001 compared to exogenous control for both genes). ANP constructs showed similar
expression levels of fibulin-4 ( = 0.99), and a slight decrease in fibrillin-1 expression
(1.5 ± 0.1 -fold,   0.001) compared to EDC constructs. The mRNA expression of LOX
on the other hand, showed higher expression for both sets of constructs treated with NPs
compared to EDC. While this difference was not significant in BNP constructs (1.5 ± 0.3
-fold compared to exogenous controls,  = 0.16), the 1.7 ± 0.5 -fold increase within
ANPs was statistically significant compared to EDC ( = 0.05). In addition to gene
expression of the above elastic matrix proteins, mRNA expression of collagen-1 was also
estimated in the different treatment conditions.

A slight decrease in collagen-1

expression compared to EDC was observed in constructs treated with NPs, but this
decrease was statistically insignificant ( = 0.1 for BNP constructs and 0.19 for ANPs).
A Fastin assay was performed to estimate the elastic matrix content in terms of
alkali –soluble and –insoluble elastin within the 3 sets of constructs (Figure 6.9). Alkali–
soluble matrix elastin content within ANP constructs (20.01 ± 1.81 μg/mg) were found to
be similar to that in EDC controls (20.97 ± 1.87 μg/mg,  = 0.73 ). These levels were
significantly greater (up to 2-fold) than in BNP construct (9.62 ± 2.34 μg/mg,   0.001
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compared to exogenous treatment controls). On the other hand, quantities of alkali–
insoluble matrix elastin was found to be barely above the detection limits of the assay kit
within the sample volumes tested (around 0.5 μg/mg for all 3 conditions). They were
statistically insignificant between the 3 conditions ( = 0.98 for BNP constructs and 0.64
for ANP, compared to EDC).

Figure 6.8: Effects of NP based delivery on mRNA expressions of elastic matrix
proteins- elastin, fibrillin-1, fibulin-5, LOX and collagen-1. Expression of LOX was
elevated in both BNP and ANP constructs. Expression of elastin was comparable
between the 2 delivery modes, and that of fibrillin and fibulin was moderately lowered.
'*' represents significant difference from EDC, '#' from BNP and '$' from every treatment
condition for p < 0.05
Western blotting was performed to estimate the levels of LOX, fibrillin-1 and
fibulin-4. As seen in Figure 6.10, band intensities of LOX protein were found to be
significantly higher in the constructs treated with NPs, both blank and agent-loaded,
compared to EDC. Their intensities for treatment controls in the 2 subsequent biological
replicates were too low to be reliably quantified. Therefore statistical comparison
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representing differences in LOX protein content have not been performed. At the 10 μg
protein concentrations tested, fibrillin-1 and fibulin-4 were undetected.

Figure 6.9: Differences in elastic matrix content between the 2 delivery modes. Elastic
matrix content measured in terms of alkali -soluble and -insoluble elastin remained
comparable between NP-based and exogenous delivery of agents. '$' represents
significant difference from every treatment condition for p < 0.05

Figure 6.10: Effects of NP-based delivery on LOX protein content. Representative
western blot of LOX protein in the 3 treatment conditions. LOX content appears to be
significantly elevated by the addition of NPs, both in BNP and ANP constructs, relative
to EDC.

6.3.7. Analysis of MMPs -2 and -9
Gene expressions of the 2 gelatinases MMP-2 and -9 were determined using RTPCR. As seen in Figure 6.11, MMP-2 gene expression was significantly increased with
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the addition of NPs. Constructs with Blank NPs showed an average of 4.25 ± 0.6 -fold
increase in MMP–2 expression compared to EDC (  0.001). The addition of factors
within NPs lowered this expression 1.8-fold compared to Blank NPs (  0.001). MMP–2
expression was 2.4 ± 0.3 -fold higher in ANP compared to EDC (  0.001). On the other
hand, expression of MMP–9 was decreased in both sets of constructs treated with NPs.
However this decrease was not statistically significant ( = 0.06 for BNP constructs, and
0.18 for ANP). It is important to note that the Ct values for MMP–9 were only slightly
above the reliable detection limits of the instrument for the cDNA concentrations tested.
MMP-2 gene expression was in general much higher than that for MMP-9.

Figure 6.11: Outcomes in mRNA expression of MMPs -2 and -9 with delivery mode.
A significant upregulation in MMP-2 is seen with the incorporation of NPs, while
MMP-9 expression appears to have been suppressed. '*' represents significant
difference from EDC, '$' with every treatment condition, for p < 0.05

Western blotting was performed to estimate the amount of MMP protein present
in the constructs. As seen in Figures 6.12 A and C, the zymogen form of MMP–2
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corresponding to the 72 kDa bands, was found to be lower in BNP constructs compared
to other 2 treatment conditions (3 ± 0.9 -fold compared to EDC,  = 0.03). Differences in
band intensities between the 2 sets of constructs with NPs, with and without factors, were
found to be insignificant ( = 0.19). In contrast, the band intensities for active MMP–2
enzyme corresponding to 66 kDa were found to be higher in both sets of NP-treated
constructs (1.7 ± 0.4 fold increase,  = 0.05 for BNP constructs, compared to EDC). No
statistical difference in band intensities of active MMP–2 between exogenous and NP
delivery of factors was observed (1.5 ± 0.4 fold increase,  = 0.27 for Factor-NPs).

Figure 6.12: Outcomes in protein quantities of MMPs -2 and -9 in response to
agent delivery mode. (A) Representative immunoblots of MMPs -2 and -9 along
with normalizing protein β-actin. Semi-quantificatitative comparison of zymogen
and active forms of MMP-2 protein (B) show an increase relative to EDC. However
incorporation of agents within NPs appears to have brought down these levels
relative to BNP. However, and MMP-9 active enzyme (C) levels are significantly
attenuated with the addition of NPs.
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Figure 6.13: Zymography of MMPs -2 and -9. (A) Representative zymograms
showing both active and inactive forms of MMP-2 enzyme, and only active form of
MMP-9 enzyme. (B) Semi-quantitative comparison of zymogen and active forms
of MMP-2

On the other hand, as seen in Figures 6.12 B and C band intensities
corresponding to the 82 kDa active MMP–9 enzyme were found to be significantly
decreased to similar extents in both sets of NP-treated constructs compared to exogenous
supplementation (4.5-fold with  = 0.001 for both NP-treated constructs with and without
agents). Zymogen forms of MMP–9 protein were undetected at the concentrations tested.
Zymography was performed to estimate the activity of the gelatinases present in
the constructs (Figure 6.13). The enzyme activity of MMP–2 was found to be
significantly elevated in the constructs with NPs compared to EDC. A 2.8 ± 0.9 fold
increase ( = 0.03) in MMP–2 zymogen, and 3.5 ± 0.5 fold increase ( = 0.001) in active
enzyme was found in BNP constructs compared to EDC. This activity was decreased
with the delivery of agents in ANP constructs, where up to a 2-fold increase was found in
the intensities of both zymogen ( = 0.2) and active enzyme ( = 0.01), compared to
EDC. On the other hand, as seen in Figure 6.13 A and B, at the protein concentrations
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tested, bands corresponding to active MMP–9 enzyme were detected only in EDC
constructs. They were not detected in either of the NP-treated constructs in any of the 3
biological replicates tested. Zymogen bands of MMP–9 enzyme were undetected in all 3
conditions.

6.3.8. Matrix Ultrastructure
Elastic matrix components elastin and fibrillin-1 were immunolabeled in 10 μm
cross and longitudinal sections of the 3 treatment conditions, and visualized using a
fluorescence microscope under a Cy5 filter. As seen in Figures 6.14 and 6.15, cells and
elastic matrix fibers appeared to be far more oriented in the longitudinal direction than
circumferentially, in all treatment conditions. Signs of circumferential orientation were
observed in the regions closer to the lumen of the constructs. Clumps of elastin and
fibrillin were found in both cross and longitudinal sections, indicating that the
synthesized fibers might be oriented in all directions. Elastin and fibrillin appeared to be
mostly co-localized. Appearance and orientation of elastic fibers as seen in IF, were
confirmed in the 30 μm sections that were stained for elastin using a modified VVG
staining kit. Elastic matrix was undetected in the longitudinal sections imaged using TEM.

6.4. DISCUSSION
In studies discussed in the previous chapters, and in prior work conducted in our
lab, we have demonstrated the elastogenic inductibility of adult vascular SMCs by
various exogenously supplemented EFs (TGF-β and HA-o)37, 173, 184. While the use of
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these EFs have shown tremendous potential in stimulating de novo synthesis of elastic
matrix in culture, it is important to evaluate strategies for their controlled and sustained
delivery in a localized manner for final clinical application of regenerative repair of
elastic matrix at sites of proteolytic disease such as AAA.

Figure 6.14: Representative images of Elastic staining of 30 μm thick cross- (CS)
and longitudinal- (LS) sections of collagen (stained pink) constructs after 21 days of
treatment. Orientation of cells and elastic fibers (stained purple/black, indicated by
red arrows) seen in the logitunal direction. Cells and matrix appear to orient in the
circumferential direction closer to the lumen (L) in the corss-sections
This evaluation is crucial especially since the outcomes of factors we have
evaluated in our studies are highly dose-dependent. For example, the regulatory effects of
growth factors like TGF-β are critically dependent on precise control of delivered dose as
they can induce extremely contrasting outcomes depending on the concentration220.
While at concentrations below 10 ng/ml, it can suppress abnormal cell proliferation and
aid in synthesis and assembly of elastin and elastic matrix components37, 262, at higher
concentrations it can induce a synthetic, osteogenic switch of SMC phenotype and induce
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rapid calcification139. Moreover, the outcomes of TGF-β supplementation is also highly
site dependent185. For example, while the use of TGF-β has positively influenced elastic
matrix synthesis by SMCs from AAA disease models, TGF-β at similar concentrations
has been shown to adversely impact thoracic AAs60-61. In fact, the use of TGF-β
antagonists such as losartan has been shown to regress thoracic AAs263-264.
A

B

Figure 6.15: Effect of agent delivery mode on outcomes of elastic matrix assembly
and ultrastructure. Representative fluorescent micrographs of 10 µm thick (A)
longitudinal- and (B) cross –sections of constructs immunolabeled for elastin (red,
top panel), fibrillin (red, bottom panel) and nuclei (blue). All three treatment
conditions showed detectable levels of both proteins. Both fibrillin and elastin
distribution appears comparable between EDC and ANP constructs. Orientation in
the longitudinal direction appeared more than circumferentially. White arrows
indicate longitudinal direction of constructs. ‘L’ = lumen. Magnification = 10 
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Several studies have also demonstrated substantial benefits in therapeutic
A
B
outcomes of localized, controlled delivery of factors over systemic delivery. For example,
many groups have evaluated various localized delivery methods for DOX, and have
shown pronounced decrease in MMP activity and preservation of elastic matrix at
concentrations even 100 fold lower than that used for systemic delivery243, 253. This has
the potential to overcome several undesirable side effects of systemic delivery of DOX
for AAA treatment242, 245. Moreover, systemic inhibition of MMPs is undesirable since
they participate in normal matrix remodeling and turnover as well83.
In the current study, we have therefore utilized the tubular collagen model
optimized in the previous chapters, to evaluate the outcomes of localized delivery of
DOX and TGF-β from nanoparticles, over their exogenous delivery. This in vitro model
allowed the benefits of assessing the direct response of SMCs to polymer-based delivery
of previously optimized elastogenic factors in a controlled microenvironment. PLGA
(50:50 blend) chosen as the polymeric nano-carrier of factors, offers several benefits as
an ideal drug delivery vehicle.
PLGA is one of the most biocompatible polymers widely used for a variety of
drug delivery applications265-267. It undergoes hydrolytic degradation into lactic acid and
glycolic acid, which have not shown to induce adverse cell response, both in vivo and in
vitro259, 268. PLGA is also easy to formulate and characterize258, and has been shown to be
compatible for delivery of both DOX269-270 and TGF-β271-272. It is also one of the very few
biomaterials approved by FDA for a variety of clinical applications265.
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The surface charge of nanoparticles has shown to play a role in mediating the
bioavailability of factors as well as in regulating cellular response, both in vitro and in
vivo. Various studies have pointed towards the benefits of utilizing cationically surfacecharged nanoparticles for vascular applications213-214, especially from the standpoint of
enhancing elastic matrix deposition. It has been suggested that the presence of cationic
amphiphiles attract the negatively charged LOX molecules, while at the same time repel
positively charged elastases215. This has been further illustrated in studies that have
utilized cationic amphiphiles such as DMAB which were shown to increase LOX protein
synthesis and significantly suppress expression and activity of proteases such as MMPs 2 and -9216,
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. In the current study, we thus initially formulated and tested DMAB-

modified PLGA NPs. However, the concentration of TGF-β1 released from these NPs
was extremely low, possibly due to interaction between the DMAB particles and the
growth factor. However, we were able to overcome this problem and obtain detectable
and consistent quantities of TGF-β1 released from anionically modified NPs.
Accordingly, in this study we have utilized anionic nanoparticles for the delivery of both
DOX and TGF-β1. While surface charge modification did not affect DOX release
profiles, DOX-loaded NPs were also synthesized using PVA to maintain consistency
between the NPs releasing both these agents.
Likely due to their failure to repel elastases, anionic NPs (both with and without
agents) resulted in a marked increase in the mRNA expression, protein synthesis as well
as enzyme activity of MMP–2. However, it was also observed that the delivery of agents
from the NPs resulted in a marked decrease in overall MMP–2 mRNA expression relative
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to BNP constructs, and a decrease in protein content of active MMP-2 enzyme to levels
seen in EDC constructs, This suggests a positive influence of addition of agent-loaded
NPs. The MMP-2 enzyme activity was similarly lowered in ANP constructs compared to
BNP constructs, but remained higher than those with exogenous factor treatment.
In contrast however, the mRNA expression, total protein content and enzyme
activity of MMP-9 was found to be significantly lowered with the addition of NPs, with
or without agents. Zymogen bands for MMP-9 enzyme were completely undetected in
both sets of the NP-treated constructs. In addition to this, the lack of difference in the
MMP-9 protein levels, as seen in immunoblots (Figure 6.10) between blank and agentloaded NPs suggests that MMP-9 inhibition may be influenced significantly more by the
PVA-modified anionic NPs, than the addition of agents. This finding is contrary to what
has been suggested in the literature regarding the positive influence of cationic
amphiphiles for elastic matrix deposition, and therefore in corollary a negative influence
of anionic amphiphiles.
On the same lines, LOX protein content was found to be significantly higher in
constructs treated with NPs, both with or without agents. Protein bands corresponding to
LOX in our immunoblots showed extremely low to negligent quantities in constructs with
exogenous factor delivery. This was consistent with the mRNA expression of LOX,
which also showed higher expression in constructs with NPs. While mRNA expression
was not significantly different between BNP and EDC, their comparable expression
levels combined with the significantly higher levels of active LOX protein within NPtreated constructs seems to suggest that LOX production is also somehow triggered by
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the PVA modified NPs. It is likely that the decrease in MMP-9 mRNA expression as well
as its diminished enzymatic activity has in a way improved LOX protein availability. To
our knowledge, no direct correlation between MMP-9 inhibition or LOX up-regulation
with the use of PLGA NPs or its surface modification with anionic amphiphiles has been
reported in literature so far. Further investigation in is regard is warranted and its
understanding would definitely help improve targeted in situ matrix repair strategies.
Similarly, alkali-soluble matrix elastin content was found to be similar in both
exogenous and NPs delivery of factors. While these levels were 2 fold lower in constructs
with Blank-NPs, it is important to note that the ~ 9 μg/mg levels of alkali-soluble matrix
elastin content was similar to that observed in constructs evaluated in the previous
chapters that were cultured without EFs or DOX. This contrasting observation however,
seems similar to proposed physical effects of Hyaluronic acid (HA) in elastic matrix
assembly274-275. Native HA is a highly anionic glycosaminoglycan (GAG) present in the
ECM of various tissues95. It facilitates synthesis of fibrillin microfibrils and directs elastic
fiber assembly by binding versican (a proteoglycan) with elastin-associated proteins42, 160.
HA also appears to stabilize elastin fibers against elastase degradation, once formed43. In
addition to this, HA is known to enhance formation of mature matrix elastin by 1)
coacervating soluble tropoelastin via their positive lysine residues and 2) facilitating lysyl
oxidase (LOX)-mediated oxidation and crosslinking of tropoelastin into insoluble elastic
fibers42-43. Studies from our lab have also confirmed such up-regulation and demonstrated
elastogenic synergy between HA oligomers (~ 756 Da) and growth factors such as TGFβ137, 44. It is likely that the anionic NPs behave in a manner similar to anionic HA.

174

However, despite the increase in LOX content and comparable levels of alkalisoluble matrix elastin, the mature alkali-insoluble matrix elastin content was found to be
extremely low and statistically similar under all treatment conditions. This is likely due to
the low mRNA expressions of fibrillin-1 and fibulin-4, the microfibrillar proteins key to
elastic fiber assembly, combined with the high expression and enzymatic activity of
MMP-2. The low alkali-insoluble matrix elastin yields could also be contributed by the
fact that the concentration of TGF-β1 delivered in this study was ~ 10 fold less than that
we previously showed to be elastogenic. Concurrently, analysis of matrix ultrastructure
of constructs did not reveal obvious differences between the three treatment conditions.
Similar to that observed in Chapters 4 and 5, the ultrastructure of all constructs showed a
higher degree of longitudinal orientation than circumferential alignment, again likely due
the application of low strains. Circumferential alignment of cells and matrix were found
in regions closer to the lumen of the constructs.
Addition of NPs did not adversely affect cell proliferation or the expression of
contractile phenotypic markers of SMC. These levels were comparable in all treatment
conditions.
One of the limitations of this study was the lack of direct visualization of NPs in
the cultured constructs, since they were not tagged with any dyes in order to minimize the
effects of any external influences. NPs were assumed to be retained in the constructs
based on the pilot study performed with DMAB NPs at similar concentrations. Moreover,
the significant differences in results which were consistent across all experimental
methods analyzed, suggest that the NPs were retained and that the factors released from
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NPs were bio-available and bioactive. Culturing an additional set of constructs with NPs
loaded with vital dyes, in parallel and under similar culture conditions detailed in this
study would help in providing a visual distribution of NPs in the constructs. This would
also help in better understanding of NP behavior such as its retention and degradation
profiles within such a collagenous microenvironment.
Another limitation of this study at present is the lack of knowledge of accurate
release profiles of the factors from NPs within the collagen constructs. While PLGA is
known to undergo only hydrolytic degradation, and therefore their release profiles can be
expected to be similar within different aqueous environments at similar pH, studies have
indicated that degradation of PLGA can be accelerated by the presence of enzymes in
serum and that released by cells in culture276-277. However, there is lack of consistency
and clarity with respect to enzymatic degradation of PLGA. Degradation of PLGA, and
generation of acidic pH is also known further increase polymeric degradation278.
However, the frequent media change performed every 2 days can aid in minimizing the
effects of increase in pH. Therefore a certain level of inequality in concentrations of
factors delivered exogenously and via NPs in this study is bound to exist. A more
systematic analysis of properties of NP-treated constructs, the concentration of unreleased agents retained within NPs at the end of culture period, and examining its
degradation profiles over a time-dependent manner would aid in normalizing these
uncertainties and help in developing more efficient strategies for elastogenic response by
adult cells.
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6.5. Conclusions
Treatment of HASMCs within tubular collagen constructs with DOX- and TGFβ1- loaded PLGA NPs positively influenced overall elastogenic outcomes. Addition of
NPs, both with and without factors did not adversely affect cell proliferation or
expression of contractile SMA phenotype, compared to exogenously agent-treated
constructs. The agents released from the NPs were found to be bioactive, as warranted by
the positive differences in results obtained between agent-loaded and no-agent NPs,
primarily in terms of elastic matrix outcomes. While the mRNA expression of elastic
matrix proteins such as elastin and fibrillin-1 were less with NP-delivery compared to
exogenous delivery, the quantity of alkali-soluble matrix elastin synthesized by cells
under both conditions was comparable. Levels of insoluble elastin were uniformly low
under all treatment conditions. LOX mRNA expression as well as active protein
quantities were significantly elevated in NP-treated constructs, both with and without
agents. Similarly, mRNA expression, protein synthesis as well as enzyme activity of
MMP-9 was significantly suppressed within both NP-treated constructs, with and without
agents. Expression and activity of MMP-2 on the other seemed to be elevated with the
addition of NPs. The level of expression and enzyme activity was however lowed in
constructs with agent-loaded NPs compared to those with blank NPs, indicating
bioactivity of encapsulated agents.
Overall, this model demonstrates that the effects of agents delivered from PLGA
NPs appeared to be comparable to their exogenously delivery, warranting that further
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studies with similar strategies can greatly benefit in situ elastic matrix repair within
diseased tissues such as AAAs.
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CHAPTER SEVEN
CONCLUSIONS AND FUTURE OUTLOOK

7.1. OVERALL CONCLUSIONS
The concurrent delivery of TGF-β1 and HA-o to adult SMC cultures evaluated in
previous studies in our lab has successfully demonstrated the elastogenic potential of
these factors. However, cells, especially SMCs behave very differently in a 2D cell
culture environment, where their response to external stimuli is often different from that
seen in vivo. The overall goal of this thesis was to therefore develop an in vitro model
system, where cellular response to induced elastogenesis will be similar to what can be
replicated in vivo. The presence of a collagenous matrix is centric to replicating vascular
tissue architecture and mechanics, and vascular cells, regardless of the choice of scaffolds,
robustly synthesize collagen. Moreover, collagenous microenvironments are known to
promote a quiescent phenotype, similar to that seen in vivo, which is often not conducive
to elastogenesis. Examining the impact of a pre-existing collagenous microenvironment
on the ability of the cells to synthesize fibrous elastic matrix on their own, and also their
response to provided elastogenic factors, would be pertinent for a relevant in vitro system.
We therefore chose a 3D collagen gel model, widely been evaluated for vascular tissue
engineering applications.
In the first set of studies, we demonstrated that the elastogenic potential of TGFβ1 - HA-o combination could be replicated within RASMCs seeded in 3D collagen gels,
maintained under static tension. We tested six dose combinations - 0.1 ng/ml, 1 ng/ml
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and 10 ng/ml TGF-β, each with 0.2 µg/ml and 2 µg/ml HA-o, which were exogenously
supplemented to RASMCs within 3D collagen constructs. Relative to untreated control,
all constructs receiving the doses were found to induce elastogenesis. While mRNA
expression of elastin remained unchanged relative to control, all 6 dose combinations upregulated mRNA expression of LOX, with highest of up to 2-fold being in constructs
with 10 ng/ml TGF-β, with both doses of HA-o. Similarly, while tropoelastin protein
quantities in all cases were comparable to untreated controls, significant increase was
seen in the presence of alkali-soluble matrix elastin. Highest quantities of the alkalisoluble matrix elastin content were seen in constructs receiving 0.1 ng/ml TGF-β with 0.2
µg/ml HA-o. However, quantities of the more crosslinked, alkali-insoluble matrix elastin
were elevated only in constructs with 10 ng/ml TGF-β and 0.2 µg/ml HA-o treatment
conditions, where LOX protein content was also moderately elevated relative to other
treatment conditions (~ 1.5-fold from constructs with 0.1 ng/ml TGF-β 0.2 µg/ml HA-o).
MMP-2 enzyme activity on the other hand, was elevated in all treatment conditions,
which likely contributed to the low alkali-soluble matrix elastin content. MMP-9 protein
content, both active and zymogen forms, was suppressed in all conditions receiving
treatment, with lowest levels seen in constructs with 0.1 ng/ml and 10 ng/ml TGF-β, with
respective doses of HA-o. These results were confirmed with histology and IF analysis,
where a high no. of aligned elastic fibers were found in all treatment conditions, with the
highest of more than 2 fold being in those with 0.1 ng/ml TGF-β and 0.2 µg/ml HA-o.
However, induced elastogenesis did not have a significant impact on the mechanical
properties of the constructs. Tensile modulus was comparable in the select 4 treatment
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conditions that were tested (~ 60 kPa). This is likely due to the fact that the elastic fibers
synthesized, though aligned, were mostly discontinuous, and were not present in their
highly crosslinked, mature forms. Their contribution to the mechanical properties would
therefore be very minimal. Constructs that received 0.1 ng/ml TGF-β1 and 0.2 µg/ml
HA-o (termed EFs) were concluded to be most elastogenic; since they induced the
synthesis of highest quantities of alkali-soluble matrix elastin as well has the highest no.
of aligned fibers.
In the next set of studies, our goal was to achieve circumferential orientation of
EF-treated cells and the synthesized matrix, similar to that needed in vivo within elastic
arteries. Different from that used in the previous study, we adopted a tubular collagen gel
model seeded with human SMCs. Since cyclic strains are known have profound impact
towards this orientation, we developed a bioreactor capable of delivering circumferential
cyclic strains to cells with the tubular collagen gels. An important consideration for the
choice of cyclic strain parameters was its impact on MMP synthesis and enzyme activity,
since it can negatively impact accumulation and assembly of newly synthesized elastic
matrix. We therefore chose to use low strains of 2.5% which induces relatively lower
levels of undesirable protease activity. These were tested under 3 frequencies of 0.5 Hz,
1.5 Hz and 3 Hz, another important parameter equally contributing to cell and matrix
alignment. EFs were added to all three sets of stretched constructs over 21 days of culture,
and results were compared with static tubular constructs with and without EFs. Cell
densities were found to be similar under all test conditions, indicating that none of the
treatment conditions adversely impacted cell growth. A bimodal trend with increasing
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frequencies was observed in outcomes of contractile SMC phenotypic markers and elastic
matrix components, with highest levels observed in constructs stretched under 1.5 Hz.
For gene expression and protein synthesis of contractile SMC markers, change in
frequency appeared to have a greater impact than addition of EFs. For example, while no
changes were found in the static constructs with addition of EFs, SMA mRNA expression
increased progressively up to 1.5 Hz, where it peaked at 4-fold relative to static
constructs, and was lowered to 2-fold within constructs stretched at 0.5 and 3 Hz.
Compared to static constructs, contractile phenotypic markers were elevated in all
stretched constructs. Application of stretch at 3Hz frequency alone appeared to induce an
osteogenic switch in SMCs, which showed ~ 2-fold increase in osteopontin mRNA
expression relative to all other conditions.
Elastic matrix outcomes were most pronounced in constructs receiving EFs with
stretch at 1.5 Hz, in terms of both mRNA expressions and matrix content. In these
constructs, up to a 7-fold increase was seen in elastin mRNA expression, and up to a 5fold increase in alkali-soluble matrix elastin content, relative to static controls. Constructs
stretched at 0.5 Hz showed similar levels of gene expression and matrix outputs as that
of EF-treated static constructs, which were both higher than untreated static controls.
Application of strains at 3 Hz frequency did not show improvement in elastic matrix
output, and its levels were comparable to that of untreated static control. Addition of EFs
or strains did not significantly influence gene expressions or protein content of other
elastic matrix proteins (fibrillin, fibulins and LOX), relative to control. Perhaps as a
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consequence, levels of alkali-insoluble matrix content were uniformly low in all
constructs.
MMP-9 gene expressions remained extremely low, but its protein content was
moderately elevated at higher strain frequencies. Application of strains at all 3
frequencies did not adversely affect gene expressions or protein content of MMP-2.
These levels were comparable in all constructs, both static and dynamic. While its
enzyme activity was also similar in all conditions, their band intensities were extremely
high even at low protein concentrations, indicating high levels of enzyme activity. This
could also be a contributive factor for the low alkali-insoluble matrix elastin outcomes.
In our next set of studies, we therefore tested the supplementation of Doxycycline
(DOX), along with EFs, in order to improve elastic matrix outcomes by suppressing
MMP-2 enzyme activity. We tested two doses of DOX – 0.1 µM and 1 µM, along with
EFs, in HASMC-seeded tubular collagen gel constructs. These doses were tested on static
constructs, and those stretched at 2.5% strain at 1.5 Hz (which was shown to promote
elastogenesis the most in the previous study). Addition of DOX at both doses with EFs
was effective in significantly suppressing mRNA expression of MMP-2, under both static
(up to 4-fold) and dynamic (up to 3-fold) conditions, relative to control. While its protein
content remained unchanged relative to other conditions, MMP-2 enzyme activity was
lowered to similar levels at both DOX concentrations (up to 2-fold under static and up to
1.5 fold under dynamic conditions). All DOX + EFs-treated constructs significantly
increased alkali-soluble matrix content to similar levels, at both DOX concentrations,
under static and dynamic conditions. Up to 3-fold increase was seen relative to static
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control, and up to 2.5-fold relative to static constructs treated with EFs alone. Addition of
0.1 µM DOX with EFs significantly increased synthesis of the mature, highly crosslinked
alkali-insoluble matrix elastin (up to 2-fold) relative to other treatment conditions. Its
quantities were similar in all other conditions. mRNA expression and quantities of other
elastic matrix components remained unchanged.
Overall, in the 3 studies discussed above we demonstrated induction of significant
levels of elastogenesis in adult cells from both rat and humans. EFs, together with DOX
and 2.5% cyclic strains at 1.5 Hz, significantly improved elastic matrix outcomes, both at
the mRNA and protein levels. However, its translation to an in vivo scenario is limited by
its highly dose-depended induction of outcomes. In the next set of studies we therefore
examined if a targeted, nanoparticle-based delivery of these factors would induce
elastogenesis to similar levels as that seen with exogenous delivery. TGF-β1 and DOX
were encapsulated separately within PLGA nanoparticles (NPs), and incorporated within
HASMC-seeded tubular collagen gel constructs, subjected to 2.5% strain at 1.5 Hz
(ANP). These were compared to constructs with blank NPs (BNP), and those treated with
exogenous supplementation of TGF-β1and DOX to culture medium, both stretched
similarly (EDC). Interestingly, while gene expressions of elastin and fibulin were
comparable to EDC, that of LOX was up-regulated to 1.5-fold relative to EDC. This is
likely due to the presence of anionic NPs, since a moderate increase in LOX expression
was seen even in BNP constructs. This was reflected at the protein levels as well, where
both NP-treated constructs showed significantly larger quantities of LOX. Matrix elastin
content, both alkali-soluble and –insoluble, in EDC and ANP were comparable, both 4-
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fold higher than BNP constructs. Gene expression, protein content as well as enzyme
activity of MMP-2 were significantly elevated in NP-treated constructs, relative to EDC.
These levels however appeared to be lowered within ADC (vs. BNP), indicating that the
bioactivity of encapsulated agents was maintained. In contrast however, relative to EDC,
the gene expression, protein content and enzyme activity were significantly lowered in
both NP-treated constructs, indicating an influence of NPs themselves. Addition of NPs
did not affect cell densities or SMC phenotype, and these were comparable in all three
conditions. It is important to note that these results were obtained at TGF-β1
concentrations 10-fold lower than what was optimized in the previous studies. Overall,
we were able to successfully demonstrate that localized delivery of TGF-β1 and DOX is
able to mirror the elastogenic benefits of their exogenous delivery, without causing any
adverse effects.
One of the limitations of the studies conducted at 2.5% strain was its effects on
cell and matrix orientation. They appeared to be oriented more in the longitudinal
direction, than circumferentially, as was expected. At higher frequencies of 1.5 Hz and 3
Hz, higher degree of circumferential orientation was observed in regions closer to the
inner silicone tubing (lumen). Perhaps as a result, compared to other conditions, these
constructs also showed lesser degree of longitudinal orientation. Any contribution of the
different treatment conditions to the mechanical properties of the constructs therefore is
likely to be reflected more in the longitudinal direction than circumferentially. We
therefore did not record any significant differences in the tensile properties (tested on
constructs in second set of studies alone) tested on ring segments of the constructs treated
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under different frequencies, or between static and dynamic. Regardless, we have been
able to adequately demonstrate the positive influence of various factors on elastogenic
induction of adult HASMCs.
Results from these studies demonstrate how even within a quiescent, collagenous
environment, TGF-β1, HA-o and DOX can be utilized to induce de novo synthesis of
elastic matrix. These will prove most beneficial in developing efficient strategies for in
vivo translation of the above factors to repair and rebuild compromised elastic matrices.

7.2. FUTURE OUTLOOK
Overall results evaluated in this thesis sufficiently demonstrate positive outcomes
of elastogenic induction of adult vascular cells using several parameters within a relevant
in vitro model. However, there are several factors that can be addressed in the future
studies to develop more efficient strategies for induced elastogenesis.
1)

One of the primary limitations of in vitro induction of elastogenesis, is the

insufficient synthesis of matrix elastin, especially the highly crosslinked form, in
absolute quantities. While various parameters discussed in the study significantly
improve these quantities relative to untreated controls, these levels are insufficient
when compared to what is present in vivo within elastic aortae. This is perhaps
also contributed to by the low levels of other elastic matrix components such
fibrillin, fibulins and LOX, all of which play an equally important role in
regenerating and repairing compromised elastic matrix. Strategies that target at
improving outcomes of these components, in addition to that needed for elastin
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synthesis, will significantly improve elastic matrix outcomes for in vivo
applications.
2)

The cyclic strains of 2.5% utilized in this study were below the 10%

strains popularly used to demonstrate call and matrix orientation. We
hypothesized that since strain frequencies play an equally important role in matrix
alignment, lowering strains levels to suppress negative impact of strain-induced
MMP activity, and at the same time testing various frequencies, would improve
orientation. While we were able to effectively suppress increase in strain-induced
MMP-2 enzyme activity and achieve some degree of circumferential orientation
at higher frequencies, the degree of orientation is insufficient. Future studies
conducted at higher strain levels, at the optimized frequency of 1.5 Hz, along with
the utilization of DOX for MMP suppression, can contribute to improving elastic
matrix quantities and orientation.
3)

Viability of cells across the thickness of the constructs were not evaluated

extensively. It is likely that the cells closer to the lumen, where the stress
concentrations are higher, will be more apoptotic than those further away from it.
Though results obtained from live-dead assays performed on test constructs
cultured for 2 days, DNA assay after 21-day treatment, and construct compaction
ratios indicate overall cell viability, they did not elucidate effect of varying stress
concentrations across the construct thickness on cell viability, which is also likely
to affect matrix output. Examining this parameter will be pertinent, especially
when higher strain amplitudes are utilized.
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4)

When TE vascular grafts are implanted in vivo, the cells within such grafts

will be subjected to both cyclic stretch (circumferential and longitudinal), as well
as shear stress due to flow of blood. The bioreactor constructed in our studies was
capable of delivering cyclic stretch, but did not incorporate the component of flow
due to the presence of the central silicone tube. The cellular response and final
matrix outcomes are therefore reflective only of effects of cyclic stretch, and not
flow. In future studies, it would be pertinent to study the effects of flow along
with cyclic stretch. However, directly subjecting the collagen gels to pulsatile
flow without the presence of a central supporting mandrel can have 2 adverse
consequences,1) irreversible creep of viscous, and insufficiently contracted gels,
and 2) apoptotic response of SMCs to shear stress which would in turn
compromise sufficient synthesis of elastic matrix. Incorporating the parameter of
flow after the gels have substantially contracted and have synthesized elastic
matrix over 3 weeks, will overcome the above consequences, while at the same
time also reflect on the effects of shear on TE vascular grafts.
5)

If the future direction of this work is towards developing purely tissue-

engineered strategies for vascular matrix repair, or even to better understand cellregulatory factors in induced elastogenesis, pre-aligned scaffolds such as
electrospun tubular collagen can be utilized. Similar parameters of strain,
frequency, and EF and Dox delivery optimized in this thesis can be then be
applied. This would be an alternative to improve cell and matrix orientation at low
strains, and at the same time suppress MMP-induced elastic matrix degradation.
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6)

In the studies utilizing NP-delivery of factors, we were able to

demonstrate how localized delivery mirrors effects of exogenous delivery.
However, the release kinetics of factors from NPs in a serum-rich, cellular, and
hydrogel/collagenous environment is poorly understood. Studies conducted in a
time-dependent manner to better understand release kinetics in such an
environment would profoundly help in efficiently strategizing better delivery
vehicles that can induce optimum cellular response. NP-based delivery and in-situ
repair is a great strategy for inducing elastogenesis in vivo. Better understanding
of parameters that contribute to their outcomes can therefore prove advantageous
and profitable for future applications.
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